
<html lang="en"     class="pb-page"  data-request-id="5042f0cb-6217-4ea9-9442-ab60a3e9ddb3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-7;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b00209;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer" /></meta><meta name="dc.Creator" content="Yongtao  Li" /></meta><meta name="dc.Creator" content="Xiaohe  Luo" /></meta><meta name="dc.Creator" content="Qingxiang  Guo" /></meta><meta name="dc.Creator" content="Yongwei  Nie" /></meta><meta name="dc.Creator" content="Tianqi  Wang" /></meta><meta name="dc.Creator" content="Chao  Zhang" /></meta><meta name="dc.Creator" content="Zhi  Huang" /></meta><meta name="dc.Creator" content="Xin  Wang" /></meta><meta name="dc.Creator" content="Yanhua  Liu" /></meta><meta name="dc.Creator" content="Yanan  Chen" /></meta><meta name="dc.Creator" content="Jianyu  Zheng" /></meta><meta name="dc.Creator" content="Shengyong  Yang" /></meta><meta name="dc.Creator" content="Yan  Fan" /></meta><meta name="dc.Creator" content="Rong  Xiang" /></meta><meta name="dc.Description" content="A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d] pyrimidin-2-..." /></meta><meta name="Description" content="A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d] pyrimidin-2-..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 8, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00209" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00209" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00209" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00209" /></link>
        
    
    

<title>Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00209" /></meta><meta property="og:title" content="Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0001.jpeg" /></meta><meta property="og:description" content="A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d] pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide (6e) was discovered. The lead compound 6e with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, respectively, can effectively induce apoptosis of cancer cell lines. The kinase profiling of compound 6e showed excellent selectivity and specificity. Compound 6e induces G2/M arrest in high concentration and G0/G1 arrest in low concentration to prevent the proliferation and differentiation of cancer cells. Mice bared-breast cancer treated with 6e showed significant antitumor efficacy. The insight into mechanisms of 6e indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53. Our data demonstrated the novel compound 6e could be a promising drug candidate for cancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00209"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00209">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00209&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00209&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00209&amp;href=/doi/10.1021/acs.jmedchem.8b00209" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3166-3192</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00208" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00261" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yongtao Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongtao Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongtao++Li">Yongtao Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaohe Luo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaohe Luo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohe++Luo">Xiaohe Luo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingxiang Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingxiang Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingxiang++Guo">Qingxiang Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongwei Nie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongwei Nie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongwei++Nie">Yongwei Nie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tianqi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tianqi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tianqi++Wang">Tianqi Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chao Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Zhang">Chao Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhi Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhi Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhi++Huang">Zhi Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Wang">Xin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanhua Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanhua Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanhua++Liu">Yanhua Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanan++Chen">Yanan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianyu Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianyu Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory and Institute of Elemento-Organic Chemistry, Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianyu++Zheng">Jianyu Zheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shengyong Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shengyong Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shengyong++Yang">Shengyong Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5147-3746" title="Orcid link">http://orcid.org/0000-0001-5147-3746</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Fan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Fan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, 94 Weijin Road, Tianjin 300071, China</div><div class="loa-info-affiliations-info">2011 Project Collaborative Innovation Center for Biotherapy of Ministry of Education, 94 Weijin Road, Tianjin 300071, China</div></div><span class="conrtib-corresp"><strong>*</strong>(Y.F.) Phone: +86 22 23509482. E-mail: <a href="/cdn-cgi/l/email-protection#c3baa2ada5a2ad83ada2ada8a2aaeda6a7b6eda0ad"><span class="__cf_email__" data-cfemail="067f6768606768466867686d676f28636273286568">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Fan">Yan Fan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8099-3203" title="Orcid link">http://orcid.org/0000-0002-8099-3203</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rong Xiang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rong Xiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</div><div class="loa-info-affiliations-info">State Key Laboratory of Medicinal Chemical Biology, 94 Weijin Road, Tianjin 300071, China</div><div class="loa-info-affiliations-info">2011 Project Collaborative Innovation Center for Biotherapy of Ministry of Education, 94 Weijin Road, Tianjin 300071, China</div></div><span class="conrtib-corresp"><strong>*</strong>(R.X.) Phone: +86 22 23509482. E-mail: <a href="/cdn-cgi/l/email-protection#1e6c66777f70795e707f70757f77307b7a6b307d70"><span class="__cf_email__" data-cfemail="ed9f95848c838aad838c83868c84c3888998c38e83">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Xiang">Rong Xiang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00209&amp;href=/doi/10.1021%2Facs.jmedchem.8b00209" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3166–3192</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 8, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 February 2018</li><li><span class="item_label"><b>Published</b> online</span>8 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 April 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00209" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00209</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3166%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYongtao%2BLi%252C%2BXiaohe%2BLuo%252C%2BQingxiang%2BGuo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D7%26contentID%3Dacs.jmedchem.8b00209%26title%3DDiscovery%2Bof%2BN1-%25284-%2528%25287-Cyclopentyl-6-%2528dimethylcarbamoyl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-2-yl%2529amino%2529phenyl%2529-N8-hydroxyoctanediamide%2Bas%2Ba%2BNovel%2BInhibitor%2BTargeting%2BCyclin-dependent%2BKinase%2B4%252F9%2B%2528CDK4%252F9%2529%2Band%2BHistone%2BDeacetlyase1%2B%2528HDAC1%2529%2Bagainst%2BMalignant%2BCancer%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3192%26publicationDate%3DApril%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00209"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2725</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">34</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00209" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yongtao&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xiaohe&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Qingxiang&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Yongwei&quot;,&quot;last_name&quot;:&quot;Nie&quot;},{&quot;first_name&quot;:&quot;Tianqi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Zhi&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yanhua&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Yanan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Jianyu&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Shengyong&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Xiang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;3166-3192&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00209&quot;},&quot;abstract&quot;:&quot;A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d] pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide (6e) was discovered. The lead compound 6e with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, respectively, can effectively induce apoptosis of cancer cell lines. The kinase profiling of compound 6e showed excellent selectivity and specificity. Compound 6e induces G2/M arrest in high concentration and G0/G1 arrest in low concentration to prevent the proliferation and differentiation of cancer cells. Mice bared-breast cancer treated with 6e showed significant antitumor efficacy. The insight into mechanisms of 6e indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53. Our data demonstrated the novel compound 6e could be a promising drug candidate for cancer therapy.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00209&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00209" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00209&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00209" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00209&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00209" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00209&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00209&amp;href=/doi/10.1021/acs.jmedchem.8b00209" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00209" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00209" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00209%26sid%3Dliteratum%253Aachs%26pmid%3D29518312%26genre%3Darticle%26aulast%3DLi%26date%3D2018%26atitle%3DDiscovery%2Bof%2BN1-%25284-%2528%25287-Cyclopentyl-6-%2528dimethylcarbamoyl%2529-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-2-yl%2529amino%2529phenyl%2529-N8-hydroxyoctanediamide%2Bas%2Ba%2BNovel%2BInhibitor%2BTargeting%2BCyclin-dependent%2BKinase%2B4%252F9%2B%2528CDK4%252F9%2529%2Band%2BHistone%2BDeacetlyase1%2B%2528HDAC1%2529%2Bagainst%2BMalignant%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D7%26spage%3D3166%26epage%3D3192%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291149" title="Apoptosis">Apoptosis</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/jmcmar.2018.61.issue-7/20180412/jmcmar.2018.61.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>6e</b>) was discovered. The lead compound <b>6e</b> with excellent CDK4/9 and HDAC1 inhibitory activity of IC<sub>50</sub> = 8.8, 12, and 2.2 nM, respectively, can effectively induce apoptosis of cancer cell lines. The kinase profiling of compound <b>6e</b> showed excellent selectivity and specificity. Compound <b>6e</b> induces G2/M arrest in high concentration and G0/G1 arrest in low concentration to prevent the proliferation and differentiation of cancer cells. Mice bared-breast cancer treated with <b>6e</b> showed significant antitumor efficacy. The insight into mechanisms of <b>6e</b> indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53. Our data demonstrated the novel compound <b>6e</b> could be a promising drug candidate for cancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is believed to result from dysregulation of normal cell cycle, which leads to abnormal proliferation and inability of cells to undergo differentiation and/or apoptosis. The cell cycle consists of four phases, G1, S, G2, and M phases, which play a critical and central role in control of cell growth and proliferation.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Cyclins and their catalytic binding partners, cyclin-dependent kinases (CDKs), maintain the regulation of the cell cycle. CDK4 formed a complex with cyclinD1, which is an important component of cell cycle activation and controls the key progression step, G1 phase, where cells grow and synthesize proteins in preparation for DNA synthesis. Deregulation of the CDK4-cyclinD-Rb pathway and CDK4 overexpression has been observed in cancer. Inhibition of CDK4 associated with cell cycle regulation by inhibitors can lead to a G1 arrest and cell cycle progression halt, which provides an effective approach to the control of tumor growth.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10 ref11">(5−11)</a></div><div class="NLM_p">Many researchers have focused their efforts on the development of small molecule inhibitors of CDK4. The first generation of CDK4 inhibitors was nonselective and caused severe toxic side effects in clinical trials. Toxicity due to poor specificity has limited their therapeutic efficacy.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> In an attempt to overcome the toxicity, potent and selective CDK4 inhibitors have received significant attentions. Palbociclib and ribociclib, which have entered clinical trials, are highly specific for CDK4.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> They all need to combine with letrozole for the treatment of ER+/HER2– metastatic breast cancer. These studies suggest that monotherapy targeting on CDK4 to induce tumor cell death may be insufficient.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Additionally, many studies have shown synergistic outcomes in reduction of tumor burden by simultaneous inhibition of more than one activated protein.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> Therefore, we reasoned that development of single drugs with multiple biological targets based on CDK4 might improve efficacy in cancer treatment.</div><div class="NLM_p">Histone deacetylases (HDACs) catalyze the deacetylation from lysine residues in histones tails, leading to chromatin condensation, thus controlling the transcriptional regulation, cell cycle progression, and apoptosis.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> Inhibition of HDACs significantly suppress cancer cell proliferation, angiogenesis, and metastasis and induce apoptosis. Interestingly, HDAC1 inhibitors that possess synergistic or additive antitumor effects in rational combinations with anticancer drugs have been investigated.<a onclick="showRef(event, 'ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31">(28−31)</a> Following the success of synergy between HDAC inhibitor and CDK inhibitor in treating neuroblastomas and melanoma,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> we conceived that multitarget inhibition using of HDAC1 inhibitor in combination with CDK4 target agent increases the efficiencies of the CDK inhibitor. There are few reports in the literature concerning bifunctional targeting of CDK and HDAC1 by single chemical inhibitors. With this approach, a novel single molecule targeting CDK4 and HDAC1 was designed to avoid side effects of more separate agents, such as drug–drug interaction or different physicochemical properties.</div><div class="NLM_p last">In our study, a series of novel dual-action compounds targeting CDK4 and HDAC1 were designed and synthesized. In vitro antiproliferative activity and kinase profiling revealed that the most active compound, <i>N</i>1-(4-((7-cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>6e</b>), was a multikinase inhibitor with excellent CDK4 inhibitory activity (IC<sub>50</sub> = 8.8 nM), HDAC1 inhibitory activity (IC<sub>50</sub> = 2.2 nM), and CDK9 inhibitory activity (IC<sub>50</sub> = 9 nM). The lead compound can induce apoptosis for a wide variety of tumor cell lines and significantly induce G2/M arrest in high concentration and G<sub>0</sub>/G<sub>1</sub> arrest in low concentration. In vivo it is effective in a 4T1 xenograft model in BALB/c mice. On the basis of these findings, it appears that compound <b>6e</b> offers potential for the treatment of a variety of tumor diseases. Herein, we report the synthesis, structure–activity relationship (SAR), kinase inhibitory profile, in vitro cytotoxicity, and tumor regression studies of this lead compound. The selection of key drug-like parameters comprising LogP and LogD were measured. This work provides a novel approach in the development of new chemotherapy for further exploration of a dual CDK-HDAC1 pathway inhibition achieved with a single molecule.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20630" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20630" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Dual CDK4-HDAC1 Inhibitors Design Strategy</h3><div class="NLM_p">Rather than linking two inhibitors together with a long chain, a merged pharmacophore is more desirable to avoid high  molecular weight. Since there is no 3D structure of CDK4-ligand complex reported at present, the structure of CDK6 in complex with an inhibitor (PDB entry: 4EZ5) was used as a template for homology modeling.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Analyzing the X-ray cocrystal structure and the third generation of CDK-directed drugs, we found all of them interact with the hinge region using the 2-aminopyrimidine group. Analysis of the structural information in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Figure S1</a> and <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> suggested that His100 in CDK6 (His95 in CDK4), an amino acid that is rarely conserved in other kinases. Previously reported structural studies with CDK inhibitors bound to CDK6 propose 2-amino and N-3 position of the pyrrolo[2,3-<i>d</i>] pyrimidine ring forming two hydrogen bonds with His100 (His95 in CDK4) as an important determinant for CDK enzyme inhibition. The 2-aminopyrimidine group, which interacts with the hinge region as its core CDK6-binding scaffold provides a suitable moiety to explore our hypothesis. Thus, it was postulated that inserting the HDAC1 binding group here would retain CDK activity. An intrinsic property that affects kinase selectivity for many drugs is lipophilicity,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> quantified by cLogP. As the cLogP of ribociclib (2.3) is significantly lower than abemaciclib (5.5) or palbociclib (2.7), we selected pyrrolo[2,3-<i>d</i>] pyrimidines-2-amine as the backbone because this class of compound showed to possess higher CDK kinase inhibitory activity and kinase selectivity. Most HDACis, such as vorinostat, are characterized by a widely accepted pharmacophore model including three moieties, the capping group, linker region and zinc binding group. The capping group interacts with residues at the entry point of the active site tunnel. The linker chain plus a connecting unit interacts mainly with hydrophobic residues of the tunnel. The zinc binding functional group, such as hydroxamic acid, binds strongly to the zinc cation or a monodentate group at the active site. According to the structural information, the zinc binding group plays a critical role in chelation of zinc ion for HDAC1 inhibition.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The hydroxamic acids moiety consistently inserts into the catalytic outer tunnel of HDAC and chelates a zinc ion, which is important for the catalytic process of HDAC. We further designed a merged molecule (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), in which the two essential pharmacophoric elements, pyrrolo[2,3-<i>d</i>] pyrimidines-2-amine and hydroxamic acid moiety. Thus, we design single compound that selectively inhibits both CDK and HDAC1 enzymes to improve efficacy in cancer treatment compared to a single inhibitor alone.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic showing design for merged CDK-HDAC pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Chemistry</h3><div class="NLM_p">All target compounds were prepared by routes outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. First, we synthesized the key intermediates and the general synthetic routes are illustrated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Briefly, commercially available <b>1a</b>–<b>1d</b> reacted with phenylenediamine (<b>2a</b>–<b>2c</b>) to provide aniline intermediate <b>3a</b>–<b>3f</b> (40–87% yield).<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> Commercial compound <b>4</b> with intermediate anilines <b>3a</b>–<b>3f</b> through palladium-catalyzed cross-coupling reaction provided compounds <b>5a</b>–<b>5f</b>. Similarly, commercially available <b>7a</b>–<b>7d</b> reacted with 4-aminobenzoic acid (<b>8</b>), which were purchased from market to provide aniline intermediate <b>9a</b>–<b>9d</b>. After that, <b>10a</b>–<b>10d</b> were obtained by <b>9a</b>–<b>9d</b> with one step. Those methyl carbonate analogues (<b>5a</b>–<b>5f</b>, <b>10a</b>–<b>10d</b>) were directly converted into the hydroxamic acids analogues (<b>6a</b>–<b>6f</b>, <b>11a</b>–<b>11d</b>) by NH<sub>2</sub>OH in CH<sub>3</sub>OH.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Aniline intermediates <b>13a</b>–<b>13f</b> were acquired by <b>12a</b>–<b>12d</b> with <i>p</i>-phenylenediamine (<b>2c</b>). Then, intermediates <b>13a</b>–<b>13d</b> with compound <b>4</b> provided compounds <b>14a</b>–<b>14d</b>.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> A primary amine <b>7b</b> was reacted with triphosgene and trimethylamine to provide isocyanate derivative <b>15</b>, which was then reacted with <i>p</i>-phenylenediamine to produce aniline intermediate <b>16</b>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Compound <b>16</b> underwent S<sub>N</sub>Ar with compound <b>4</b> to produce <b>17</b>, which was then directly converted into <b>18</b> by NH<sub>2</sub>OH in CH<sub>3</sub>OH.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Derivatives of <b>5a–5f</b>, <b>6a–6f</b>, <b>10a–10d</b>, <b>11a–11d</b>, <b>14a–14d</b>, <b>17</b>, and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EDCI, HOBt, DIEA, rt, 12 h, 39–80% yield for <b>3a</b>–<b>3f</b>, 63–87% yield for <b>9a</b>–<b>9d</b>, 40–82% yield for <b>13a</b>–<b>13d</b>; (b) Pd(OAc)<sub>2</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 12 h, 73–89% yield for <b>5a</b>–<b>5f</b>, 76-84% yield for <b>10a</b>–<b>10d</b>, 80–84% yield for <b>14a</b>–<b>14d</b>, 45% yield for <b>17</b>; (c) NH<sub>2</sub>OH, CH<sub>3</sub>OH, reflux, 18 h, 48–76% yield for <b>6a</b>–<b>6f</b>, 58–71% yield for <b>11a</b>–<b>11d</b>, 68% yield for <b>18</b>; (d) triphosgene, Et<sub>3</sub>N, DCM; (e) Et<sub>3</sub>N, DMF, 78% yield over two steps.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, compound <b>4</b> was coupled to the diphenylmethanimine to obtain <b>8</b>, which was not necessary to further purify, and treated with concentrated HCl to obtain <b>20</b>.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Compound <b>4</b> was heated with N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O in EtOH to give <b>21</b>.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Compound <b>1c</b> was condensed with <b>20</b>, <b>21</b>, ribociclib, 4-(aminomethyl)anilinedihydrochloride, and <i>tert</i>-butyl (5-aminopyridin-2-yl)carbamate to provide <b>22</b>, <b>23</b>, <b>24</b>, <b>26</b>, and <b>29</b>, respectively. Similarly, <b>26</b> underwent S<sub>N</sub>Ar with <b>4</b> to produce <b>27</b>, which was then directly converted into <b>28</b> by NH<sub>2</sub>OH in CH<sub>3</sub>OH. Removal of the protecting group of <b>29</b> provided aniline <b>30</b>, which underwent S<sub>N</sub>Ar with <b>4</b> to produce <b>31</b>. Compound <b>31</b> was heated with NH<sub>2</sub>OH in MeOH to give <b>32</b>. Compound <b>33</b> was obtained by the procedure from <b>1c</b> reacting with 5-nitropyridin-2-amine, and the nitro was reduced to produce <b>34</b>. The synthesis procedure of <b>35</b> is similar to that of <b>31</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Derivatives of <b>22–25</b>, <b>27</b>, <b>28</b>, <b>31–32</b>, and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 12 h, 79% yield for <b>27</b>, 46% yield for <b>31</b>, 77% yield for <b>35</b>; (b) conc. HCl, THF, 84% yield for <b>20</b> over two steps, 66% yield for <b>30</b>; (c) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (80%), EtOH, 80°C, 6 h, 79% yield; (d) EDCI, HOBt, DIEA, rt, 12 h, 72% yield for <b>22</b>, 32% yield for <b>23</b>, 49% yield for <b>24</b>, 67% yield for <b>26</b>; (e) NH<sub>2</sub>OH, CH<sub>3</sub>OH, reflux, 18 h, 67% yield for <b>25</b>, 49% yield for <b>28</b>, 64% yield for <b>32</b>; (f) 5-nitropyridin-2-amine, SOCl<sub>2</sub>, pyridine, THF, 80°C, 6 h, 10% yield; (g) Pd/C, HCOONH<sub>4</sub>, EtOH, 80°C, 12 h, 88% yield.</p></p></figure><div class="NLM_p">In <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, to view the contribution of the <i>N</i>,<i>N</i>-dimethylamide substituent, the unsubstituted intermediates 2-chloro-9-cyclopentyl-9<i>H</i>-purine (<b>40</b>) and 5-chloro-3-cyclopentyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>43</b>) were required. Commercially available 2,4-dichloro-5-nitropyrimidine (<b>36</b>) as the starting material reacted with cyclopentylamine (<b>37</b>) to give compound <b>38</b>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> which was treated with SnCl<sub>2</sub>·2H<sub>2</sub>O for reduction of nitro to obtain compound <b>39</b>.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The compound <b>40</b> was prepared from <b>39</b> by treatment with trimethyl orthoformate in 47% yield. Compound <b>39</b> was treated with NaNO<sub>2</sub> under concentrated HCl conditions to produce compound <b>43</b>. A palladium catalyzed cross-coupling reaction of compounds <b>40</b> and <b>43</b> with intermediate aniline <b>3e</b> provided compounds <b>41</b> and <b>44</b> followed by conversion into the hydroxamic acid compounds <b>42</b> and <b>45</b> by NH<sub>2</sub>OH in CH<sub>3</sub>OH. The compound <b>46</b> was prepared by reduction of compound <b>5e</b> with lithium aluminum hydride in THF.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Hydrolysis of <b>5e</b> gave the acetic acid derivative <b>47</b>, followed by condensation with dimethylamine in the presence of EDCI, HOBt, and DIEA to afford the amide derivative <b>48</b>.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Derivatives of <b>41–42</b>, <b>44–45</b>, and <b>46–48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIEA, EA, −40°C to rt, 2 h, 99% yield; (b) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH, reflux, 2 h, 85% yield; (c) triethylorthoformate, MgSO<sub>4,</sub> DMF, 130°C, 2 h, 47% yield; (d) Pd(OAc)<sub>2</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 12 h, 77% yield for <b>41</b>, 45% yield for <b>44</b>; (e) NaNO<sub>2,</sub> conc. HCl, 0 °C to rt, 3.25 h, 65% yield; (f) NH<sub>2</sub>OH, CH<sub>3</sub>OH, reflux, 18 h, 45% yield for <b>42</b>, 32% yield for <b>45</b>; (g) LiAlH<sub>4</sub>, THF, 0°C to rt, 4 h, 57% yield; (h) NaOH, THF/CH<sub>3</sub>OH/H<sub>2</sub>O, rt, 12 h, 93% yield; (i) HN(CH<sub>3</sub>)<sub>2</sub>, EDCI, HOBt, DIEA, rt, 12 h, 61% yield.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">2.3.  Enzyme Inhibitory Activity and SAR</h3><div class="NLM_p">It is evident from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> that the nature of substituent Y-6 position in the general structure specifies the enzyme activity of the molecules on CDK4/cyclinD.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Placing dimethylcarbamoyl in Y-6 position and keeping other positions constant, the molecule showed better activity targeting CDK4. As the dimethylcarbamoyl was displaced, inhibitory properties of compounds as shown for <b>41</b>, <b>42</b>, <b>44</b> and <b>45</b>, were decreased by several fold compared to other molecules. These data clearly show that a dimethylcarbamoyl group at Y-6 position is the most optimal substituent, suggesting that the dimethylcarbamoyl group at the Y-6 position of the pyrrolo[2,3-<i>d</i>]pyrimidine ring is critical for its activity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values for Enzymatic Inhibition of CDK4 and HDAC1</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0014.gif" alt="" id="gr100" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0015.gif" alt="" id="gr101" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0016.gif" alt="" id="gr102" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0017.gif" alt="" id="gr103" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0018.gif" alt="" id="gr104" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">CDK inhibition values were determined by Eurofins. HDAC inhibition values were determined by Shanghai Chempartner Co.,Ltd. The data represent the mean values of two independent experiments.</p></div></div><div></div></div><div class="NLM_p">Once we identified suitable substituents for the Y-6 position, we then investigate whether the aromatic ring moiety, between the pyrrolo[2,3-<i>d</i>] pyrimidine and zinc binding group, was important for potent inhibition of CDK4/cyclinD. The results of enzyme inhibitory activity studies showed that all of the molecules with phenyl substituent between the pyrrolo[2,3-<i>d</i>] pyrimidine and zinc binding group were similar active with CDK inhibitor ribociclib. These compounds fared better with half-maximal inhibitory concentrations (IC<sub>50</sub>) values ranging from 4.8 nM to 30 nM, such as compounds <b>5b</b>–<b>f</b>, <b>6b</b>–<b>6f</b>, <b>10a</b>–<b>d</b>, <b>11a</b>–<b>d</b>, <b>14a</b>–<b>b</b>, <b>18, 27</b>, <b>28</b>, and <b>46</b> to <b>48</b>. Other derivatives focusing on the position connecting to the C-2 position of the pyrrolo [2,3-<i>d</i>] pyrimidine-6-one was varied in an attempt to further improve the potency for CDK4/cyclinD. When the position changed to pyridine moiety, the molecules (<b>31</b> and <b>32</b>) were several-fold less active than aboved compounds. Compound <b>5a</b> and <b>6a</b>, which possess an ortho-aniline group instead of a para-aniline, showed lower binding affinity (IC<sub>50</sub> > 5000 nM), most likely because of unfavorable steric interactions with the pocket of CDK4/cyclinD. Analogues <b>22</b> and <b>23</b> with progressive decrease of IC<sub>50</sub> values were also observed. 5-(piperazin-1-yl) pyridin-2-yl group in <b>24</b> and <b>25</b> conferred high CDK4/cyclinD potency.</div><div class="NLM_p last">Several substituents, such as hydroxamic acids, methyl ester, dimethylcarbamoyl group, alkyl and hydroxy, were designed as a zinc binding group. We have selected some representative compounds to detect the HDAC1 inhibition activities. Among these compounds, the ester group, dimethylcarbamoyl group, alkyl and hydroxy were completely inactive against HDAC1 at the highest concentration tested (5 μM) in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, due to the weak chelating effect to the zinc cation in the HDAC1 active site. Therefore, hydroxamic acid is essential for good zinc binding and activity, thus the hydroxamic derivatives showed significant inhibition of HDAC1 activity in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. These compounds were 10–100-fold more potent than positive control, HDAC1 inhibitor (vorinostat). Compounds afforded strong HDAC1 inhibition, such as <b>6b</b>, <b>6d–f</b>, <b>11b–d</b> and <b>42</b> especially compound <b>6d</b> (IC<sub>50</sub> = 0.84 nM) and <b>11b</b> (IC<sub>50</sub> = 0.53 nM). The SAR appears to mirror that observed for a series of homologues in which the linking section between the hydroxamic acid and amide must be at least five carbon atoms in length, with length of five being optimal.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Compound <b>6c</b> (IC<sub>50</sub> = 27 nM) did not demonstrated outstanding HDAC1 inhibition activity, probably due to the short distance between the acid and the pyrrolo[2,3-<i>d</i>] pyrimidine. Compound <b>6a</b> was not particularly active, probably because the dimethylcarbamoyl is ortho to 2-aminopyrimidine group resulting in steric hindrance. With HDAC1 inhibitory of IC<sub>50</sub> = 53 nM, the compound <b>28</b> with a methylene spacer was found to be less active than the parent molecule, probably because of the benzyl amine group increasing the flexibility of the zinc binding moiety. In comparison with vorinostat, compound <b>11a</b>–<b>d</b> was made as reversed amide. The observed low HDAC1 inhibition of <b>25</b>, <b>32</b> and <b>45</b> is probably due to the differences in the cap binding region of the CDK.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.4.  Cellular Assays</h3><div class="NLM_p">We focused our efforts on the evaluation of our bifunctional inhibitors. Whether the kinase inhibitory activity of the dual-action molecules transfer to tumor cell lines was next explored with cancer cell proliferation assays. We screened dual-acting compounds exhibiting better kinase inhibitory than ribiciclib and vorinostat to do the preliminary cell inhibition assays (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Table S1</a>). Then, IC<sub>50</sub> values were further detected on compounds that exhibit better cell inhibition in a panel of cancer cell line growth using standard CCK8 assay. Despite being highly potent against both CDK4 and HDAC1, analogues <b>6d</b>, <b>6f</b>, and <b>11b</b>, with five or seven carbon atoms in length of the linking section between the hydroxamic acid and amide, were only weakly antitumor activities in these cells (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Table S2</a>). The best tumor cell potency of these analogues was obtained for six carbon linked molecule <b>6e</b>, which was also outstanding inhibitor of CDK4 and HDAC1 with IC<sub>50</sub> values of 8.8 and 2.2 nM. It was probably due to compound <b>6e</b> with a comfortable and optimal merged pharmacophore for cell uptake. As attributes of a truly merged bispecific pharmacophore and the results of antitumor activity in cell lines showed that <b>6e</b> is the best in this class, we performed all subsequent in vitro and in vivo biological studies using this compound. The compound was next evaluated in a dose response study against breast cancer cell lines (4T1, T47D, and MDA-MB-231), lung cancer cell lines (A549 and H460), and liver cancer cell lines (HepG2 and Hep3B) to test cytotoxic activity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">S3</a>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Compounds ribociclib and vorinostat were used as references. Compound <b>6e</b> showed potent profile in vitro, with around 1 μM IC<sub>50</sub> values in the 4T1, MDA-MB-231, A549, H1299, and Hep3B cell lines and about 2–3 μM in other cell lines. The CDK4 selective inhibitor ribociclib was not potent in these cells, which indicated CDK4 monotherapy lack sensitivity. This result demonstrated that combination CDK and HDAC1 inhibition in a single molecule led to synergy at the cellular level more efficiently.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cytotoxic Activity of Compound <b>6e</b> against Cancer Cell Lines<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> value (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center">CDK inhibitor ribociclib</th><th class="colsep0 rowsep0" align="center">compound <b>6e</b></th><th class="colsep0 rowsep0" align="center">HDAC inhibitor vorinostat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4T1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.11 ± 0.45</td><td class="colsep0 rowsep0" align="center">4.76 ± 0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.86 ± 0.45</td><td class="colsep0 rowsep0" align="center">2.59 ± 0.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-468</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.82 ± 0.35</td><td class="colsep0 rowsep0" align="center">2.69 ± 0.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T47D</td><td class="colsep0 rowsep0" align="center">6.23 ± 4.04</td><td class="colsep0 rowsep0" align="center">2.59 ± 0.59</td><td class="colsep0 rowsep0" align="center">3.01 ± 1.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.33 ± 0.57</td><td class="colsep0 rowsep0" align="center">3.70 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1299</td><td class="colsep0 rowsep0" align="center">5.46 ± 2.65</td><td class="colsep0 rowsep0" align="center">1.87 ± 0.27</td><td class="colsep0 rowsep0" align="center">3.46 ± 0.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H460</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.78 ± 0.86</td><td class="colsep0 rowsep0" align="center">6.29 ± 1.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hep G2</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.37 ± 0.33</td><td class="colsep0 rowsep0" align="center">2.57 ± 0.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hep 3B</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.24 ± 0.27</td><td class="colsep0 rowsep0" align="center">2.30 ± 0.46</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> values are shown in the forms. The cytotoxic effect of compounds were assayed using CCK-8 assay with 72 h incubation. Data are mean ± SD values from three independent experiments.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.5.  Kinase Selectivity Profiling</h3><div class="NLM_p">To investigate the kinase selectivity, kinase inhibition profiling assays with a fixed concentration of 1 μM compound <b>6e</b> were first carried out against a series of 375 kinases through the Eurofins kinase profiling. The results are provided in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Table S4</a>. Further IC<sub>50</sub> values of the kinases that showed a high inhibitory rate at 1 μM were examined, and the results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Interestingly, ribociclib with high selectivity for CDK4/6 relative to other human protein<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> was detected with the IC<sub>50</sub> of CDK4/cyclinD at 13 nM, and IC<sub>50</sub> of CDK9/cyclinT at 197 nM. Our compound <b>6e</b> showed higher inhibitory activity against CDK4/cyclinD (IC<sub>50</sub> = 8.8 nM) and CDK9/cyclinT (IC<sub>50</sub> = 9 nM) over other CDKs. Resulting from high homology, identical substrate specificities and enzymatic activities of CDK4 and CDK6 have overlapping functions in development. In light of this fact, many of the third generation CDK4 inhibitors such as abemaciclib, dinaciclib, ribociclib, palbociclib, and AG-024322 also inhibited CDK6.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Therefore, the development of ATP-competitive CDK4 inhibitors that are selective over CDK6 may offer an improved therapeutic potential as well as dual CDK4/CDK6 inhibitors. CDK4 along with cyclins D is involved in the regulation of cell cycle, while CDK9 along with cyclins T is a key player in transcription regulation/RNA processing. Compound <b>6e</b> that targets cell cycle-related CDK4 and transcription-related CDK9 might contribute to the antitumor activity. Compound <b>6e</b> has additional kinase activities (six human protein kinases have IC<sub>50</sub> < 50 nmol/L), all of which are intimately associated with the growth, survival, and metastasis in tumor cells.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase binding selectivity for compound <b>6e</b> shown on the human kinome dendrogram. The inhibition rates were determined using the KinaseProfiler of Eurofins. The figure was generated by using an online Kinome Render program (<a href="http://www.biophys.umontreal.ca/nrg/NRG/KinomeRender.html" class="extLink">http://www.biophys.umontreal.ca/nrg/NRG/KinomeRender.html</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinase Inhibition Profile of Compound <b>6e</b> against Selected Protein Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">inhibition (%) at 1 μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4/cyclinD3(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.0088</td><td class="colsep0 rowsep0" align="left">CDK1/cyclinB(h)</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK9/cyclin T1(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="left">CDK2/cyclinA(h)</td><td class="colsep0 rowsep0" align="char" char=".">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora-A(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="left">CDK2/cyclinE(h)</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora-B(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="left">CDK3/cyclinE(h)</td><td class="colsep0 rowsep0" align="char" char=".">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora-C(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td><td class="colsep0 rowsep0" align="left">CDK4/cyclinD3(h)</td><td class="colsep0 rowsep0" align="char" char=".">101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CaMKK2(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.053</td><td class="colsep0 rowsep0" align="left">CDK5/p25(h)</td><td class="colsep0 rowsep0" align="char" char=".">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt4(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="left">CDK5/p35(h)</td><td class="colsep0 rowsep0" align="char" char=".">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LIMK1(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.044</td><td class="colsep0 rowsep0" align="left">CDK6/cyclinD3(h)</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAO2(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.084</td><td class="colsep0 rowsep0" align="left">CDK7/cyclinH/MAT1(h)</td><td class="colsep0 rowsep0" align="char" char=".">–11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TrkA(h)</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td><td class="colsep0 rowsep0" align="left">CDK9/cyclin T1(h)</td><td class="colsep0 rowsep0" align="char" char=".">97</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values and inhibition values were determined using KinaseProfiler by Eurofins. The data represent the mean values of two independent experiments.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.6.  Molecular Modeling of Compound <b>6e</b></h3><div class="NLM_p">Molecular docking studies were carried out to investigate the binding modes of compound <b>6e</b> in CDK4, CDK9, and HDAC1, respectively. Since there is no 3D structure of CDK4-ligand complex reported at present, the structure of CDK6 in complex with an inhibitor (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EZ5">4EZ5</a>) was used as a template for homology modeling. MODELER<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> in the Discovery Studio (DS, Accelrys Inc., USA) was employed for the homology modeling. Then the compound <b>6e</b> was docked to CDK4, CDK9 (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>), and HDAC1 (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>) by GOLD (version 5.0). Hydrogen atoms were added to the proteins by using DS 3.1. GoldScore was selected as the scoring function, and other parameters were set as default. The image was created using PyMOL.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> illustrates the predicted binding modes and the detailed protein–inhibitor interactions of compound <b>6e</b> with CDK4, HDAC1, and CDK9, respectively. For comparison, the binding mode of <b>6e</b> was superimposed on that of ribociclib or vorinostat. Compound <b>6e</b> is a potent inhibitor of CDK4 with an IC<sub>50</sub> of 8.8 nM, and ribociclib shows a similar level of CDK4 inhibition, with an IC<sub>50</sub> of 13 nM. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, <b>6e</b> could tightly bind to the ATP-binding site of CDK4 in a binding mode similar to that of ribociclib. Hydrogen bonds appear to be formed between the aminopyrimidine and the backbone residue of Val96 and His95. Given that these hydrogen bonds are critical for binding to CDK4, it is satisfying to find that NH of aminopyrimidine may also be serving a similar role in its interactions with HDAC1. From this point of view, <b>6e</b> displays attributes of a truly merged bispecific pharmacophore. In an attempt to find the reasons for the HDAC1 inhibitor of the compound <b>6e</b>, we docked compound <b>6e</b> into the HDAC1 protein. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, the hydroxamic acid could insert into the catalytic outer tunnel of HDAC1, and the group also chelates a zinc ion, which is important for the catalytic process of HDAC1. In addition, the 2-aminopyrimidine group contributes to the hydrogen-bonding interaction with the residue in the catalytic tunnel. In contrast to vorinostat that contain simple heterocycle to exert cap action, our results of molecular modeling reveal that placing 2-aminopyrimidine substituents at proper locations forms a hydrogen bonding interaction with Glu-98. This deeper and closer binding of compound <b>6e</b> to HDAC1 may explain the better binding affinity of compound <b>6e</b> for HDAC1, about 10-fold more than vorinostat. The CDK9 inhibitory IC<sub>50</sub> of compound <b>6e</b> is 9 nM, while ribociclib is 197 nM. From <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C, we can see that, compared with ribociclib, compound <b>6e</b> gains another new hydrogen bonding interaction between hydroxamic acid group and Thr-29, which could be used to interpret the phenomena that <b>6e</b> showed a stronger activity against the CDK9 kinase than ribociclib.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Representation of the predicted binding modes of compound <b>6e</b> (purple) and ribociclib (yellow) in the ATP pocket of CDK4, which employed CDK6 (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EZ5">4EZ5</a>) as the template for homology modeling. Dashed lines indicate the H-bond interaction between compounds and CDK4. (B) Predicted binding mode of compound <b>6e</b> (yellow) and vorinostat (green) with HDAC1. The crystal structure of HDAC1 was taken from the RCSB Protein Data Bank (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>). (C) Proposed binding mode of compound <b>6e</b> (orange) and ribociclib (cyan) within the active site of CDK9 (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>). The dashed lines represent the H-bond interaction between compounds and CDK9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In order to illustrate the SARs, more rational, molecular modeling studies are employed to select <b>5c</b> and <b>11b</b> as the best candidate for CDK4 and HDAC1 enzyme inhibition, respectively. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Figure S2</a>. Compared with <b>6e</b>, compound <b>5c</b> gains another new hydrogen bonding interaction with Arg101, which could explain that <b>5c</b> showed a stronger CDK4 inhibition than <b>6e</b> and ribociclib. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Figure S3</a>, the length of the linking section with four carbon atoms between the hydroxamic acid and amide made the structure of compound <b>11b</b> expanded, which led to greater suitability in the active pocket of HDAC1. That may be the reason for the inhibition difference between compounds <b>6e</b> and <b>11b</b>. The SAR findings according to the docking poses coordinate with our SAR results discussed above.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.7.  Effect of Compound <b>6e</b> on Cell Cycle Progression</h3><div class="NLM_p">We therefore wondered whether this cell apoptotic and kinase inhibition effect could partly result from growth arrest induction and cell cycle inhibition. We next investigated the effect of compound <b>6e</b> treatment on breast cancer cell lines (T47D and MDA-MB-231), lung cancer cell lines (A549 and H460), and liver cancer cell lines (HepG2 and Hep3B) cell cycle kinetics (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Cells were treated with compound <b>6e</b> with varying concentration, according to IC<sub>50</sub> values, of ribociclib and vehicle (DMSO) for 24 h, which were stained with propidium iodide and subjected to flow cytometric analysis to determine the distribution of cells in various phases of the cell cycle. Similar effects were observed in three types of cells. Compared to the vehicle-treated cells, cancer cells treated with compound <b>6e</b> demonstrate a loss of S-phase cells and an increase in the percentage of cells in G2 and G0/G1. Ribociclib treatment led to a massive accumulation of cells in G0/G1. It was evident that compound <b>6e</b> blocked the cells in G2 at high dose of 2.5 and 10 μM, while at low dose of 625 nM, it induced an increase in cells in G0/G1 phase, which resulted in decreased S-phase populations. It is well-known that CDK4 plays a critical role in the G1/S transition of the cell cycle. Inhibition of cellular CDK4 activity is expected for cell cycle arrest in the G1 phase. Analyses of our result demonstrated the ability of compound <b>6e</b> to affect the activities of CDK4 in cells and led to support of the hypothesis of a blockage during the G1 phase of compound <b>6e</b> with lower concentration. The effects on G0/G1 phase inhibition are consistent with the inhibition of CDK4. Compound <b>6e</b> blocked both G0/G1 and G2-M transitions. The G2 phase inhibition is indicative of cells undergoing apoptosis.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Additionally, there may be a role for inhibition of CDK9 and HDAC1, which are inhibited by compound <b>6e</b> with similar potency as CDK4. This result indicated that compound <b>6e</b> has cellular HDAC1 or CDK9 inhibitory activity at a higher concentration and a cellular CDK4 inhibitory activity with a lower concentration. The results confirmed that compound <b>6e</b> had antiproliferative properties, suggesting the existence of multi-intracellular targets.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compound <b>6e</b> on cell cycle progression of human tumor cell lines. Compound <b>6e</b> induces G2 arrest in high concentration and induces G1 arrest in low concentration. (A) MDA-MB-231 and T47D cell lines; (B) H460 and A549 cell lines; (C) HepG2 and Hep3B cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.8.  Effect of Compound <b>6e</b> on Cell Apoptosis</h3><div class="NLM_p">The Hoechst 33342 staining was used to verify if compound <b>6e</b> was able to affect cell growth through apoptosis. As shown by representative pictures of T47D (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A), the apoptotic bodies of cells have been investigated and revealed a dose-dependent increase of apoptosis in cell cultures after 48 h of incubation with compound <b>6e</b>, consistent with the effect on cell proliferation. Compound <b>6e</b> generated an increase of the presence of apoptotic cells compared to untreated cells.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>6e</b> induces cell apoptosis in vitro. (A) Hoechst 33342 nuclear staining of T47D cell line, showing the basal level of cells with apoptotic bodies in untreated control (left) and a dose-dependent increase in the number of apoptotic cells after treatment with compound <b>6e</b>. Representative pictures, scale bar 20 μm. (B) Flow cytometry and (C) quantitative analysis of apoptotic cells. Cells were incubated with the indicated concentrations of compound <b>6e</b> or vorinostat for 48 h and were stained with FITC-Annexin V/PI, followed by flow cytometry analysis. Data are expressed as means ± SD of the percentages of apoptotic cells from three independent experiments, ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It was subjected to an apoptotic assay for further evaluation of the antiproliferative activities of our compound against breast, lung, and liver cancer cell lines. Cells were treated with compound <b>6e</b>, vorinostat as reference drug, and vehicle (DMSO) for 48 h, which were analyzed by annexin V/PI staining (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Compound <b>6e</b> induced cell apoptosis in a dose-dependent manner. The percentage of apoptotic cells was defined as the sum of early and late apoptosis (annexin V-positive and PI-positive cells). Compared with the vehicle condition, compound <b>6e</b> was significantly more active in apoptosis induction as the concentration increased. Compound <b>6e</b>-treated T47D, H460, and HepG2 cells exhibited significantly better inhibition. Taken together, compound <b>6e</b> could induce cell death via apoptosis.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.9.  Molecular Mechanisms of Activity for Compound <b>6e</b></h3><div class="NLM_p">As compound <b>6e</b> exhibited clear cell cycle suppression and significant induction of apoptosis, we decided to characterize the cellular effects of compound <b>6e</b> in more detail. To further confirm the CDK inhibitory, we first performed Western blot analysis to evaluate the protein levels of CDK4 inhibition (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Similar results were obtained for six cell types. Compound <b>6e</b> exhibited stronger inhibition of CDK4 enzymes. Treated cells exhibited dose-dependent reductions in the level of the protein CDK4 and cyclinD1, which is consistent with the known mechanisms of action for CDK4 inhibitors. Compound suppressed CDK4 at 1 μM in cells, which is in accord with the IC<sub>50</sub> value in cell viability assays. To evaluate if the antiproliferative activity of compound <b>6e</b> is caused by inhibition of cellular CDK4 and CDK9, we selected inhibition of Rb phosphorylation at the CDK-specific sites Ser807/811. The results of this study (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) show that compound <b>6e</b> effectively suppressed phosphorylation of Rb Ser807/811 at 1 μM, confirming that CDK is one target of this compound. The intracellular histone acetylation status is a direct marker of class I HDAC1 inhibition. To further investigate whether the dual enzyme inhibition profile of compound <b>6e</b> translates into intracellular inhibition against HDAC1 pathway, we performed Western blot analysis to study the effect of compound <b>6e</b> in the six cell line types. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, compound <b>6e</b> affected the acetyl-histone H3 expression level, resulting in upregulation of acetyl-histone H3, especially in breast cancer cell lines and lung cancer cell lines. In liver cancer cell line, the assay showed that compound <b>6e</b> showed a similar level of acetyl-histone H3 with vorinostat.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Western blotting analysis for inhibition of (A) CDK4 and (B) histone acetylation pathway. Breast cell lines (MDA-MB-231 and T47D), lung cancer cell lines (H460 and A549), and liver cancer cell lines (HepG2 and Hep3B) were treated with 1 and 5 μM compound <b>6e</b> and vorinostat for 48 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As illustrated in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B, to confirm further the apoptosis induction of compound <b>6e</b>, we examined the expression of apoptotic proteins Bcl-2 and the cleavage states of caspase 3. Cells were treated with or without compound <b>6e</b> and control for 48 h and then lysed and analyzed by Western blot. It was revealed that treatment with compound <b>6e</b> dramatically increased the relative levels of antiapoptotic Bcl-2 expression in a dose-dependent manner. Furthermore, compound <b>6e</b> resulted in more significant cleavaged caspase 3 to different extents than the control group. Additionally, the inhibition of both HDAC1 and transcriptional CDK9 might also induce cell death through the down-regulation of these short-lived antiapoptotic proteins Bcl-2. This implies that compound <b>6e</b> may induce cell death by both transcriptional and HDAC1 repression. It is well-known that phosphorylation of p53 results in DNA damage induced by treatment with HDAC1 inhibitors. Next, we wanted to detected whether compound <b>6e</b>-induced apoptosis depends on the expression of p53. Protein level of P-p53 detected by Western blot was enhanced in compound <b>6e</b>-treated cells with respect to control groups. This finding led to the conclusion that compound <b>6e</b>-induced apoptosis is associated with p53 phosphorylation.</div><div class="NLM_p">The above results re-emphasized that compound <b>6e</b> inhibits CDK4/9 and HDAC1 activity and is efficient in cultured breast cancer cells, lung cancer cells , and liver cancer cells. The correlation between the suppression of CDK4, Rb phosphorylation, and onset of apoptosis suggests that the mechanism of action of compound <b>6e</b>, in these six cancer cell lines, proceed through inhibition of CDK and HDAC1 critical.</div><div class="NLM_p">Immunofluorescence (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) were carried out to demonstrate the inhibitory activity of compound <b>6e</b> on CDK4 and deacetylation of histone H3. A549 cell line has been selected as a representative model because it resulted as being nearly the most sensitive to the compound <b>6e</b> antiproliferative effect. It was demonstrated above that compound <b>6e</b> induced an increase in cells in G0/G1 phase at low concentration, which is consistent with the inhibition of CDK4. The 100 nM concentration and 1 μM concentrations of compound <b>6e</b> were chosen and used in the immunofluorescence assay to detect the effect on CDK4 and acetyl-histone H3, respectively. After 24 h of treatment with compound <b>6e</b> and vehicle condition, a significant inhibition of CDK4 and increase of acetylation, observable staining of CDK4 and acetyl-histone H3, were detected by immunofluorescence analysis (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Immunofluorescence staining of (A) CDK4 in untreated cells (control, upper panel) or treated with compound <b>6e</b> (lower panel) at 100 nM and (B) acetyl-histone H3 in untreated cells (control, upper panel) or treated with compound <b>6e</b> (lower panel) at 1 μM. Nuclei were counterstained with DAPI. The merged images are shown in the right column. Representative images, scale bar is 10 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.10.  Lipophilicity</h3><div class="NLM_p last">LogP and LogD describe a compound’s lipophilicity, and values often correlate with a number of key biopharmaceutical parameters in drug discovery. We detected the experimental LogP and LogD<sub>7.4</sub> values and calculated LogP (cLogP) value for compound <b>6e</b>. The values were measured using the traditional shake flask method. LogP value for <b>6e</b> is 2.62, and LogD<sub>7.4</sub> value is 2.02. Using ChemDraw Ultra 12 software, the cLogP for the virtual compound <b>6e</b> is 2.08. Our results indicated that compound <b>6e</b> has a reasonable lipophilicity. We also detected the solubility of <b>6e</b>. The solubility of <b>6e</b> in PBS at pH 7.4 is 0.35 μg/mL, and in the methanesulfonic acid formulation, 526 μg/mL. Methanesulfonic acid formulation is compound <b>6e</b> combined with one equiv of methanesulfonic acid. As the solubility of compound <b>6e</b> in other acid formulation was not good, data were not shown. Despite its limited solubility, <b>6e</b> exhibited good lipophilicity.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">2.11.  Pharmacokinetic Properties of <b>6e</b> in Rats</h3><div class="NLM_p">Considering the excellent antitumor activities of compounds <b>6e</b> both in vitro and in vivo, pharmacokinetic (PK) properties of these compound was further evaluated. Key PK parameters are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. After iv administration of 20 mg/kg compound <b>6e</b>, the area under the concentration–time curve (AUC<sub>0–∞</sub>) was about 6158 μg/L·h, and the half-life (<i>t</i><sub>1/2</sub>) was about 10.76 h. After ip administration of 20 mg/kg compound <b>6e</b>, the area under the concentration–time curve (AUC<sub>0–∞</sub>) was about 2133.7 μg/L·h, and the half-life (<i>t</i><sub>1/2</sub>) was about 9.65 h. In addition, after ip compound <b>6e</b> achieved a maximum plasma concentration (<i>C</i><sub>m</sub><sub>a</sub><sub>x</sub>) of 359.6 μg/L, it showed a clearance rate (CL) of 12.61 L/h/kg and apparent distribution volume (Vss) of 119.94 L/kg. When administered 20 mg/kg compound <b>6e</b> orally, the area under the concentration–time curve (AUC<sub>0–∞</sub>) was about 1130.6 μg/L·h, and the half-life (<i>t</i><sub>1/2</sub>) was about 14.91 h. After op compound <b>6e</b> achieved a maximum plasma concentration (<i>C</i><sub>m</sub><sub>a</sub><sub>x</sub>) of 136.8 μg/L, it showed a clearance rate (CL) of 20.62 L/h/kg and apparent distribution volume (Vss) of 431.52 L/kg. All of these indicated that compound <b>6e</b> has moderate PK properties.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pharmacokinetic Characteristics of Compound <b>6e</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">iv (20 mg/kg)</th><th class="colsep0 rowsep0" align="center">ip (20 mg/kg)</th><th class="colsep0 rowsep0" align="center">po (20 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-∞</sub> (μg/L·h)</td><td class="colsep0 rowsep0" align="center">6158</td><td class="colsep0 rowsep0" align="center">2133.7</td><td class="colsep0 rowsep0" align="center">1130.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/L)</td><td class="colsep0 rowsep0" align="center">3853</td><td class="colsep0 rowsep0" align="center">359.8</td><td class="colsep0 rowsep0" align="center">136.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">0.262</td><td class="colsep0 rowsep0" align="center">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">34.7</td><td class="colsep0 rowsep0" align="center">18.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0-∞</sub> (h)</td><td class="colsep0 rowsep0" align="center">14.07</td><td class="colsep0 rowsep0" align="center">13.75</td><td class="colsep0 rowsep0" align="center">20.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="center">48.99</td><td class="colsep0 rowsep0" align="center">119.94</td><td class="colsep0 rowsep0" align="center">431.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="center">4.14</td><td class="colsep0 rowsep0" align="center">12.61</td><td class="colsep0 rowsep0" align="center">20.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">10.76</td><td class="colsep0 rowsep0" align="center">9.65</td><td class="colsep0 rowsep0" align="center">14.91</td></tr></tbody></table></div></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">2.12.  In Vivo Anticancer Activity of Compound <b>6e</b></h3><div class="NLM_p">We next carried out studies to determine the maximum tolerated dose of compound <b>6e</b> in mice. BALB/c female mice (<i>n</i> = 4) received different doses (45, 90, and 130 mg/kg) of compound <b>6e</b> intraperitoneally for 16 consecutive days and were monitored over signs of toxicity (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). No signs of toxicity or weight loss were observed. 4T1 cells were labeled with a reporter system encoding of firefly luciferase (Fluc) by lentiviral transduction. To determine the efficacy of compound <b>6e</b> in vivo using tumor xenograft models, Fluc-4T1 cells were orthotopically implanted into the mammary fat pads of 6–8 week old female BALB/c mice. Once the tumors reached an average volume of 100 mm<sup>3</sup>, compound <b>6e</b> was administered daily via IP injection based on the toxicity results and literature.<a onclick="showRef(event, 'ref14 ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref14 ref56 ref57 ref58">(14,56−58)</a> The bioluminescence imaging was performed on the representative animals at 8 days and 25 days for Fluc reporter gene expression to reflect the number of viable tumor cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). The tumor treated with compound <b>6e</b> therapy demonstrated a great decrease in the strength of Fluc signal, which suggested a considerable extent of tumor inhibition. Quantitative analysis of bioluminescence imaging signals at day 25 demonstrated that compound <b>6e</b> showed significantly better inhibition (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). The results of this study (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D) showed that compound <b>6e</b> administered on this schedule led to a dose-dependent inhibition of tumor growth. Tumor growth inhibitions of 78.4% and 84.8% were observed at doses of 90 and 130 mg/kg, respectively. In contrast, vorinostat and ribociclib as the positive controls were less potent (76.8% and 68.5%) than <b>6e</b> at the same dose, respectively. As positive controls, 130 mg/kg vorinostat and ribociclib showed weaker antitumor activities compared with that of the compound <b>6e</b>. A decrease in tumor weight was also observed at the end-point of the study (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E). No overt signs of toxicity were observed in the <b>6e</b> treated groups (body weights was not shown), indicating that compound <b>6e</b> is well-tolerated in vivo. Administration of compound <b>6e</b> by oral gavage was also effective. IHC staining showed that the expression level of p-Rb and Bcl-2 was suppressed in <b>6e</b> treatment groups (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Tumor growth inhibitions of 70.3% and 79.3% were observed in the 4T1 model at doses of 90 and 130 mg/kg, respectively. In contrast, vorinostat and ribociclib as the positive controls were less potent (75.6% and 38.9%) than <b>6e</b> at the same dose, respectively. Compound <b>6e</b> exhibited potent activity in vivo after both intraperitoneal and oral administration. Intraperitoneal administration showed a high antitumor efficacy compared with oral administration at the same doses, which coordinate with our bioavailability results as shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo antitumor efficacy of compound <b>6e</b> against 4T1 tumor xenograft models with IP administration. (A) Effects of compound <b>6e</b>, ribociclib, and vorinostat on toxicity and animal survival. (B) Representative animals injected with 5 × 10<sup>4</sup> Fluc-4T1 shows significant bioluminescence activity at day 8 and day 25. (C) Quantitative analysis of tumor inhibitory responses by bioluminescence imaging signals at day 25 demonstrated that compound <b>6e</b> showed significantly better inhibitory. (D,E) Tumor volumes were recorded. Animals were treated with solvent control, compound <b>6e</b> at doses of 90 and 130 mg/kg/day, and ribociclib and vorinostat at a dose of 130 mg/kg/day through IP injection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo antitumor efficacy of compound <b>6e</b> against 4T1 tumor xenograft models with oral administration. (A) Antitumor efficacy of <b>6e</b>, ribociclib, and vorinostat treated 4T1 xenograft tumor. (B) Average body weights for <b>6e</b>, ribociclib, and vorinostat treated mice groups. (C) p-Rb and Bcl-2 staining of tumor tissues showing the down-regulation in <b>6e</b> groups compared to other groups. Scale bar, 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through designing and structural optimization targeting on CDK4 and HDAC1, we finally discovered a new compound, <b>6e</b>. Compound <b>6e</b> is a multikinase inhibitor, which potently inhibited CDK4, CDK9, and HDAC1 with IC<sub>50</sub> values of 8.8, 9, and 2.2 nM, respectively. Compound <b>6e</b> also inhibited several kinases, such as the Aurora-A/B/C, Flt4, LIMK1, and TrkA, with IC<sub>50</sub> < 50 nmol/L. Even so, it is not a promiscuous agent and showed good selectivity in a kinase profiling assay against 375 kinases. In in vitro cellular assays, <b>6e</b> showed potent activities against breast cancer cell lines, T47D and MDA-MB-231 (triple negative breast cancer cell line), lung cancer cell lines, A549 and H460, and liver cancer cell lines, HepG2 and Hep3B. In cell cycle assays, compound <b>6e</b> could block the six tumor cells mentioned above in G2 at high doses of 2.5 and 10 μM, while at a low dose of 625 nM, it induces an increase in cells in G0/G1 phase, which resulted in decreased S-phase populations. The effect on the cell cycle progression confirmed that compound <b>6e</b> has cellular HDAC1 or CDK9 inhibitory activity at a higher concentration and a cellular CDK4 inhibitory activity with a lower concentration. In vivo antitumor activity assays showed that intraperitoneal and oral administration of compound <b>6e</b> led to potent tumor regression in the 4T1 xenograft models. Studies of mechanisms of action indicated that <b>6e</b> down-regulated the activity of CDK4 and cyclinD1 kinase and the phosphorylation of protein Rb. In addition, <b>6e</b> significantly upregulated acetyl-histone H3 and the relative levels of antiapoptotic Bcl-2 expression and cleaved-caspase-3. Compound <b>6e</b> also enhanced the protein level of P-p53, which led to the conclusion that compound <b>6e</b>-induced apoptosis is associated with DNA damage. All of the studies presented here support <b>6e</b> as a novel drug candidate targeting on CDK4/9 and HDAC1 and deserve further research and development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">4.1.  Chemistry Methods</h3><div class="NLM_p">All reagents and solvents were obtained from commercial suppliers and used without further purification unless otherwise indicated. Melting points (mp) were taken in open capillaries on a Mettler MP 50 melting-point system. All reactions were monitored by thin-layer chromatography (TLC), and silica gel plates with fluorescence F-254 were used and visualized with UV light. <sup>1</sup>H NMR (400 MHz) and <sup>13</sup>C NMR (101 MHz) spectra were taken on a Bruker AV-400 MHz spectrometer, and chemical shifts were reported in ppm downfield from internal Me<sub>4</sub>Si. High-resolution mass spectra (HRMS) were recorded on a VG ZAB-HS mass spectrometer under electron spray ionization (ESI). All of the solvents were purified and distilled according to the standard procedure. The commercially obtained materials were used directly without further purification unless otherwise noted. All of the final compounds were purified to >95% purity, as determined by high-performance liquid chromatography (HPLC). The purity was found by HPLC analysis on a Shimadzu Prominence-i LC-2030C 3D system (column, InertSustain C18, 4.6 mm × 250 mm, 5 μM; mobile phase, gradient elution of methanol/H<sub>2</sub>O; low rate, 1.0 mL/min; UV wavelength, 190–800 nm; temperature, 40 °C; injection volume, 10 μL). <sup>1</sup>H and <sup>13</sup>C spectra of test compounds are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure for the Synthesis of <b>3a–3f</b></h4><div class="NLM_p">A mixture of acid <b>1a</b>–<b>1d</b> (30 mmol, 1 equiv), amine <b>2b</b>–<b>2c</b> (60 mmol, 2 equiv), EDCI (8.27 g, 45 mmol, 1.5 equiv), HOBt (4.87 g, 36 mmol, 1.2 equiv), and DIEA (7.76 g, 60 mmol, 2 equiv) was stirred in DMF (60 mL) at room temperature for 12 h. After completion of the reaction, the mixture was quenched by water and extracted by ethyl acetate. The combined organic layer was washed with brine solution and dried by MgSO<sub>4</sub>. The solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 98:2) to yield the desired aniline reagents <b>3a</b>–<b>3f</b>.</div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27">4.1.1.  Methyl 8-((2-Aminophenyl)amino)-8-oxooctanoate (<b>3a</b>)</h5><div class="NLM_p last">Light-brown solid; 69% yield; mp 81.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.40 (d, <i>J</i> = 12.0 Hz, 1H), 7.19–7.12 (m, 1H), 7.04 (td, <i>J</i> = 7.7, 1.4 Hz, 1H), 6.81–6.73 (m, 2H), 3.66 (s, 3H), 2.39–2.27 (m, 4H), 1.77–1.57 (m, 4H), 1.43–1.29 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.26, 171.85, 140.74, 127.14, 125.27, 124.40, 119.54, 118.23, 51.53, 36.78, 33.95, 28.81, 28.74, 25.56, 24.70. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 279.1703, found 279.1703 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28">4.1.2.  Methyl 8-((3-Aminophenyl)amino)-8-oxooctanoate (<b>3b</b>)</h5><div class="NLM_p last">Yellow oil; 78% yield; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.52–7.41 (m, 1H), 7.17 (t, <i>J</i> = 2.2 Hz, 1H), 7.04 (t, <i>J</i> = 8.0 Hz, 1H), 6.67 (dd, <i>J</i> = 7.9, 2.1 Hz, 1H), 6.40 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 3.65 (s, 3H), 2.32–2.26 (m, 4H), 1.65 (dt, <i>J</i> = 30.0, 7.1 Hz, 4H), 1.40–1.28 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.31, 171.42, 147.22, 139.08, 129.63, 110.90, 109.63, 106.56, 51.53, 37.63, 33.96, 28.78, 28.76, 25.38, 24.71. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 279.1703, found 279.1705 [M + H]<sup>+</sup>. HPLC purity 96%.</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29">4.1.3.  Methyl 6-((4-Aminophenyl)amino)-6-oxohexanoate (<b>3c</b>)</h5><div class="NLM_p last">Gray solid; 39% yield; mp 70.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.26–7.20 (m, 2H), 6.59 (dt, <i>J</i> = 8.8, 2.0 Hz, 2H), 3.65 (s, 3H), 2.35–2.23 (m, 4H), 1.74–1.61 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.14, 170.90, 143.28, 129.35, 122.14, 115.34, 51.63, 36.86, 33.71, 25.08, 24.39. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 251.1390, found 251.1390 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30">4.1.4.  Methyl 7-((4-Aminophenyl)amino)-7-oxoheptanoate (<b>3d</b>)</h5><div class="NLM_p last">Gray solid; 77% yield; mp 80.3 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.26–7.19 (m, 2H), 6.62–6.54 (m, 2H), 3.63 (s, 3H), 3.57 (br, 2H), 2.33–2.21 (m, 4H), 1.74–1.55 (m, 4H), 1.39–1.29 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.28, 171.23, 143.18, 129.42, 122.08, 115.37, 51.56, 37.05, 33.84, 28.65, 25.32, 24.55. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 265.1547, found 265.1546 [M + H]<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31">4.1.5.  Methyl 8-((4-Aminophenyl)amino)-8-oxooctanoate (<b>3e</b>)</h5><div class="NLM_p last">Off-white solid; 63% yield; mp 77.6 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.42 (s, 1H), 7.19 (d, <i>J</i> = 8.5 Hz, 2H), 6.47 (d, <i>J</i> = 8.5 Hz, 2H), 4.82 (s, 2H), 3.57 (s, 3H), 2.29 (t, <i>J</i> = 7.4 Hz, 2H), 2.19 (t, <i>J</i> = 7.4 Hz, 2H), 1.53 (h, <i>J</i> = 7.4 Hz, 4H), 1.35–1.19 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.82, 170.64, 144.98, 129.04, 121.31, 114.22, 51.62, 36.60, 33.69, 28.83, 28.72, 25.61, 24.80. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 279.1703, found 279.1704 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32">4.1.6.  Methyl 9-((4-Aminophenyl)amino)-9-oxononanoate (<b>3f</b>)</h5><div class="NLM_p last">Reddish solid; 80% yield; mp 93.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.23 (d, <i>J</i> = 8.2 Hz, 2H), 6.57 (d, <i>J</i> = 7.4 Hz, 2H), 3.63 (s, 3H), 2.31–2.19 (m, 4H), 1.68–1.50 (m, 4H), 1.34–1.24 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.41, 171.45, 143.20, 129.46, 122.02, 115.31, 51.52, 37.37, 34.03, 29.03, 28.97, 28.92, 25.67, 24.85. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 293.1860, found 293.1861 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Procedure for the Synthesis of <b>5a–5f</b></h4><div class="NLM_p">To a suspension of 2-chloro-7-cyclopentyl-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>4</b>) (586 mg, 2 mmol, 1 equiv) in 20 mL of 1,4-dioxane was added compound <b>3a</b>–<b>3f</b> (2 mmol, 1 equiv), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol, 0.25 equiv), BINAP (62 mg, 0.1 mmol, 0.05 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol, 2.1 equiv), and the flask was purged with N<sub>2</sub>. Then the flask was sealed, and the mixture was heated for 12 h at 100 °C. The reaction was cooled to room temperature, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 96:4) to obtain the desired product <b>5a</b>–<b>5f</b>.</div><div id="sec4_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34">4.1.7.  Methyl 8-((2-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoate (<b>5a</b>)</h5><div class="NLM_p last">White solid; 83% yield; mp 52.1 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.59 (s, 1H), 8.10 (s, 1H), 7.85–7.79 (m, 1H), 7.65–7.57 (m, 1H), 7.38 (s, 1H), 7.15 (dq, <i>J</i> = 6.8, 4.1, 2.6 Hz, 2H), 6.38 (s, 1H), 4.78–4.61 (m, 1H), 3.63 (s, 3H), 3.12 (s, 6H), 2.36–2.19 (m, 6H), 2.02–1.91 (m, 2H), 1.88–1.76 (m, 2H), 1.70–1.46 (m, 6H), 1.36–1.20 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.19, 171.76, 164.71, 163.98, 156.81, 152.36, 151.77, 132.08, 131.84, 131.74, 125.19, 124.63, 124.08, 112.52, 100.86, 57.62, 51.45, 37.35, 33.95, 30.61, 28.79, 28.74, 25.39, 24.86, 24.69. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 535.3027, found 535.3030 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35">4.1.8.  Methyl 8-((3-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoate (<b>5b</b>)</h5><div class="NLM_p last">White solid; 84% yield; mp 128.5 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.63 (s, 1H), 7.83 (s, 1H), 7.56–7.45 (m, 3H), 7.23 (t, <i>J</i> = 8.1 Hz, 1H), 7.16 (d, <i>J</i> = 8.1 Hz, 1H), 6.40 (s, 1H), 4.91–4.70 (m,1H), 3.64 (s, 3H), 3.13 (s, 6H), 2.60–2.45 (m, 2H), 2.36–2.24 (m, 4H), 2.11–1.92 (m, 4H), 1.76–1.55 (m, 6H), 1.42–1.28 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.24, 171.26, 164.16, 155.40, 152.09, 151.57, 140.75, 138.57, 131.88, 129.18, 114.52, 113.27, 112.39, 110.05, 101.00, 57.73, 51.50, 37.58, 33.97, 30.26, 28.82, 28.79, 25.34, 24.71, 24.69. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 535.3027, found 535.3030 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div><div id="sec4_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">4.1.9.  Methyl 6-((4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)amino)-6-oxohexanoate (<b>5c</b>)</h5><div class="NLM_p last">White solid; 89% yield; mp 164.9 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.51 (s, 1H), 8.20 (s, 1H), 7.96 (s, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (d, <i>J</i> = 8.0 Hz, 2H), 6.29 (s, 1H), 4.64 (q, <i>J</i> = 8.8 Hz, 1H), 3.63 (s, 3H), 3.11 (s, 6H), 2.57–2.46 (m, 2H), 2.33 (t, <i>J</i> = 6.7 Hz, 4H), 2.04–1.91 (m, 4H), 1.78–1.57 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.04, 170.89, 164.46, 155.43, 151.97, 151.48, 136.69, 131.95, 131.42, 120.99, 118.87, 112.02, 100.88, 57.99, 51.58, 36.87, 33.74, 30.07, 25.10, 24.60, 24.44. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 507.2714, found 507.2714 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37">4.1.10.  Methyl 7-((4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)amino)-7-oxoheptanoate (<b>5d</b>)</h5><div class="NLM_p last">White solid; 73% yield; mp 151.7 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.54 (s, 1H), 8.07 (s, 1H), 7.82 (s, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 2H), 7.30 (d, <i>J</i> = 8.4 Hz, 2H), 6.32 (s, 1H), 4.66 (p, <i>J</i> = 8.9 Hz, 1H), 3.64 (s, 3H), 3.13 (s, 6H), 2.59–2.44 (m, 2H), 2.35–2.27 (m, 4H), 2.03–1.96 (m, 4H), 1.76–1.63 (m, 6H), 1.47–1.32 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.19, 171.19, 164.40, 155.47, 151.99, 151.56, 136.65, 132.03, 131.46, 120.87, 118.90, 112.06, 100.91, 57.97, 51.52, 37.10, 33.84, 30.08, 28.70, 25.29, 24.61, 24.57. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>37</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 521.2871, found 521.2872 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38">4.1.11.  Methyl 8-((4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoate (<b>5e</b>)</h5><div class="NLM_p last">White solid; 82% yield; mp 171.0 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.57 (s, 1H), 7.77 (s, 1H), 7.65–7.53 (m, 3H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 6.36 (s, 1H), 4.70 (p, <i>J</i> = 8.9 Hz, 1H), 3.65 (s, 3H), 3.14 (s, 6H), 2.55 (t, <i>J</i> = 10.7 Hz, 2H), 2.31 (dt, <i>J</i> = 11.1, 7.5 Hz, 5H), 2.08–1.93 (m, 5H), 1.77–1.57 (m, 4H), 1.36 (dq, <i>J</i> = 8.6, 4.5 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.76, 171.13, 163.38, 156.04, 152.52, 151.74, 136.78, 133.41, 131.79, 119.80, 118.91, 111.73, 101.18, 57.41, 51.58, 36.71, 35.03, 33.68, 30.03, 28.84, 28.72, 25.49, 24.79, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 535.3027, found 535.3031 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39">4.1.12.  Methyl 9-((4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)amino)-9-oxononanoate (<b>5f</b>)</h5><div class="NLM_p last">White solid; 73% yield; mp 139.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.58 (s, 1H), 7.68 (s, 1H), 7.59 (d, <i>J</i> = 8.5 Hz, 2H), 7.54 (s, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 2H), 6.37 (s, 1H), 4.71 (t, <i>J</i> = 8.9 Hz, 1H), 3.65 (s, 3H), 3.14 (s, 6H), 2.69–2.41 (m, 2H), 2.40–2.24 (m, 4H), 2.11–1.95 (m, 4H), 1.80–1.51 (m, 6H), 1.42–1.24 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.34, 171.30, 164.30, 155.44, 152.09, 151.49, 136.57, 132.22, 131.70, 120.75, 119.05, 112.18, 100.99, 57.99, 51.51, 37.54, 34.07, 30.16, 29.09, 29.00, 28.96, 25.61, 24.89, 24.67. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>41</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 549.3184, found 549.3179 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure for the Synthesis of <b>6a–6f</b></h4><div class="NLM_p">To a stirred solution of the compound <b>5a</b>–<b>f</b> (1 mmol,) in methanol (20 mL) was added a solution of hydroxylamine (50% in water, 5.5 mL). The resulting solution was stirred for 18 h under reflux. Then the solvent was removed under vacuum, and the crude residue was purified by chromatography on a silica gel column (dichloromethane–methanol, gradient 100:0 → 90:10) to obtain the desired hydroxamic acids <b>6a</b>–<b>6f</b>.</div><div id="sec4_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41">4.1.13.  <i>N</i>1-(2-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>6a</b>)</h5><div class="NLM_p last">White solid; 62% yield; mp 166.9 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 8.71 (s, 1H), 8.37 (s, 1H), 7.99 (d, <i>J</i> = 8.1 Hz, 1H), 7.39 (d, <i>J</i> = 7.9 Hz, 1H), 7.23–7.12 (m, 1H), 7.04 (t, <i>J</i> = 7.6 Hz, 1H), 6.56 (s, 1H), 4.67 (p, <i>J</i> = 8.7 Hz, 1H), 3.04 (s, 6H), 2.50 (t, <i>J</i> = 2.0 Hz, 1H), 2.41–2.22 (m, 4H), 1.92 (t, <i>J</i> = 7.3 Hz, 4H), 1.86–1.78 (m, 2H), 1.64–1.40 (m, 6H), 1.34–1.20 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.44, 169.48, 163.33, 156.20, 152.67, 151.74, 133.77, 132.12, 129.65, 125.37, 123.31, 123.17, 112.33, 100.97, 57.11, 36.30, 35.05, 32.72, 30.53, 28.89, 28.79, 25.70, 25.51, 24.95. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 536.2980, found 536.2985 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42">4.1.14.  <i>N</i>1-(3-((7-cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>6b</b>)</h5><div class="NLM_p last">White solid; 49% yield; mp 176.2 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.78 (s, 1H), 9.48 (s, 1H), 8.73 (s, 1H), 8.69 (s, 1H), 8.08 (s, 1H), 7.54–7.43 (m, 1H), 7.17 (t, <i>J</i> = 8.0 Hz, 1H), 7.07 (d, <i>J</i> = 8.0 Hz, 1H), 6.57 (s, 1H), 4.86 (p, <i>J</i> = 8.9 Hz, 1H), 3.14–2.96 (m, 6H), 2.41–2.24 (m, 4H), 2.01–1.81 (m, 6H), 1.67–1.53 (m, 4H), 1.48 (q, <i>J</i> = 7.1 Hz, 2H), 1.35–1.19 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.41, 169.54, 163.53, 156.14, 152.38, 151.85, 141.60, 139.81, 131.86, 128.70, 114.17, 113.01, 111.81, 110.66, 101.13, 56.88, 36.79, 32.72, 30.38, 28.95, 28.93, 25.53, 24.67. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 536.2980, found 536.2988 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div><div id="sec4_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43">4.1.15.  <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>6-hydroxyadipamide (<b>6c</b>)</h5><div class="NLM_p last">White solid; 48% yield; mp 211.9 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 9.77 (s, 1H), 9.45 (s, 1H), 8.78–8.63 (m, 2H), 7.74 (d, <i>J</i> = 8.5 Hz, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 6.57 (s, 1H), 4.72 (t, <i>J</i> = 8.8 Hz, 1H), 3.05 (s, 6H), 2.49–2.40 (m, 2H), 2.33–2.22 (m, 2H), 2.04–1.89 (m, 6H), 1.72–1.61 (m, 2H), 1.60–1.46 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.66, 169.11, 163.06, 155.71, 152.24, 151.41, 136.47, 133.05, 131.51, 119.49, 118.61, 111.42, 100.85, 57.07, 36.25, 34.75, 32.34, 29.71, 25.07, 24.33. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 508.2667, found 508.2671 [M + H]<sup>+</sup>. HPLC purity 96%.</div></div><div id="sec4_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44">4.1.16.  <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>7-hydroxyheptanediamide (<b>6d</b>)</h5><div class="NLM_p last">White solid; 57% yield; mp 180.7 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.76 (s, 1H), 9.46 (s, 1H), 8.72 (s, 1H), 8.71–8.67 (m, 1H), 7.74 (d, <i>J</i> = 8.8 Hz, 2H), 7.51 (d, <i>J</i> = 8.7 Hz, 2H), 6.56 (s, 1H), 4.72 (p, <i>J</i> = 8.9 Hz, 1H), 3.16–2.95 (m, 6H), 2.49–2.39 (m, 2H), 2.27 (t, <i>J</i> = 7.3 Hz, 2H), 2.03–1.88 (m, 6H), 1.72–1.46 (m, 6H), 1.34–1.21 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.08, 169.51, 163.37, 156.02, 152.56, 151.72, 136.76, 133.39, 131.81, 119.78, 118.91, 111.73, 101.19, 57.39, 36.63, 32.63, 30.03, 28.76, 25.43, 25.39, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>36</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 522.2823, found 522.2825 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45">4.1.17.  <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>6e</b>)</h5><div class="NLM_p last">White solid; 76% yield; mp 182.7 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 9.73 (s, 1H), 9.42 (s, 1H), 8.71 (s, 1H), 8.66 (s, 1H), 7.79–7.65 (m, 2H), 7.58–7.46 (m, 2H), 6.56 (s, 1H), 4.80–4.62 (m, 1H), 3.05 (s, 6H), 2.50–2.39 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 2.03–1.89 (m, 6H), 1.70–1.45 (m, 6H), 1.35–1.22 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.15, 169.57, 163.42, 156.05, 152.53, 151.76, 136.77, 133.41, 131.86, 119.83, 118.96, 111.75, 101.15, 57.40, 36.75, 32.73, 30.05, 28.94, 28.89, 25.57, 25.52, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 536.2980, found 536.2985 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46">4.1.18.  <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo [2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>9-hydroxynonanediamide (<b>6f</b>)</h5><div class="NLM_p last">White solid; 49% yield; mp 185.5 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.75 (s, 1H), 9.46 (s, 1H), 8.71 (s, 1H), 8.69 (s, 1H), 7.74 (d, <i>J</i> = 8.5 Hz, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 6.56 (s, 1H), 4.72 (p, <i>J</i> = 8.9 Hz, 1H), 3.05 (t, <i>J</i> = 6.8 Hz, 6H), 2.49–2.40 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 2.05–1.87 (m, 6H), 1.69–1.42 (m, 6H), 1.33–1.18 (m, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.18, 169.58, 163.38, 156.02, 152.55, 151.72, 136.76, 133.40, 131.81, 119.80, 118.93, 111.73, 101.19, 65.38, 57.39, 36.78, 32.72, 30.03, 29.10, 29.02, 28.95, 25.64, 25.58, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 550.3136, found 550.3141 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> General Procedure for the Synthesis of <b>9a–9d</b></h4><div class="NLM_p">The title compound was prepared from <b>7a</b>–<b>7d</b> (14.6 mmol, 1 equiv), 4-aminobenzoic acid (<b>8</b>) (2 g, 14.6 mmol, 1 equiv), EDCI (4.2 g, 21.9 mmol, 1.5 equiv), HOBt (2.37 g, 17.52 mmol, 1.2 equiv), DIEA (5.06 g, 43.8 mmol, 3 equiv), and DMF (30 mL) using the procedure described for compounds <b>3a</b>–<b>3f</b> to obtain the desired products <b>9a</b>–<b>9d</b>.</div><div id="sec4_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48">4.1.19.  Methyl 5-(4-Aminobenzamido)pentanoate (<b>9a</b>)</h5><div class="NLM_p last">Light-brown oil; 63% yield; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.66–7.56 (m, 2H), 6.69–6.61 (m, 2H), 6.21 (s, 1H), 3.66 (s, 3H), 3.41 (q, <i>J</i> = 6.6 Hz, 2H), 2.36 (t, <i>J</i> = 7.1 Hz, 2H), 1.76–1.52 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.10, 167.28, 149.44, 128.60, 124.22, 114.17, 51.63, 39.34, 33.53, 29.15, 22.12. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 251.1390, found 251.1395 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49">4.1.20.  Methyl 6-(4-Aminobenzamido)hexanoate (<b>9b</b>)</h5><div class="NLM_p last">Light-brown solid; 66% yield; mp 118.3 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97 (t, <i>J</i> = 5.5 Hz, 1H), 7.67–7.48 (m, 2H), 6.62–6.47 (m, 2H), 5.57 (s, 2H), 3.57 (s, 3H), 3.18 (q, <i>J</i> = 6.6 Hz, 2H), 2.29 (t, <i>J</i> = 7.2 Hz, 2H), 1.50 (dp, <i>J</i> = 23.1, 7.5 Hz, 4H), 1.28 (td, <i>J</i> = 8.6, 4.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.30, 166.08, 151.39, 128.57, 121.40, 112.46, 51.11, 38.71, 33.20, 29.03, 25.94, 24.20. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 265.1547, found 265.1550 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50">4.1.21.  Methyl 7-(4-Aminobenzamido)heptanoate (<b>9c</b>)</h5><div class="NLM_p last">Light-brown solid; 87% yield; mp 95.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.57 (dd, <i>J</i> = 8.5, 2.4 Hz, 2H), 6.72–6.49 (m, 2H), 6.40–6.05 (m, 1H), 4.03 (s, 2H), 3.63 (s, 3H), 3.40–3.27 (m, 2H), 2.35–2.22 (m, 2H), 1.56 (dp, <i>J</i> = 15.5, 7.4 Hz, 4H), 1.41–1.24 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.27, 167.38, 149.62, 128.59, 124.09, 114.09, 51.50, 39.79, 33.96, 29.58, 28.78, 26.61, 24.79. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 279.1703, found 279.1704 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51">4.1.22.  Methyl 8-(4-Aminobenzamido)octanoate (<b>9d</b>)</h5><div class="NLM_p last">Light-brown solid; 73% yield; mp 59.6°p0C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.62–7.55 (m, 2H), 6.63 (dd, <i>J</i> = 8.7, 2.4 Hz, 2H), 3.64 (s, 3H), 3.37 (td, <i>J</i> = 7.2, 5.8 Hz, 2H), 2.28 (t, <i>J</i> = 7.5 Hz, 2H), 1.58 (dt, <i>J</i> = 14.2, 7.2 Hz, 4H), 1.37–1.27 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.31, 167.26, 149.36, 128.56, 124.36, 114.18, 51.49, 39.87, 34.03, 29.73, 29.01, 28.95, 26.80, 24.83. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 293.1860, found 293.1856 [M + H]<sup>+</sup>. HPLC purity 95%.</div></div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure for the Synthesis of <b>10a–10d</b></h4><div class="NLM_p">The title compound was prepared from <b>9a</b>–<b>9d</b> (2 mmol, 1 equiv), compound <b>4</b> (586 mg, 2 mmol, 1 equiv), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol, 0.025 equiv), BINAP (62 mg, 0.1 mmol, 0.05 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol, 2.1 equiv), and 1,4-dioxane (20 mL) using the procedure described for compounds <b>5a</b>–<b>5f</b> to obtain the desired products <b>10a</b>–<b>10d</b>.</div><div id="sec4_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53">4.1.23.  Methyl 5-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamido)pentanoate (<b>10a</b>)</h5><div class="NLM_p last">White solid; 77% yield; mp 195.0 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1H), 8.79 (s, 1H), 8.29 (t, <i>J</i> = 5.7 Hz, 1H), 7.97–7.88 (m, 2H), 7.84–7.73 (m, 2H), 6.61 (s, 1H), 4.86–4.66 (m, 1H), 3.58 (s, 3H), 3.25 (q, <i>J</i> = 6.2 Hz, 2H), 3.06 (s, 6H), 2.50–2.42 (m, 2H), 2.35 (t, <i>J</i> = 6.9 Hz, 2H), 2.07–1.95 (m, 4H), 1.74–1.63 (m, 2H), 1.62–1.48 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.75, 166.17, 163.32, 155.52, 152.53, 151.49, 144.04, 132.53, 128.23, 126.89, 117.36, 112.41, 101.05, 57.51, 51.63, 40.01, 39.10, 33.45, 30.39, 30.11, 29.22, 24.66, 22.48. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 507.2714, found 507.2720 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54">4.1.24.  Methyl 6-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamido)hexanoate (<b>10b</b>)</h5><div class="NLM_p last">White solid; 84% yield; mp 190.1 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.66 (s, 1H), 7.79–7.73 (m, 4H), 7.71 (s, br, 1H), 6.44 (s, 1H), 6.30–6.22 (m, 1H), 4.85–4.67 (m, 1H), 3.65 (s, 3H), 3.46 (q, <i>J</i> = 6.7 Hz, 2H), 3.15 (s, 6H), 2.68–2.49 (m, 2H), 2.33 (t, <i>J</i> = 7.4 Hz, 2H), 2.15–1.98 (m, 4H), 1.80–1.58 (m, 6H), 1.50–1.35 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.14, 167.07, 163.94, 154.73, 151.78, 151.49, 143.09, 132.40, 127.87, 127.27, 117.45, 112.79, 100.89, 58.05, 51.56, 39.71, 33.88, 30.14, 29.42, 26.45, 24.66, 24.49. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>37</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 521.2871, found 521.2873 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55">4.1.25.  Methyl 7-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-2-yl)amino)benzamido)heptanoate (<b>10c</b>)</h5><div class="NLM_p last">White solid; 76% yield; mp 87.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.65 (s, 1H), 7.90 (d, <i>J</i> = 9.5 Hz, 1H), 7.74 (s, 4H), 6.42 (s, 1H), 6.29 (q, <i>J</i> = 5.4 Hz, 1H), 4.83–4.68 (m, 1H), 3.64 (s, 3H), 3.42 (q, <i>J</i> = 6.8 Hz, 2H), 3.14 (s, 6H), 2.64–2.51 (m, 2H), 2.29 (t, <i>J</i> = 7.5 Hz, 2H), 2.10–1.99 (m, 4H), 1.73–1.57 (m, 6H), 1.43–1.29 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.23, 167.11, 163.96, 154.80, 151.76, 151.52, 143.12, 132.33, 127.84, 127.29, 117.46, 112.75, 100.89, 58.04, 51.52, 39.90, 33.96, 30.13, 29.59, 28.79, 26.63, 24.80, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>39</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 535.3027, found 535.3029 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56">4.1.26.  Methyl 8-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzamido)octanoate (<b>10d</b>)</h5><div class="NLM_p last">White solid; 78% yield; mp 166.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.65 (d, <i>J</i> = 3.2 Hz, 1H), 7.82–7.65 (m, 4H), 6.43 (d, <i>J</i> = 4.8 Hz, 1H), 4.91–4.53 (m, 1H), 3.65 (s, 3H), 3.52–3.32 (m, 2H), 3.15 (s, 6H), 2.67–2.50 (m, 2H), 2.36–2.24 (m, 2H), 2.15–1.98 (m, 4H), 1.70 (t, <i>J</i> = 6.1 Hz, 2H), 1.67–1.54 (m, 4H), 1.41–1.25 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.30, 167.09, 163.96, 154.74, 151.78, 151.52, 143.05, 132.40, 127.85, 127.36, 117.46, 112.79, 100.89, 58.04, 51.51, 40.00, 34.03, 30.14, 29.73, 29.03, 28.96, 26.82, 24.83, 24.66. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>41</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 549.3184, found 549.3189 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> General Procedure for the Synthesis of <b>11a–11d</b></h4><div class="NLM_p">The title compound was prepared from <b>10a</b>–<b>10d</b> (2 mmol, 1 equiv), solution of hydroxylamine (50% in water, 10 mL), and CH<sub>3</sub>OH (20 mL) using the procedure described for compounds <b>6a</b>–<b>6f</b> to obtain the desired products <b>11a</b>–<b>11d</b>.</div><div id="sec4_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58">4.1.27.  7-Cyclopentyl-2-((4-((5-(hydroxyamino)-5-oxopentyl)carbamoyl)phenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-<i>7</i>H-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>11a</b>)</h5><div class="NLM_p last">White solid; 62% yield; mp 189.0 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 9.83 (s, 1H), 8.79 (s, 1H), 8.70 (s, 1H), 8.31 (t, <i>J</i> = 5.7 Hz, 1H), 7.92 (d, <i>J</i> = 8.4 Hz, 2H), 7.82 (d, <i>J</i> = 8.5 Hz, 2H), 6.60 (s, 1H), 5.75 (s, 1H), 4.83–4.63 (m, 1H), 3.25 (q, <i>J</i> = 6.2 Hz, 2H), 3.12–2.95 (m, 6H), 2.51–2.43 (m, 2H), 2.10–1.92 (m, 6H), 1.76–1.60 (m, 2H), 1.62–1.43 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.51, 166.16, 163.31, 155.51, 152.54, 151.48, 144.03, 132.51, 128.25, 126.89, 117.35, 112.40, 101.07, 57.51, 55.37, 35.09, 32.54, 30.10, 29.46, 24.66, 23.28. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>34</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 508.2667, found 508.2671 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59">4.1.28.  7-Cyclopentyl-2-((4-((6-(hydroxyamino)-6-oxohexyl)carbamoyl)phenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>11b</b>)</h5><div class="NLM_p last">White solid; 62% yield; mp 94.5 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.84 (s, 1H), 8.79 (s, 1H), 8.69 (s, 1H), 8.30 (t, <i>J</i> = 5.8 Hz, 1H), 7.99–7.76 (m, 4H), 6.61 (s, 1H), 4.75 (p, <i>J</i> = 8.9 Hz, 1H), 3.23 (q, <i>J</i> = 6.7 Hz, 2H), 3.06 (s, 6H), 2.50–2.40 (m, 2H), 2.09–1.88 (m, 6H), 1.77–1.63 (m, 2H), 1.56–1.42 (m, 4H), 1.37–1.23 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.52, 166.10, 163.29, 155.50, 152.56, 151.46, 144.01, 132.49, 128.24, 126.89, 117.32, 112.38, 101.09, 57.50, 35.11, 32.72, 30.09, 29.58, 27.85, 26.64, 25.43, 24.66. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>36</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 522.2823, found 522.2831 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60">4.1.29.  7-Cyclopentyl-2-((4-((7-(hydroxyamino)-7-oxoheptyl)carbamoyl)phenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>11c</b>)</h5><div class="NLM_p last">White solid; 58% yield; mp 112.2 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.85 (s, 1H), 8.79 (s, 1H), 8.29 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (d, <i>J</i> = 8.6 Hz, 2H), 7.81 (d, <i>J</i> = 8.5 Hz, 2H), 6.61 (s, 1H), 4.75 (p, 1H), 3.24 (q, <i>J</i> = 6.7 Hz, 2H), 3.05 (s, 6H), 2.49–2.40 (m, 2H), 2.07–1.97 (m, 4H), 1.94 (t, <i>J</i> = 7.3 Hz, 2H), 1.76–1.60 (m, 2H), 1.57–1.43 (m, 4H), 1.38–1.22 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.55, 166.12, 163.29, 155.50, 152.56, 151.45, 144.00, 132.48, 128.24, 126.91, 117.33, 112.38, 101.09, 57.50, 35.06, 32.71, 30.08, 29.71, 28.85, 26.75, 25.59, 24.98, 24.66. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 536.2980, found 536.2985 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61">4.1.30.  7-Cyclopentyl-2-((4-((8-(hydroxyamino)-8-oxooctyl)carbamoyl)phenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>11d</b>)</h5><div class="NLM_p last">White solid; 71% yield; mp 105.9 °C (decompose); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.85 (s, 1H), 8.79 (s, 1H), 8.30 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (d, <i>J</i> = 8.5 Hz, 2H), 7.81 (d, <i>J</i> = 8.5 Hz, 2H), 6.61 (s, 1H), 4.75 (p, 1H), 3.24 (q, <i>J</i> = 6.7 Hz, 2H), 3.05 (s, 6H), 2.52–2.39 (m, 2H), 2.07–1.96 (m, 4H), 1.93 (t, <i>J</i> = 7.4 Hz, 2H), 1.74–1.63 (m, 2H), 1.55–1.42 (m, 4H), 1.33–1.18 (m, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.56, 166.12, 163.29, 155.50, 152.56, 151.45, 144.00, 132.48, 128.24, 126.91, 117.33, 112.38, 101.08, 57.50, 35.06, 32.72, 30.09, 29.78, 29.04, 29.00, 26.93, 25.57, 24.66. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 550.3136, found 550.3141 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> General Procedure for the Synthesis of <b>13a–13d</b></h4><div class="NLM_p">The title compound was prepared from <b>12a</b>–<b>12d</b> (60 mmol, 1 equiv), <i>p</i>-phenylenediamine (<b>2c</b>) (6.49 g, 60 mmol, 2 equiv), EDCI (8.27 g, 45 mmol, 1.5 equiv), HOBt (4.87 g, 36 mmol, 1.2 equiv), DIEA (7.76 g, 60 mmol, 2 equiv), and DMF (60 mL) using the procedure described for compounds <b>3a</b>–<b>3f</b> to obtain the desired products <b>13a</b>–<b>13d</b>.</div><div id="sec4_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63">4.1.31.  <i>N</i>-(4-Aminophenyl)hexanamide (<b>13a</b>)</h5><div class="NLM_p last">White solid; 60% yield; mp 87.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.78 (s, 1H), 7.26–7.21 (m, 2H), 6.58–6.53 (m, 2H), 3.57 (s, 2H), 2.31–2.19 (m, 2H), 1.75–1.59 (m, 2H), 1.36–1.26 (m, 4H), 0.90–0.84 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.74, 143.17, 129.50, 122.16, 115.33, 37.41, 31.48, 25.53, 22.47, 14.00. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>19</sub>N<sub>2</sub>O<sup>+</sup> 207.1492, found 207.1494 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64">4.1.32.  <i>N</i>-(4-Aminophenyl)heptanamide (<b>13b</b>)</h5><div class="NLM_p last">White solid; 40% yield; mp 89.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.31–7.23 (m, 2H), 7.15 (s, 1H), 6.62 (d, <i>J</i> = 8.6 Hz, 2H), 3.67–3.37 (m, 2H), 2.29 (t, <i>J</i> = 7.6 Hz, 2H), 1.69 (p, <i>J</i> = 7.5 Hz, 2H), 1.42–1.22 (m, 6H), 0.91–0.86 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.25, 143.19, 129.39, 122.01, 115.39, 37.63, 31.59, 28.99, 25.75, 22.53, 14.06. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>21</sub>N<sub>2</sub>O<sup>+</sup> 221.1648, found 221.1650 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65">4.1.33.  <i>N</i>-(4-Aminophenyl)octanamide (<b>13c</b>)</h5><div class="NLM_p last">White solid; 82% yield; mp 98.8 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.63 (s, 1H), 7.26–7.21 (m, 2H), 6.60–6.54 (m, 2H), 3.57 (br, 2H), 2.26 (t, <i>J</i> = 7.6 Hz, 2H), 1.66 (t, <i>J</i> = 7.3 Hz, 2H), 1.37–1.18 (m, 8H), 0.86 (t, <i>J</i> = 6.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.63, 143.17, 129.47, 122.13, 115.34, 37.51, 31.73, 29.30, 29.11, 25.85, 22.64, 14.12. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>23</sub>N<sub>2</sub>O<sup>+</sup> 235.1805, found 235.1807 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66">4.1.34.  <i>N</i>-(4-Aminophenyl)nonanamide (<b>13d</b>)</h5><div class="NLM_p last">White solid; 66% yield; mp 99.2 °C; <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.28 (d, <i>J</i> = 3.6 Hz, 2H), 7.10 (s, 1H), 6.64 (d, <i>J</i> = 8.4 Hz, 2H), 3.59 (s, 2H), 2.31 (t, <i>J</i> = 7.6 Hz, 2H), 1.71 (p, <i>J</i> = 7.4 Hz, 2H), 1.41–1.21 (m, 10H), 0.89 (t, <i>J</i> = 6.5 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.22, 143.19, 129.38, 122.00, 115.39, 37.65, 31.84, 29.37, 29.32, 29.17, 25.78, 22.66, 14.11. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>25</sub>N<sub>2</sub>O<sup>+</sup> 249.1961, found 249.1963 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> General Procedure for the Synthesis of <b>14a–14d</b></h4><div class="NLM_p">The title compound was prepared from <b>13a</b>–<b>13d</b> (2 mmol, 1 equiv), compound <b>4</b> (586 mg, 2 mmol, 1 equiv), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol, 0.025 equiv), BINAP (62 mg, 0.1 mmol, 0.05 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol, 2.1 equiv), and 1,4-dioxane (20 mL) using the procedure described for compounds <b>5a</b>–<b>5f</b> to obtain the desired products <b>14a</b>–<b>14d</b>.</div><div id="sec4_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68">4.1.35.  7-Cyclopentyl-2-((4-hexanamidophenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>14a</b>)</h5><div class="NLM_p last">White solid; 84% yield; mp 171.8 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 9.42 (s, 1H), 8.72 (s, 1H), 7.78–7.60 (m, 2H), 7.57–7.43 (m, 2H), 6.56 (s, 1H), 4.80–4.62 (m, 1H), 3.05 (s, 6H), 2.49–2.39 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 2.05–1.86 (m, 4H), 1.73–1.52 (m, 4H), 1.39–1.22 (m, 4H), 0.87 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.17, 163.41, 156.06, 152.53, 151.76, 136.76, 133.43, 131.85, 119.81, 118.96, 111.75, 101.15, 57.40, 36.76, 31.41, 30.05, 27.62, 25.35, 24.64, 22.38, 14.34. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>35</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> 463.2816, found 463.2822 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69">4.1.36.  7-Cyclopentyl-2-((4-heptanamidophenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>14b</b>)</h5><div class="NLM_p last">White solid; 82% yield; mp 114.0 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 9.42 (s, 1H), 8.72 (s, 1H), 7.78–7.66 (m, 2H), 7.55–7.45 (m, 2H), 6.56 (s, 1H), 4.79–4.65 (m, 1H), 3.05 (s, 6H), 2.50–2.38 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 1.97–1.92 (m, 2H), 1.71–1.50 (m, 4H), 1.34–1.20 (m, 6H), 0.86 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.17, 163.41, 156.06, 152.53, 151.76, 136.76, 133.43, 131.85, 119.81, 118.96, 111.75, 101.14, 57.40, 36.80, 31.52, 30.05, 28.85, 25.63, 24.64, 22.47, 14.39. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>37</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> 477.2973, found 477.2977 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70">4.1.37.  7-Cyclopentyl-<i>N</i>,<i>N</i>-dimethyl-2-((4-octanamidophenyl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>14c</b>)</h5><div class="NLM_p last">White solid; 81% yield; mp 176.4 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 9.42 (s, 1H), 8.71 (s, 1H), 7.81–7.61 (m, 2H), 7.55–7.45 (m, 2H), 6.56 (s, 1H), 4.80–4.60 (m, 1H), 3.05 (s, 6H), 2.50–2.41 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 2.04–1.89 (m, 4H), 1.74–1.52 (m, 4H), 1.35–1.19 (m, 8H), 0.84 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.17, 163.41, 156.06, 152.52, 151.76, 136.77, 133.43, 131.84, 119.82, 118.95, 111.74, 101.15, 57.40, 36.80, 31.65, 30.05, 29.15, 28.95, 25.67, 24.64, 22.54, 14.39. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>39</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> 491.3129, found 491.3132 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71">4.1.38.  7-Cyclopentyl-<i>N</i>,<i>N</i>-dimethyl-2-((4-nonanamidophenyl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>14d</b>)</h5><div class="NLM_p last">White solid; 80% yield; mp 168.2 °C; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 9.42 (s, 1H), 8.71 (s, 1H), 7.79–7.58 (m, 2H), 7.58–7.44 (m, 2H), 6.56 (s, 1H), 4.72 (p, <i>J</i> = 8.9 Hz, 1H), 3.05 (s, 6H), 2.49–2.41 (m, 2H), 2.26 (t, <i>J</i> = 7.4 Hz, 2H), 1.97 (dtd, <i>J</i> = 15.7, 8.7, 7.9, 3.9 Hz, 4H), 1.69–1.51 (m, 4H), 1.34–1.19 (m, 10H), 0.84 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.16, 163.41, 156.05, 152.52, 151.75, 136.76, 133.42, 131.84, 119.81, 118.94, 111.74, 101.15, 57.40, 36.80, 31.73, 30.05, 29.25, 29.18, 29.07, 25.66, 24.64, 22.55, 14.41. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>41</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> 505.3286, found 505.3290 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72">4.1.39.  Methyl 6-(3-(4-Aminophenyl)ureido)hexanoate (<b>16</b>)</h5><div class="NLM_p last">To a methyl 6-aminohexanoate hydrochloride (<b>7b</b>) (3.63 g, 20 mmol) in 50 mL of dichloromethane was added triphosgene (7.05 g, 24 mmol) at 0 °C. Then triethylamine (5.06 g, 50 mmol) was added dropwise. After the completion of the dropwise addition, the cooling bath was removed, and the reaction mixture was stirred at room temperature for about 3 h. Then the mixture was added dropwise into <i>p</i>-phenylenediamine (<b>2c</b>) (4.33 g, 40 mmol) and triethylamine (2.02 g, 20 mmol) in 50 mL of DMF, and the reaction mixture was stirred at room temperature for about 12 h. The solvent was removed under reduced pressure, and the residue was added to sodium bicarbonate solution (200 mL) and extracted by ethyl acetate. The combine organic was washed by water and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 95:5) to obtain 4.4 g (78%) of <b>16</b> as a white solid, mp 100.4 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.83 (s, 1H), 7.01–6.96 (m, 2H), 6.50–6.42 (m, 2H), 5.87 (t, <i>J</i> = 5.6 Hz, 1H), 4.67 (s, 2H), 3.58 (s, 3H), 3.02 (q, <i>J</i> = 6.6 Hz, 2H), 2.30 (t, <i>J</i> = 7.4 Hz, 2H), 1.60–1.47 (m, 2H), 1.46–1.33 (m, 2H), 1.32–1.21 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.80, 156.16, 143.75, 130.11, 120.65, 114.59, 51.65, 39.36, 33.71, 30.09, 26.34, 24.69. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> 280.1656, found 280.1660 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73">4.1.40.  Methyl 6-(3-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)ureido)hexanoate (<b>17</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>4</b> (586 mg, 2 mmol), compound <b>16</b> (558 mg, 2 mmol), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol), BINAP (62 mg, 0.1 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol), and 1,4-dioxane (20 mL) using the procedure described for <b>5a</b>–<b>5f</b> in 45% yield as a white solid, mp 161.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (s, 1H), 8.70 (s, 1H), 8.26 (s, 1H), 7.66 (d, <i>J</i> = 8.6 Hz, 2H), 7.29 (d, <i>J</i> = 8.6 Hz, 2H), 6.56 (s, 1H), 6.02 (t, <i>J</i> = 5.7 Hz, 1H), 4.71 (p, <i>J</i> = 9.0 Hz, 1H), 3.58 (s, 3H), 3.13–2.94 (m, 8H), 2.45 (t, <i>J</i> = 10.5 Hz, 2H), 2.31 (t, <i>J</i> = 7.4 Hz, 2H), 1.96 (q, <i>J</i> = 9.0, 8.4 Hz, 4H), 1.71–1.59 (m, 2H), 1.54 (p, <i>J</i> = 7.5 Hz, 2H), 1.41 (p, <i>J</i> = 7.1 Hz, 2H), 1.34–1.24 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.79, 163.40, 156.18, 155.82, 152.55, 151.81, 135.18, 134.72, 131.62, 119.35, 118.47, 111.54, 101.21, 57.36, 51.65, 33.71, 30.03, 26.34, 24.68, 24.64. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 537.3013, found 537.2932 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74">4.1.41.  7-Cyclopentyl-2-((4-(3-(6-(hydroxyamino)-6-oxohexyl)ureido)phenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>18</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>17</b> (900 mg, 1.71 mmol) and a solution of hydroxylamine (50% in water, 9 mL) and CH<sub>3</sub>OH (36 mL) using the procedure described for <b>6a</b>–<b>6f</b> in 68% yield as a white solid, mp 210.8 °C (decompose). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.30 (s, 1H), 8.69 (s, 1H), 8.30 (s, 1H), 7.66 (d, <i>J</i> = 8.4 Hz, 2H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 6.55 (s, 1H), 6.07 (s, 1H), 4.71 (p, <i>J</i> = 8.8 Hz, 1H), 3.18–2.98 (m, 8H), 2.49–2.40 (m, 2H), 2.03–1.87 (m, 6H), 1.71–1.58 (m, 2H), 1.51 (p, <i>J</i> = 7.4 Hz, 2H), 1.45–1.37 (m, 2H), 1.27 (q, <i>J</i> = 7.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.47, 163.44, 156.21, 155.87, 152.51, 151.85, 135.17, 134.79, 131.67, 119.40, 118.50, 111.56, 101.17, 57.36, 39.47, 32.70, 30.08, 30.07, 26.54, 26.50, 25.40, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>37</sub>N<sub>8</sub>O<sub>4</sub><sup>+</sup> 537.2932, found 537.2932 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75">4.1.42.  2-Amino-7-cyclopentyl-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>20</b>)</h5><div class="NLM_p last">To a suspension of 2-chloro-7-cyclopentyl-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>4</b>) (2.93 g, 10 mmol) in 50 mL of 1,4-dioxane were added diphenylmethanimine (1.95 g, 10.5 mmol), Pd(OAc)<sub>2</sub> (110 mg, 0.5 mmol), BINAP (0.31 mg, 0.5 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (4.89 g, 15 mmol), and the flask was purged with N<sub>2</sub>. Then the flask was sealed, and the mixture was heated for 12 h at 100 °C. The reaction was cooled to room temperature, then a suspension with ethyl acetate and water was added. The solvent was extracted with ethyl acetate, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified to obtain 4.16 g of 7-cyclopentyl-2-((diphenylmethylene)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>19</b>) as a yellow solid. The residue was added to THF (30 mL) and concentrated (HCl 5 mL), and the mixture was stirred for 3 h. This solvent was basified to pH 10 with aqueous 25% NaOH solution and extracted with ethyl acetate. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 94:6) to obtain 2.28 g (84%, two steps) of <b>20</b> as a white solid, mp 132.1 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.52 (s, 1H), 6.35 (s, 1H), 4.95 (s, 2H), 4.74 (p, <i>J</i> = 8.7 Hz, 1H), 3.11 (s, 6H), 2.38 (ddd, <i>J</i> = 14.5, 6.4, 3.4 Hz, 2H), 2.10–1.85 (m, 4H), 1.68–1.52 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.75, 160.37, 153.29, 152.44, 130.51, 110.45, 101.30, 56.42, 34.97, 30.44, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>20</sub>N<sub>5</sub>O<sup>+</sup> 274.1662, found 274.1660 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76">4.1.43.  7-Cyclopentyl-2-hydrazinyl-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>21</b>)</h5><div class="NLM_p last">To a suspension of 2-chloro-7-cyclopentyl-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>4</b>) (2.93 g, 10 mmol) in 10 mL of ethanol were added N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (80% in water, 2.5 mL). The mixture was heated for 6 h at 80 °C. The reaction was cooled to room temperature, the solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 93:7) to obtain 2.28 g (79%) of <b>21</b> as a light-yellow solid, mp 121.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (s, 1H), 7.93 (s, 1H), 6.49 (s, 1H), 4.87–4.63 (m, 1H), 4.15 (s, 2H), 3.11–2.94 (m, 7H), 2.41–2.26 (m, 2H), 2.01–1.85 (m, 4H), 1.58 (q, <i>J</i> = 6.2 Hz, 2H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.13, 161.33, 152.24, 151.86, 130.26, 110.31, 100.76, 56.18, 34.48, 30.09, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>21</sub>N<sub>6</sub>O<sup>+</sup> 289.1771, found 289.1767 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77">4.1.44.  Methyl 8-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)-8-oxooctanoate (<b>22</b>)</h5><div class="NLM_p last">To a two-necked flask, compound <b>20</b> (547 mg, 2 mmol), suberic acid monomethyl ester (<b>1c</b>) (412 mg, 2.2 mmol), DCC (454 mg, 2.2 mmol), DMAP (280 mg, 2.2 mmol) and dichloromethane (20 mL) were charged. The mixture was stirred at reflux for 36 h, then quenched by saturated aqueous NaHCO<sub>3</sub> solution. The mixture was extracted by dichloromethane, and the combined organic layers were dried by anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 95:5) to obtain 638 mg (72%) of <b>22</b> as a white solid, mp 149.9 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.85 (s, 1H), 6.64 (s, 1H), 4.82–4.61 (m, 1H), 3.56 (s, 3H), 3.03 (s, 6H), 2.53 (t, <i>J</i> = 8.3 Hz, 2H), 2.41–2.31 (m, 2H), 2.28 (t, <i>J</i> = 7.4 Hz, 2H), 1.96 (dq, <i>J</i> = 16.5, 8.8, 7.1 Hz, 4H), 1.65–1.44 (m, 6H), 1.37–1.23 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.77, 171.90, 163.18, 152.59, 151.89, 151.25, 134.33, 114.59, 100.25, 57.29, 51.60, 36.70, 34.98, 33.68, 30.68, 28.80, 28.74, 25.00, 24.80, 24.75. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>34</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> 444.2605, found 444.2604 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78">4.1.45.  Methyl 8-(2-(7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)hydrazinyl)-8-oxooctanoate (<b>23</b>)</h5><div class="NLM_p last">To a two-necked flask, suberic acid monomethyl ester (<b>1c</b>) (482 mg, 2.4 mmol), compound <b>21</b> (577 mg, 2 mmol), EDCI (575 mg, 3 mmol), HOBt (325 mg, 2.4 mmol), DIEA (517 mg, 4 mmol) and DMF (10 mL) were charged. The mixture was stirred at 60 °C for 12 h, then quenched by water. The mixture was extracted by ethyl acetate, and the combined organic layer was washed with brine solution and dried by anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 95:5) to obtain 293 mg (32%) of <b>23</b> as an off-white solid, mp 131.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.63 (d, <i>J</i> = 2.1 Hz, 1H), 8.62 (s, 1H), 8.56 (d, <i>J</i> = 2.0 Hz, 1H), 6.52 (s, 1H), 4.68 (p, <i>J</i> = 8.5 Hz, 1H), 3.58 (s, 3H), 3.03 (s, 6H), 2.35–2.26 (m, 4H), 2.16 (t, <i>J</i> = 7.5 Hz, 2H), 1.97–1.81 (m, 4H), 1.60–1.48 (m, 6H), 1.33–1.18 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.78, 172.26, 163.48, 159.93, 152.49, 152.19, 131.74, 112.19, 100.80, 56.90, 51.62, 35.02, 33.70, 30.54, 28.85, 28.69, 25.25, 24.99, 24.78. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>35</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 459.2714, found 459.2707 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79">4.1.46.  Methyl 8-(4-(6-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-8-oxooctanoate (<b>24</b>)</h5><div class="NLM_p last">To a two-necked flask, suberic acid monomethyl ester (<b>1c</b>) (0.55 mmol, 104 mg), Lee011 (0.46 mmol, 200 mg), EDCI (0.69 mmol, 132 mg), DIEA (0.69 mmol, 89 mg), and DMF (3 mL) were charged. The mixture was stirred at room temperature for 12 h, then quenched by water. The mixture was extracted by ethyl acetate, and the combined organic layer was washed with brine solution and dried by anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 95:5) to obtain 135 mg (49%) of <b>24</b> as a light-brown solid, mp 159.6 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.64 (s, 1H), 8.82 (s, 1H), 8.21 (d, <i>J</i> = 9.0 Hz, 1H), 8.08 (d, <i>J</i> = 3.0 Hz, 1H), 7.47 (dd, <i>J</i> = 9.2, 3.1 Hz, 1H), 6.60 (s, 1H), 4.74 (p, <i>J</i> = 8.9 Hz, 1H), 3.72–3.52 (m, 7H), 3.16–2.96 (m, 10H), 2.48–2.38 (m, 2H), 2.38–2.23 (m, 4H), 1.98 (p, <i>J</i> = 10.3, 8.9 Hz, 4H), 1.70–1.59 (m, 2H), 1.58–1.46 (m, 4H), 1.38–1.22 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.78, 171.06, 163.34, 155.16, 152.58, 151.66, 147.04, 142.51, 136.71, 132.37, 126.46, 112.95, 112.29, 101.08, 57.43, 51.61, 49.95, 49.54, 45.21, 41.26, 33.69, 32.58, 30.19, 28.87, 28.76, 25.07, 24.80, 24.67. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>45</sub>N<sub>8</sub>O<sub>4</sub><sup>+</sup> 605.3558, found 605.3563 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80">4.1.47.  7-Cyclopentyl-2-((5-(4-(8-(hydroxyamino)-8-oxooctanoyl)piperazin-1-yl)pyridin-2-yl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>25</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>24</b> (750 mg, 1.24 mmol) and a solution of hydroxylamine (50% in water, 7.5 mL) and CH<sub>3</sub>OH (30 mL) using the procedure described for <b>6a</b>–<b>6f</b> in 67% yield as a white solid, mp 135.5 °C (decompose). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 9.67 (s, 1H), 8.82 (s, 1H), 8.67 (s, 1H), 8.21 (d, <i>J</i> = 8.9 Hz, 1H), 8.09 (s, 1H), 7.48 (d, <i>J</i> = 9.2 Hz, 1H), 6.61 (s, 1H), 4.74 (p, <i>J</i> = 8.8 Hz, 1H), 3.68–3.49 (m, 4H), 3.18–2.96 (m, 10H), 2.47–2.38 (m, 2H), 2.07–1.87 (m, 8H), 1.74–1.56 (m, 2H), 1.54–1.42 (m, 4H), 1.35–1.19 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.09, 169.57, 163.35, 155.15, 152.58, 151.66, 147.04, 142.51, 136.68, 132.39, 126.51, 112.96, 112.30, 101.10, 57.44, 49.95, 49.54, 45.22, 41.26, 32.73, 32.66, 30.20, 28.98, 28.93, 25.52, 25.16, 24.68. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>44</sub>N<sub>9</sub>O<sub>4</sub><sup>+</sup> 606.3511, found 606.3521 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81">4.1.48.  Methyl 8-((4-Aminobenzyl)amino)-8-oxooctanoate (<b>26</b>)</h5><div class="NLM_p last">To a two-necked flask, suberic acid monomethyl ester (<b>1c</b>) (4.82 g, 25.6 mmol), 4-(aminomethyl)anilinedihydrochloride (5 g, 25.63 mmol), EDCI (7.34 g, 38.45 mmol), HOBt (4.16 g, 30.76 mmol), DIEA (13.25 g, 102.54 mmol), and DMF (50 mL) were charged. The mixture was stirred at room temperature for 12 h, then quenched by water. The mixture was extracted by ethyl acetate, and the combined organic layer was washed with brine solution and dried by anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 96:4) to obtain 5.032 g (67%) of <b>26</b> as a light-brown solid, mp 87.3 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.04 (dt, <i>J</i> = 8.8, 2.5 Hz, 2H), 6.62 (dt, <i>J</i> = 7.2, 2.6 Hz, 2H), 4.28 (dt, <i>J</i> = 6.2, 3.0 Hz, 2H), 3.64 (d, <i>J</i> = 2.6 Hz, 3H), 2.27 (dd, <i>J</i> = 9.2, 6.2 Hz, 2H), 2.15 (dd, <i>J</i> = 9.4, 6.3 Hz, 2H), 1.69–1.52 (m, 4H), 1.30 (p, <i>J</i> = 3.7 Hz, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.23, 172.69, 145.88, 129.17, 128.15, 115.19, 51.50, 43.24, 36.66, 33.97, 28.87, 28.79, 25.54, 24.75. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> 293.1860, found 293.1859 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82">4.1.49.  Methyl 8-((4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzyl)amino)-8-oxooctanoate (<b>27</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>4</b> (586 mg, 2 mmol), compound <b>26</b> (558 mg, 2 mmol), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol), BINAP (62 mg, 0.1 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol), and 1,4-dioxane (20 mL) using the procedure described for <b>5a</b>–<b>5f</b> in 79% yield as a light-yellow solid, mp 54.8 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.59 (s, 1H), 7.84 (s, 1H), 7.67–7.57 (m, 2H), 7.16 (d, <i>J</i> = 8.1 Hz, 2H), 6.37 (s, 1H), 6.10 (s, 1H), 4.73 (p, <i>J</i> = 9.1 Hz, 1H), 4.35 (d, <i>J</i> = 5.5 Hz, 2H), 3.62 (s, 3H), 3.11 (s, 6H), 2.61–2.46 (m, 2H), 2.31–2.22 (m, 2H), 2.21–2.12 (m, 2H), 2.07–1.92 (m, 4H), 1.72–1.51 (m, 6H), 1.35–1.24 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.23, 172.88, 164.17, 155.45, 152.04, 151.64, 139.65, 131.87, 131.57, 128.37, 118.70, 112.32, 100.99, 57.97, 51.52, 43.19, 36.65, 34.02, 30.16, 28.96, 28.87, 25.63, 24.80, 24.69. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>41</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 549.3184, found 549.3186 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83">4.1.50.  <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)benzyl)-<i>N</i>8-hydroxyoctanediamide (<b>28</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>27</b> (710 mg, 1.29 mmol) and a solution of hydroxylamine (50% in water, 7 mL) and CH<sub>3</sub>OH (28 mL) using the procedure described for <b>6a–6f</b> in 49% yield as a white solid, mp 123.5 °C (decompose). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.51 (s, 1H), 8.73 (s, 1H), 8.68 (s, 1H), 8.25 (t, <i>J</i> = 5.9 Hz, 1H), 7.78 (d, <i>J</i> = 8.1 Hz, 2H), 7.15 (d, <i>J</i> = 8.2 Hz, 2H), 6.58 (s, 1H), 4.82–4.61 (m, 1H), 4.21 (d, <i>J</i> = 5.8 Hz, 2H), 3.17 (d, <i>J</i> = 4.4 Hz, 1H), 3.05 (s, 6H), 2.49–2.41 (m, 2H), 2.11 (t, <i>J</i> = 7.4 Hz, 2H), 2.04–1.87 (m, 6H), 1.73–1.60 (m, 2H), 1.57–1.43 (m, 4H), 1.33–1.18 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.40, 169.52, 163.36, 155.95, 152.56, 151.66, 140.13, 132.42, 131.97, 127.85, 118.49, 111.86, 101.13, 65.38, 57.43, 42.09, 35.84, 32.72, 30.01, 28.94, 28.87, 25.77, 25.51, 24.60. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 550.3136, found 550.3146 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div><div id="sec4_1_8_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84">4.1.51.  Methyl 8-((6-((<i>tert</i>-Butoxycarbonyl)amino)pyridin-3-yl)amino)-8-oxooctanoate (<b>29</b>)</h5><div class="NLM_p last">To a two-necked flask, suberic acid monomethyl ester (<b>1c</b>) (531 mg, 2.82 mmol), <i>tert</i>-butyl (5-aminopyridin-2-yl)carbamate (590 mg, 2.82 mmol), EDCI (649 mg, 3.38 mmol), DMAP (35 mg, 0.28 mmol), DIEA (437 mg, 3.38 mmol), and DMF (10 mL) were charged. The mixture was stirred at room temperature for 12 h, then quenched by water. The mixture was extracted by ethyl acetate, and the combined organic layer was washed with brine solution and dried by anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (petroleum ether–ethyl acetate, gradient 100:00 → 50:50) to obtain 570 mg (53%) of <b>29</b> as a white solid, mp 164.4 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.39 (s, 1H), 8.01 (s, 1H), 7.96–7.86 (m, 2H), 7.55 (s, 1H), 3.66 (s, 3H), 2.46–2.09 (m, 4H), 1.77–1.67 (m, 2H), 1.66–1.57 (m, 2H), 1.51 (s, 9H), 1.41–1.30 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.32, 171.55, 152.45, 148.25, 139.21, 130.63, 130.13, 112.27, 81.09, 51.55, 37.12, 33.91, 28.70, 28.64, 28.29, 25.23, 24.63. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>30</sub>N<sub>3</sub>O<sub>5</sub><sup>+</sup> 380.2180, found 380.2181 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85">4.1.52.  Methyl 8-((6-Aminopyridin-3-yl)amino)-8-oxooctanoate (<b>30</b>)</h5><div class="NLM_p last">To a suspension of compound (<b>29</b>) (570 mg, 1.5 mmol) in 10 mL of THF was added concentrated HCl (10 mL), and the mixture was stirred for 1 h. This solvent was basified to pH > 8 with aqueous Na<sub>2</sub>CO<sub>3</sub> solution and extracted with ethyl acetate. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 95:5) to obtain 275 mg (66%) of <b>30</b> as a white solid, mp 129.1 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, 1H), 8.04 (d, <i>J</i> = 2.6 Hz, 1H), 7.53 (dd, <i>J</i> = 8.8, 2.7 Hz, 1H), 6.39 (d, <i>J</i> = 8.8 Hz, 1H), 5.65 (s, 2H), 3.57 (s, 3H), 2.29 (t, <i>J</i> = 7.4 Hz, 2H), 2.22 (t, <i>J</i> = 7.4 Hz, 2H), 1.59–1.47 (m, 4H), 1.32–1.23 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.80, 171.13, 156.64, 139.98, 130.74, 126.18, 107.84, 51.62, 36.37, 33.70, 28.78, 28.68, 25.47, 24.78. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> 280.1656, found 280.1657 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86">4.1.53.  Methyl 8-((6-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)pyridin-3-yl)amino)-8-oxooctanoate (<b>31</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>4</b> (586 mg, 2 mmol), compound <b>36</b> (558 mg, 2 mmol), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol), BINAP (62 mg, 0.1 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol), and 1,4-dioxane (20 mL) using the procedure described for <b>5a–5f</b> in 46% yield as a white solid, mp 205.9 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.92 (s, 1H), 9.61 (s, 1H), 8.80 (s, 1H), 8.50 (d, <i>J</i> = 2.6 Hz, 1H), 8.25 (d, <i>J</i> = 9.0 Hz, 1H), 7.96 (dd, <i>J</i> = 9.0, 2.7 Hz, 1H), 6.62 (s, 1H), 4.74 (p, <i>J</i> = 8.9 Hz, 1H), 3.58 (s, 3H), 3.05 (s, 6H), 2.49–2.38 (m, 2H), 2.30 (td, <i>J</i> = 7.4, 1.5 Hz, 4H), 2.04–1.89 (m, 4H), 1.73–1.46 (m, 6H), 1.30 (p, <i>J</i> = 3.7 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.80, 171.63, 163.31, 154.91, 152.55, 151.49, 149.23, 139.47, 132.65, 130.60, 128.87, 112.60, 112.21, 100.97, 57.43, 51.62, 36.51, 33.70, 31.64, 30.20, 28.78, 28.69, 25.35, 24.78, 24.71. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 536.2980, found 536.2979 [M + H]<sup>+</sup>. HPLC purity 96%.</div></div><div id="sec4_1_8_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87">4.1.54.  <i>N</i>1-(6-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)pyridin-3-yl)-<i>N</i>8-hydroxyoctanediamide (<b>32</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>31</b> (1.03 g, 1.92 mmol) and a solution of hydroxylamine (50% in water, 10 mL) and CH<sub>3</sub>OH (40 mL) using the procedure described for <b>6a</b>–<b>6f</b> in 64% yield as a white solid, mp 118.0 °C (decompose). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.93 (s, 1H), 9.72 (s, 1H), 8.82 (s, 1H), 8.53 (d, <i>J</i> = 2.6 Hz, 1H), 8.26 (d, <i>J</i> = 9.0 Hz, 1H), 7.97 (dd, <i>J</i> = 9.1, 2.7 Hz, 1H), 6.62 (s, 1H), 4.74 (p, <i>J</i> = 8.9 Hz, 1H), 3.05 (s, 6H), 2.47–2.38 (m, 2H), 2.31 (t, <i>J</i> = 7.4 Hz, 2H), 2.20 (t, <i>J</i> = 7.3 Hz, 2H), 2.04–1.87 (m, 4H), 1.74–1.46 (m, 6H), 1.37–1.23 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.00, 171.65, 163.31, 154.91, 152.57, 151.49, 149.23, 139.52, 132.66, 130.60, 128.91, 112.59, 112.19, 100.99, 57.44, 36.55, 34.16, 30.20, 28.88, 28.81, 25.41, 24.88, 24.71. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>37</sub>N<sub>8</sub>O<sub>4</sub><sup>+</sup> 537.2932, found 537.2930 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88">4.1.55.  Methyl 8-((5-Nitropyridin-2-yl)amino)-8-oxooctanoate (<b>33</b>)</h5><div class="NLM_p last">To a suspension of suberic acid monomethyl ester (<b>1c</b>) (5.65 g, 30 mmol) in 50 mL of THF was added SOCl<sub>2</sub> (8.41 g, 66 mmol) and heated for 3 h at 60 °C. The reaction was cooled to room temperature, the solvent was removed under reduced pressure, and the residue was added to 50 mL of THF, 50 mL of pyridine, and 5-nitropyridin-2-amine (4.17 g, 30 mmol). The mixture was heated for 3 h at 60 °C. The reaction was cooled to room temperature, the solvent was removed under reduced pressure, and the residue was added to water (200 mL) and extracted by ethyl acetate. The combine organic was washed by water and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (petroleum ether–ethyl acetate, gradient 100:00 → 60:40) to obtain 913.2 mg (10%) of <b>33</b> as a brown solid, mp 172.3 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.19 (s, 1H), 9.16 (d, <i>J</i> = 2.8 Hz, 1H), 8.59 (dd, <i>J</i> = 9.3, 2.9 Hz, 1H), 8.30 (d, <i>J</i> = 9.3 Hz, 1H), 3.57 (s, 3H), 2.45 (t, <i>J</i> = 7.4 Hz, 2H), 2.29 (t, <i>J</i> = 7.4 Hz, 2H), 1.64–1.47 (m, 4H), 1.28 (p, <i>J</i> = 3.6 Hz, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.80, 173.57, 156.63, 145.21, 140.12, 134.67, 112.86, 51.64, 36.57, 33.66, 28.63, 24.94, 24.72. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O<sub>5</sub><sup>+</sup> 310.1397, found 310.1393 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89">4.1.56.  Methyl 8-((5-Aminopyridin-2-yl)amino)-8-oxooctanoate (<b>34</b>)</h5><div class="NLM_p last">To a suspension of compound <b>33</b> (913 mg, 2.94 mmol) in 10 mL of ethanol and 10 mL of ethyl acetate were added palladium 10% on carbon (91 mg, wetted with ca. 55% Water) and ammonium formate (927 mg, 14.7 mmol), and the flask was purged with N<sub>2</sub>. Then the flask was sealed, and the mixture was heated for 12 h at 80 °C. The reaction was cooled to rt, and 200 mL of ethyl acetate was added. The organic was washed by water and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 95:5) to obtain 728.6 mg (88%) of <b>34</b> as a brown solid, mp 112.0 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.71 (m, 1H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 7.72 (d, <i>J</i> = 2.8 Hz, 1H), 7.08–7.02 (m, 1H), 3.73 (s, 2H), 3.63 (s, 3H), 2.36–2.21 (m, 4H), 1.71–1.52 (m, 4H), 1.37–1.23 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.25, 171.29, 143.85, 139.46, 133.91, 124.89, 115.00, 51.51, 37.37, 33.96, 28.82, 28.79, 25.27, 24.72. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> 280.1656, found 280.1655 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90">4.1.57.  Methyl 8-((5-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)pyridin-2-yl)amino)-8-oxooctanoate (<b>35</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>4</b> (586 mg, 2 mmol), compound <b>34</b> (559 mg, 2 mmol), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol), BINAP (62 mg, 0.1 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol), and 1,4-dioxane (20 mL) using the procedure described for <b>5a–5f</b> in 77% yield as a light-brown solid, mp 153.9 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.64 (s, 1H), 8.49 (d, <i>J</i> = 2.5 Hz, 1H), 8.29 (dd, <i>J</i> = 9.1, 2.9 Hz, 1H), 8.22 (d, <i>J</i> = 9.0 Hz, 1H), 6.43 (s, 1H), 4.75 (t, <i>J</i> = 8.9 Hz, 1H), 3.64 (d, <i>J</i> = 1.4 Hz, 2H), 3.14 (s, 6H), 2.56–2.43 (m, 2H), 2.38 (t, <i>J</i> = 7.5 Hz, 2H), 2.28 (t, <i>J</i> = 6.7 Hz, 2H), 2.09–1.92 (m, 4H), 1.76–1.56 (m, 6H), 1.42–1.29 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 179.05, 174.27, 163.84, 154.75, 152.04, 150.52, 146.03, 136.78, 133.47, 132.68, 129.47, 114.43, 112.35, 101.06, 58.09, 51.50, 37.30, 34.01, 31.47, 30.20, 28.84, 27.75, 25.19, 24.75, 24.48. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> 536.2980, found 536.2985 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91">4.1.58.  2-Chloro-<i>N</i>-cyclopentyl-5-nitropyrimidin-4-amine (<b>38</b>)</h5><div class="NLM_p last">2,4-Dichloro-5-nitropyrimidine (1.94 g, 10 mmol) and DIEA (1.29 g, 10 mmol) were dissolved in ethyl acetate (20 mL) and cooled to −40 °C. Cyclopentylamine (1.94 g, 10 mmol) was dissolved in ethyl acetate (20 mL) and added dropwise. After the completion of the dropwise addition, the cooling bath was removed, and the reaction mixture was stirred at room temperature for about 2 h. Then ethyl acetate (200 mL) was added to the organic, and the organic was washed by saturated citric acid aqueous solution, water, and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and the solvent evaporated to obtain 2.42 g (99%) of <b>38</b> as a yellow solid, mp 126.3 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 9.01 (s, 1H), 8.37 (s, 1H), 4.58 (h, <i>J</i> = 7.0 Hz, 1H), 2.32–2.08 (m, 2H), 1.87–1.61 (m, 4H), 1.64–1.42 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 164.14, 157.09, 154.98, 126.46, 53.27, 33.02, 23.73. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>12</sub>ClN<sub>4</sub>O<sub>2</sub><sup>+</sup> 243.0643, found 243.0645 [M + H]<sup>+</sup>. HPLC purity 97%.</div></div><div id="sec4_1_8_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92">4.1.59.  2-Chloro-<i>N</i>4-cyclopentylpyrimidine-4,5-diamine (<b>39</b>)</h5><div class="NLM_p last">To a suspension of compound <b>38</b> (2.42 g, 10 mmol) in 50 mL of ethanol was added stannous chloride dihydrate (9.03 g, 40 mmol), and the mixture was heated for 2 h at reflux. The reaction was cooled to room temperature and ethyl acetate (250 mL) added. The solvent was washed by saturated sodium carbonate solution, water, and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 90:10) to obtain 1.8 g (85%) of <b>39</b> as a black solid, mp 47.8 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.54 (s, 1H), 5.18 (d, <i>J</i> = 7.3 Hz, 1H), 4.46–4.27 (m, 1H), 3.10 (s, 3H), 2.26–1.89 (m, 2H), 1.80–1.51 (m, 4H), 1.52–1.32 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 156.84, 152.63, 141.35, 123.75, 52.55, 33.16, 23.73. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>14</sub>ClN<sub>4</sub><sup>+</sup> 213.0902, found 213.0902 [M + H]<sup>+</sup>. HPLC purity 95%.</div></div><div id="sec4_1_8_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93">4.1.60.  2-Chloro-9-cyclopentyl-9<i>H</i>-purine (<b>40</b>)</h5><div class="NLM_p last">To a suspension of compound <b>39</b> (4.02 g, 18.81 mmol) in 100 mL of DMF were added triethyl orthoformate (17.32 g, 188.1 mmol) and MgSO<sub>4</sub> (2.26 g, 18.81 mmol), and the mixture was heated for 2 h at 130 °C. The reaction was cooled to room temperature, the solvent was removed under reduced pressure, and ethyl acetate (200 mL) added. The solvent was washed by water and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (petroleum ether–ethyl acetate, gradient 100:00 → 50:50) to obtain 1.97 g (47%) of <b>40</b> as a brown solid, mp 117.1 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.94 (s, 1H), 8.13 (s, 1H), 5.08–4.73 (m, 1H), 2.38–2.22 (m, 2H), 2.05–1.89 (m, 4H), 1.86–1.73 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.07, 153.20, 150.03, 144.33, 133.45, 56.14, 32.73, 23.85. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>10</sub>H<sub>12</sub>ClN<sub>4</sub><sup>+</sup> 223.0745, found 223.0743 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94">4.1.61.  Methyl 8-((4-((9-Cyclopentyl-9<i>H</i>-purin-2-yl)amino)phenyl)amino)-8-oxooctanoate (<b>41</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>40</b> (445 mg, 2 mmol), compound <b>3e</b> (558 mg, 2 mmol), Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol), BINAP (62 mg, 0.1 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol), and 1,4-dioxane (20 mL) using the procedure described for <b>5a</b>–<b>5f</b> in 77% yield as a white solid, mp 156.7 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 8.74 (s, 1H), 7.84 (s, 1H), 7.82–7.67 (m, 2H), 7.67–7.60 (m, 2H), 7.53–7.47 (m, 2H), 4.81 (p, <i>J</i> = 7.5 Hz, 1H), 3.64 (s, 3H), 2.29 (ddt, <i>J</i> = 19.5, 12.2, 6.6 Hz, 6H), 2.12–1.99 (m, 2H), 1.94 (tt, <i>J</i> = 6.9, 3.7 Hz, 2H), 1.85–1.65 (m, 4H), 1.60 (p, <i>J</i> = 7.3 Hz, 2H), 1.35 (qd, <i>J</i> = 8.1, 5.1, 4.6 Hz, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.29, 171.31, 156.10, 152.58, 149.25, 141.42, 136.29, 132.60, 128.91, 120.64, 119.25, 55.98, 51.53, 37.44, 33.95, 32.28, 28.82, 28.77, 25.45, 24.71, 24.11. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>33</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> 465.2609, found 465.2613 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95">4.1.62.  <i>N</i>1-(4-((9-Cyclopentyl-9<i>H</i>-purin-2-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>42</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>41</b> (350 mg, 0.75 mmol) and a solution of hydroxylamine (50% in water, 5 mL) and CH<sub>3</sub>OH (5 mL) using the procedure described for <b>6a</b>–<b>6f</b> in 45% yield as a yellow solid, mp 177.2 °C (decompose). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 9.75 (s, 1H), 9.53 (s, 1H), 8.73 (d, <i>J</i> = 35.5 Hz, 2H), 8.26 (s, 1H), 7.73 (d, <i>J</i> = 8.4 Hz, 2H), 7.50 (d, <i>J</i> = 8.6 Hz, 2H), 4.99–4.73 (m, 1H), 2.37–2.00 (m, 6H), 2.00–1.81 (m, 4H), 1.71 (s, 2H), 1.53 (d, <i>J</i> = 31.4 Hz, 4H), 1.28 (s, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.15, 169.56, 156.47, 152.46, 149.46, 142.99, 136.75, 133.46, 128.80, 119.91, 119.03, 55.87, 36.74, 32.72, 31.90, 28.92, 28.89, 25.59, 25.52, 24.22. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>32</sub>N<sub>7</sub>O<sub>3</sub><sup>+</sup> 466.2561, found 466.2563 [M + H]<sup>+</sup>. HPLC purity 96%.</div></div><div id="sec4_1_8_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96">4.1.63.  5-Chloro-3-cyclopentyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine (<b>43</b>)</h5><div class="NLM_p last">A suspension of 2-chloro-<i>N</i>4-cyclopentyl pyrimidine-4,5-diamine (<b>39</b>) (2.13 g, 10 mmol) in conc. HCl (20 mL) was stirred for 15 min at 0 °C. Then NaNO<sub>2</sub> (828 mg, 12 mmol) was dissolved in water (5 mL) and added dropwise. After the completion of the dropwise addition, the cooling bath was removed, and the reaction mixture was stirred at room temperature for about 3 h. Then the reaction was poured into 200 mL of sodium bicarbonate solution and extracted by ethyl acetate. The combine organic was washed by water and brine. The organic phase was dried over MgSO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (petroleum ether–ethyl acetate, gradient 100:00 → 60:40) to obtain 1.45 g (65%) of <b>43</b> as a white solid, mp 64.9 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 9.34 (s, 1H), 5.32 (p, <i>J</i> = 7.1 Hz, 1H), 2.40–2.18 (m, <i>J</i> = 6.5 Hz, 4H), 2.10–1.96 (m, 2H), 1.90–1.66 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 158.34, 153.04, 150.47, 135.13, 59.53, 32.70, 24.42. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>9</sub>H<sub>11</sub>ClN<sub>5</sub><sup>+</sup> 224.0697, found 224.0697 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97">4.1.64.  Methyl 8-((4-((3-Cyclopentyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)amino)phenyl)amino)-8-oxooctanoate (<b>44</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>43</b> (336 mg, 1.5 mmol), compound <b>3e</b> (461 mg, 1.65 mmol), Pd(OAc)<sub>2</sub> (8 mg, 0.04 mmol), BINAP (47 mg, 0.08 mmol), Cs<sub>2</sub>CO<sub>3</sub> (538 mg, 1.65 mmol), and 1,4-dioxane (15 mL) using the procedure described for <b>5a</b>–<b>5f</b> in 77% yield as a yellow solid, mp 131.6 °C. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 9.09 (s, 1H), 7.93 (s, 1H), 7.66 (d, <i>J</i> = 8.8 Hz, 3H), 7.59–7.51 (m, 2H), 5.21 (p, <i>J</i> = 7.3 Hz, 1H), 3.65 (s, 3H), 2.35 (t, <i>J</i> = 7.5 Hz, 2H), 2.29 (q, <i>J</i> = 6.4, 5.5 Hz, 6H), 2.09–1.95 (m, 3H), 1.86–1.66 (m, 4H), 1.61 (p, <i>J</i> = 7.3 Hz, 2H), 1.36 (dt, <i>J</i> = 8.5, 5.1 Hz, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 174.32, 171.40, 158.02, 152.57, 150.11, 135.07, 133.60, 132.23, 120.59, 120.04, 58.87, 51.56, 37.47, 33.95, 32.25, 28.81, 28.76, 25.42, 24.70, 24.66. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>32</sub>N<sub>7</sub>O<sub>3</sub><sup>+</sup> 466.2561, found 466.2567 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98">4.1.65.  <i>N</i>1-(4-((3-Cyclopentyl-3<i>H</i>-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-5-yl)amino)phenyl)-<i>N</i>8-hydroxyoctanediamide (<b>45</b>)</h5><div class="NLM_p last">The title compound was prepared from compound <b>44</b> (150 mg, 0.32 mmol) and a solution of hydroxylamine (50% in water, 3 mL) and ethanol (5 mL) using the procedure described for <b>6a</b>–<b>6f</b> in 32% yield as a yellow solid, mp 199.4 °C (decompose). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.96 (s, 1H), 10.16 (s, 1H), 9.82 (s, 1H), 9.31 (s, 1H), 7.76 (d, <i>J</i> = 8.6 Hz, 2H), 7.56 (d, <i>J</i> = 8.7 Hz, 2H), 5.24 (p, <i>J</i> = 7.3 Hz, 1H), 2.34–2.15 (m, 8H), 2.01–1.85 (m, 2H), 1.76 (p, <i>J</i> = 7.8, 5.6 Hz, 2H), 1.54 (dt, <i>J</i> = 32.4, 7.0 Hz, 4H), 1.40–1.24 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.02, 171.31, 158.48, 153.36, 149.97, 135.36, 134.68, 131.90, 120.11, 119.80, 58.71, 36.76, 34.15, 32.11, 28.90, 28.82, 25.52, 24.89, 24.76. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>31</sub>N<sub>8</sub>O<sub>3</sub><sup>+</sup> 467.2514, found 467.2543 [M + H]<sup>+</sup>. HPLC purity 98%.</div></div><div id="sec4_1_8_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99">4.1.66.  7-Cyclopentyl-2-((4-(8-hydroxyoctanamido)phenyl)amino)-<i>N</i>,<i>N</i>-dimethyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine-6-carboxamide (<b>46</b>)</h5><div class="NLM_p last">To a suspension of compound <b>5e</b> (268 mg, 0.5 mmol) in 5 mL of THF was added LiAlH<sub>4</sub> (29 mg, 0.75 mmol) at 0 °C. After the completion of the addition, the cooling bath was removed, and the reaction mixture was stirred at room temperature for about 4 h. To the reaction were addedNaOH aqueous solution (0.03 mL, 2 N) and water 0.1 mL, and it was filtered and washed by dichloromethane. The organic phase was washed by water and brine. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 90:10) to obtain 144 mg (57%) of <b>46</b> as a yellow solid, mp 159.7 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.82–9.64 (m, 1H), 9.54–9.36 (m, 1H), 8.71 (q, <i>J</i> = 5.5, 4.6 Hz, 1H), 7.84–7.66 (m, 2H), 7.50 (d, <i>J</i> = 7.2 Hz, 2H), 6.56 (q, <i>J</i> = 6.1, 5.0 Hz, 1H), 4.70 (q, <i>J</i> = 9.4, 8.7 Hz, 1H), 4.34 (d, <i>J</i> = 6.8 Hz, 1H), 3.03 (s, 6H), 2.48 (s, 2H), 2.25 (d, <i>J</i> = 8.1 Hz, 2H), 1.96 (dd, <i>J</i> = 13.7, 7.3 Hz, 4H), 1.60 (d, <i>J</i> = 30.4 Hz, 4H), 1.39 (s, 2H), 1.27 (d, <i>J</i> = 8.2 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.18, 163.37, 156.02, 152.57, 151.71, 136.75, 133.40, 131.80, 119.78, 118.92, 111.72, 101.19, 61.15, 57.39, 36.78, 35.14, 32.99, 30.02, 29.25, 29.22, 25.89, 25.65, 24.64. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>39</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> 507.3078, found 507.3080 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100">4.1.67.  8-((4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)amino)-8-oxooctanoic Acid (<b>47</b>)</h5><div class="NLM_p last">To a suspension of compound <b>5e</b> (536 mg, 1 mmol) in THF/CH<sub>3</sub>OH/H<sub>2</sub>O (5 mL/5 mL/5 mL) was added NaOH (60 mg, 4.5 mmol), and the mixture was stirred for 12 h at room temperature. To the reaction was added saturated ammonium chloride aqueous solution (20 mL), and it extracted by ethyl acetate. The organic phase was washed by water and brine. The organic phase was dried over MgSO<sub>4</sub> and evaporated, and the residue was purified by recrystallization (ethanol/toluene) to obtain 484 mg (93%) of <b>47</b> as an orange solid, mp 218.7 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.01 (s, 1H), 9.75 (s, 1H), 9.46 (s, 1H), 8.71 (s, 1H), 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 6.55 (s, 1H), 4.72 (p, <i>J</i> = 8.9 Hz, 1H), 3.04 (d, <i>J</i> = 7.5 Hz, 6H), 2.50–2.39 (m, 2H), 2.27 (t, <i>J</i> = 7.4 Hz, 2H), 2.20 (t, <i>J</i> = 7.3 Hz, 2H), 2.02–1.90 (m, 4H), 1.70–1.54 (m, 4H), 1.55–1.46 (m, 2H), 1.35–1.25 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.47, 170.66, 162.89, 155.54, 152.04, 151.24, 136.28, 132.92, 131.31, 119.33, 118.44, 111.24, 100.69, 56.91, 36.25, 34.55, 33.61, 29.55, 28.43, 28.34, 25.06, 24.38, 24.16. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>37</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> 521.2871, found 521.2872 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div><div id="sec4_1_8_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101">4.1.68.  <i>N</i>1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-yl)amino)phenyl)-<i>N</i>8,<i>N</i>8-dimethyloctanediamide (<b>48</b>)</h5><div class="NLM_p last">To a two-necked flask, compound <b>47</b> (0.21 mmol, 110 mg), dimethylamine (0.42 mmol, 0.21 mL, 2.0 mol/L in THF), EDCI (0.32 mmol, 61 mg), HOBt (0.25 mmol, 34 mg), DIEA (0.42 mmol, 54 mg), and THF (5 mL) were charged. The mixture was stirred at room temperature for 12 h, then quenched by water. The mixture was extracted by ethyl acetate, and the combined organic layer was washed with brine solution and dried by anhydrous magnesium sulfate. The solvent was evaporated, and the residue was purified by silica gel column chromatography (dichloromethane–methanol, gradient 100:0 → 94:6) to obtain 70.2 mg (61%) of 48 as a yellow solid, mp 169.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.76 (s, 1H), 9.46 (s, 1H), 8.71 (s, 1H), 7.74 (d, <i>J</i> = 8.5 Hz, 2H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 6.56 (s, 1H), 4.72 (p, <i>J</i> = 8.8 Hz, 1H), 3.04 (s, 6H), 2.92 (s, 3H), 2.78 (s, 3H), 2.49–2.41 (m, 2H), 2.26 (q, <i>J</i> = 8.0 Hz, 4H), 2.04–1.88 (m, 4H), 1.72–1.52 (m, 4H), 1.48 (t, <i>J</i> = 7.3 Hz, 2H), 1.35–1.21 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.32, 171.17, 163.38, 156.04, 152.54, 151.73, 136.76, 133.42, 131.81, 119.79, 118.91, 111.73, 101.18, 57.40, 37.12, 36.76, 35.19, 35.06, 32.74, 30.03, 29.07, 25.59, 25.02, 24.65. ESI-HRMS <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>42</sub>N<sub>7</sub>O<sub>3</sub><sup>+</sup> 548.3344, found 548.3346 [M + H]<sup>+</sup>. HPLC purity 99%.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102">4.2.  Biology</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103">4.2.1.  Materials and Methods</h4><div class="NLM_p last">Human lung cancer cell lines A549 and H460 cells, human breast cancer cell lines MDA-MB-231 and T47D cells, human hepatic cancer cell lines HEPG2 and HEP3B, and 4T1 triple negative breast cancer cells were purchased from ATCC. All the cell lines were recently authenticated by cellular morphology and short tandem repeat analysis at Microread Inc. (Beijing, China; May 2014) according to the guideline from ATCC.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104">4.2.2.  Cytotoxicity Assays</h4><div class="NLM_p last">Cells were seeded at a cell density of 3 × 10<sup>3</sup> cells/0.1 mL/well in a 96-well plate. The compounds were added 24 h postplating at the indicated concentrations. Cell counts were determined from duplicate wells 72 h post-treatment. The total number of viable cells was determined using the CCK-8 assay (Promega, WI) in conjunction with the Microplate reader (Promega, WI).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105">4.2.3.  Kinase Inhibition Assays</h4><div class="NLM_p last">Kinase inhibition profiles were determined using KinaseProfiler services provided by Eurofins, and ATP concentrations used are the <i>K</i><sub>m</sub> of corresponding kinases. The binding affinities of <b>6e</b> projected on the human kinome tree were generated using the online Kinome Render program.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106">4.2.4.  Cell Cycle Assay</h4><div class="NLM_p last">The different cell lines were plated onto 100 mm<sup>3</sup> dishes at a cell density of 1.0 × 10<sup>6</sup> cells/dish. All cells were treated with increasing concentrations of the indicated compounds 24 h postplating. Cells were harvested 24 h post-treatment, washed in phosphate buffered saline (PBS), and fixed in ice cold 70% ethanol for at least 24 h. The fixed cells were then washed with room temperature PBS and stained with propidium iodide (50 mg/mL) in the presence of RNase A (0.5 mg) for 30 min at 37 °C. The stained cells were then analyzed using a flow cytometer, and the resulting data were analyzed with cell cycle analysis software (Modfit, BD).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107">4.2.5.  Apoptosis Assay</h4><div class="NLM_p last">Cells (3 × 10<sup>5</sup> cells/mL) were seeded in six-well plates and treated with compounds at different concentration for 48 h. The cells were then harvested by trypsinization and washed twice with cold PBS. After centrifugation and removal of the supernatants, cells were resuspended in 500 μL of 1× binding buffer, which was then added to 5 μL of annexin V-FITC and incubated at room temperature for 15 min. After adding 10 μL of PI, the cells were incubated at room temperature for another 15 min in dark. The stained cells were analyzed by a flow cytometer. All experiments were performed three times.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108">4.2.6.  Western Blotting</h4><div class="NLM_p last">Cell lysates from different cell lines were prepared with RIPA buffer in the presence of protease inhibitor cocktails and Phosphatase Inhibitor Cocktails 2 and 3 (P8340, P5726, and P0044, Sigma-Aldrich, St. Louis, MO, USA). Protein (20–50 μg) was separated by 8–15% Tris-acrylamide gels and transferred onto PVDF membrane; the membrane was blocked in 5% skim milk, subsequently incubated with primary antibodies at 4 °C overnight, followed by incubation with peroxidase-conjugated goat antimouse IgG or goat antirabbit IgG, and developed with Pierce ECL reagent (cat. #17153, Millipore, Billerica, MA, USA). Antibody information: antiphosphospecific Rb<sup>Ser807/811</sup> (Cell Signaling Technology; catalogue no. 8516), Rb (Cell Signaling; catalogue no. 9309), Acetyl-Histone H3 (Cell Signaling Technology, catalogue no. 9649), phosphospecific p53<sup>Ser15</sup> (Cell Signaling Technology; catalogue no. 9286), and Caspase 3 (Santa Cruz; catalogue no. 271028).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109">4.2.7.  Immunofluorescence Staining</h4><div class="NLM_p last">Briefly, cells were obtained and seeded on glass coverslips in complete 1640 in order to induce cell adhesion and then incubated with the inhibitors at different concentration. After 24 h, the cells were fixed in 4% paraformaldehyde, permeabilized in 0.15% Triton X-100, saturated using 4% BSA in PBS at room temperature for 1 h, and incubated overnight with anti-CDK4 or anti-acetyl histone H3 at 1:200 dilutions in PBS–4% BSA and then with a FITC-conjugated secondary antibody. Slides were mounted in glycerol–DABCO and observed using a Nikon Eclipse E600 microscope equipped with a digital camera. Images were elaborated only for brightness and contrast using Adobe Photoshop 7.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110">4.2.8.  In Vivo Assay</h4><div class="NLM_p last">The experimental procedures of the animal study were proved by the Animal Care and Use Committee at Nankai University. 4T1 triple negative breast cancer cells (5× 10<sup>4</sup>) were injected bilaterally in the mammary fat pads of 6–8 week old female BALB/c mice (Taconic, NY). Once the tumors grew to a volume of approximately 100 mm<sup>3</sup> they were placed into five treatment groups (<i>n</i> = 4, with a total tumor number of 20). The mice were treated daily for 18 days by via intraperitoneal administration or 24 days via oral gavage. Body weights and tumor size were determined every other day. Tumor measurements were found using a digital vernier caliper, and the volumes were determined using the following calculation: (short<sup>2</sup>) × long × 0.5. Experiments were performed under an approved IACUC protocol according to federal and institutional guidelines and regulations. Inhibition rate of tumor growth was calculated using the following formula: 100 × {1 – [(tumor volume<sub>final</sub> – tumor volume<sub>initial</sub>) for <b>9m</b>-treated group]/[(tumor volume<sub>final</sub> – tumor volume<sub>initial</sub>) for the vehicle-treated group]}.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111">4.2.9.  Immunohistochemistry Staining</h4><div class="NLM_p last">Immunohistochemistry staining was performed on the tumor BALB/c mice by using antibody against Bcl2 (BDbioscience, USA) and p-Rb (Cell Signaling Technology, USA), separately, followed by the standard labeled streptavidin–biotin method by using the 3,3′-diaminobenzidine (DAB) substrate. The images were recorded on an Olympus BX51 Epi-fluorescent microscope (Olympus Co. Tokyo, Japan) based on the images observed under a 20× objective.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112">4.2.10.  Procedure for LogP and LogD<sub>7.4</sub> Determination</h4><div class="NLM_p">LogP and LogD<sub>7.4</sub> were determined by using the well-known “shake-flask” method, and the concentrations of the test compound in the two phases were determined by HPLC (Shimadzu Prominence-i LC-2030C 3D system; column, InertSustain C18, 4.6 mm × 250 mm, 5 μm; mobile phase, gradient elution of methanol/H<sub>2</sub>O; low rate, 1.0 mL/min; UV wavelength, 190–800 nm; temperature, 40 °C; injection volume, 10 μL).</div><div class="NLM_p last">The LogP/D<sub>7.4</sub> was calculated by employing the following equation:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_m001.gif" alt="" id="_i113" /></img></span>where <i>C</i><sub>OCT</sub> and <i>C</i><sub>H2O</sub> is the compound’s concentration in each phase, respectively.<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_m002.gif" alt="" id="_i114" /></img></span>where <i>C</i><sub>OCT</sub> and <i>C</i><sub>PBS</sub> is the compound’s concentration in each phase, respectively.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115">4.2.11.  Aqueous Solubility Determination</h4><div class="NLM_p last">One milligram of <b>6e</b> was weighed and placed into 1 mL of PBS at 7.4, and 1 mg of methanesulfonic acid formulation was weighed and placed into 1 mL of water. The samples were sonicated, vortexed, and equilibrated by stirring at 100 rpm for 24 h and subsequently left standing, unstirred, for an additional 24 h at room temperature. At the end of equilibration, the entire sample volume was filtered manually through a 2.5 μm glass fiber syringe filter. The filtrate was subsequently analyzed by HPLC for solubility, and the solubility of the samples was determined in triplicate.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116">4.2.12.  Assessments of Pharmacokinetic Properties</h4><div class="NLM_p last">The pharmacokinetics analysis of <b>6e</b> was conducted in male Sprague–Dawley rats (Chinese Academy of Medical Science, Beijing, China). Briefly, catheters were surgically placed into the jugular veins of the rats to collect serial blood samples. Compound <b>6e</b> was dissolved in saline with 5% (v/v) DMSO. The animals were administered a single dose of 20 mg/kg <b>6e</b> by iv and ip after fasting overnight. Blood was collected and centrifuged immediately to isolate plasma. The plasma concentrations were determined using high performance liquid chromatography with HPLC analysis on a Shimadzu Prominence-i LC-2030C 3D system.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117">4.2.13.  Statistical Analysis</h4><div class="NLM_p last">Values were expressed as means ± SEM. Significance was determined by χ<sup>2</sup> test; others were determined by Student’s <i>t</i> test. A value of <i>P</i> < 0.05 was used as the criterion for statistical significance. *Indicates significant difference with <i>P</i> < 0.05, **indicates significant difference with <i>P</i> < 0.01, and ***indicates significant difference with <i>P</i> < 0.001.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i118"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00209" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00209" class="ext-link">10.1021/acs.jmedchem.8b00209</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Pharmacophore features we defined based on the complex structure between CDK4 and HDAC1 with their ligands; preliminary screen of dual-action compounds; in vitro growth inhibitory activities of dual-action compounds; GI<sub>50</sub> value of compound <b>6e</b>; kinase profiling results of compound <b>6e</b>; molecular docking of the best candidate for enzyme inhibition; <sup>1</sup>H and <sup>13</sup>C spectra of compounds; ESI-HRMS spectra and HPLC purity analysis for compound <b>6e</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf">jm8b00209_si_001.pdf (7.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_002.csv">jm8b00209_si_002.csv (3.76 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00209" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Fan</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, 94 Weijin Road, Tianjin 300071, China</span>; 
    <span class="hlFld-Affiliation affiliation">2011 Project
Collaborative Innovation Center for Biotherapy of Ministry of Education, 94 Weijin Road, Tianjin 300071, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8099-3203" title="Orcid link">http://orcid.org/0000-0002-8099-3203</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dea7bfb0b8bfb09eb0bfb0b5bfb7f0bbbaabf0bdb0"><span class="__cf_email__" data-cfemail="3c455d525a5d527c525d52575d5512595849125f52">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Xiang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Medicinal Chemical Biology, 94 Weijin Road, Tianjin 300071, China</span>; 
    <span class="hlFld-Affiliation affiliation">2011 Project
Collaborative Innovation Center for Biotherapy of Ministry of Education, 94 Weijin Road, Tianjin 300071, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#57252f3e363930173936393c363e79323322793439"><span class="__cf_email__" data-cfemail="57252f3e363930173936393c363e79323322793439">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongtao Li</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohe Luo</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingxiang Guo</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongwei Nie</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianqi Wang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Zhang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhi Huang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Wang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanhua Liu</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanan Chen</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianyu Zheng</span> - <span class="hlFld-Affiliation affiliation">State Key Laboratory and Institute of Elemento-Organic Chemistry,
Collaborative Innovation Center of Chemical Science and Engineering, Nankai University, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shengyong Yang</span> - <span class="hlFld-Affiliation affiliation">Medical Oncology, Cancer Center, State Key Laboratory
of Biotherapy, West China Hospital, Sichuan
University, Chengdu 610041, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5147-3746" title="Orcid link">http://orcid.org/0000-0001-5147-3746</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y. Li and X.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i120">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Project of Science and Technology Assistance in Developing Countries (KY201501006), the National Natural Science Foundation of China (81470354), and the Natural Science Foundation of Tianjin (17JCQNJC13500)</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS USED</td></tr><tr><td class="NLM_term">CDKs</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">HDACs</td><td class="NLM_def"><p class="first last">histone deacetylases</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine;</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i122">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45015" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45015" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 59 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+history+and+future+of+targeting+cyclin-dependent+kinases+in+cancer+therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0ljraqCcCGP7kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520history%2520and%2520future%2520of%2520targeting%2520cyclin-dependent%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grana, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (cdks), growth suppressor genes and cyclin-dependent kinase inhibitors (ckis)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=211-219&author=X.+Granaauthor=E.+P.+Reddy&title=Cell+cycle+control+in+mammalian+cells%3A+Role+of+cyclins%2C+cyclin+dependent+kinases+%28cdks%29%2C+growth+suppressor+genes+and+cyclin-dependent+kinase+inhibitors+%28ckis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrana%26aufirst%3DX.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCell%2520cycle%2520control%2520in%2520mammalian%2520cells%253A%2520Role%2520of%2520cyclins%252C%2520cyclin%2520dependent%2520kinases%2520%2528cdks%2529%252C%2520growth%2520suppressor%2520genes%2520and%2520cyclin-dependent%2520kinase%2520inhibitors%2520%2528ckis%2529%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">To cycle or not to cycle: A critical decision in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=To+cycle+or+not+to+cycle%3A+A+critical+decision+in+cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0ljraqCcCGP7kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DTo%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520A%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, cdks and cancer: A changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+cdks+and+cancer%3A+A+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0ljhwBhOc530wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520cdks%2520and%2520cancer%253A%2520A%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Cdk4: A key player in the cell cycle, development, and cancer</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1177/1947601913478972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1177%2F1947601913478972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=23634254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Wls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=658-669&author=S.+J.+Bakerauthor=E.+P.+Reddy&title=Cdk4%3A+A+key+player+in+the+cell+cycle%2C+development%2C+and+cancer&doi=10.1177%2F1947601913478972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4: a key player in the cell cycle, development, and cancer</span></div><div class="casAuthors">Baker, Stacey J.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">658-669, 12</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  The cell cycle is regulated in part by cyclins and their assocd. serine/threonine cyclin-dependent kinases, or CDKs.  CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell preps. to initiate DNA synthesis.  Although CDK4-null mutant mice are viable and cell proliferation is not significantly affected in vitro due to compensatory roles played by other CDKs, this gene plays a key role in mammalian development and cancer.  This review discusses the role that CDK4 plays in cell cycle control, normal development, and tumorigenesis as well as how small mol. inhibitors of CDK4 can be used to treat disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrm4MktbeTP7Vg90H21EOLACvtfcHk0ljhwBhOc530wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Wls7g%253D&md5=a9b5bbdff7e0c4bc6c350f210bc483b0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1177%2F1947601913478972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601913478972%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCdk4%253A%2520A%2520key%2520player%2520in%2520the%2520cell%2520cycle%252C%2520development%252C%2520and%2520cancer%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D658%26epage%3D669%26doi%3D10.1177%2F1947601913478972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: Cdk4 inhibitors for cancer therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3379</span>– <span class="NLM_lpage">3383</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1078-0432.CCR-13-1551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=24795392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKksr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=3379-3383&author=M.+A.+Dickson&title=Molecular+pathways%3A+Cdk4+inhibitors+for+cancer+therapy&doi=10.1158%2F1078-0432.CCR-13-1551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: CDK4 Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Dickson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3379-3383</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common.  CDK4 is the key regulator of the G1-S transition.  In complex with cyclin D, CDK4 phosphorylates retinoblastoma protein (Rb) and drives cell-cycle progression, a process inhibited by p16.  The p16-CDK4-cyclin D-Rb is aberrant in the majority of cancers and is, thus, a logical target for anticancer therapy.  Previous attempts to block CDK4 with nonselective cyclin-dependent kinase (CDK) inhibitors led to toxicity and little efficacy.  However, the recent development of selective CDK4 inhibitors launched the first successful efforts to target the pathway for cancer therapy.  Three oral selective CDK4 inhibitors have entered clin. trials: palbociclib (PD0332991), LEE011, and LY2835219.  CDK4 inhibitors have in vitro activity against a broad range of cancers and in patients have shown antitumor activity in breast cancer, lymphoma, sarcoma, and other tumors.  Major efforts are under way to develop biomarkers of response, understand potential mechanisms of resistance, and develop rational combinations of CDK4 inhibitors with chemotherapy and other targeted drugs.  Clin Cancer Res; 20(13); 3379-83. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMbU-VJN7oubVg90H21EOLACvtfcHk0ljhwBhOc530wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKksr3O&md5=90a6fdde00acbc1b4bbe69472859176a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1551%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520pathways%253A%2520Cdk4%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D3379%26epage%3D3383%26doi%3D10.1158%2F1078-0432.CCR-13-1551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 inhibitors: Promising opportunities beyond breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F2159-8290.CD-16-0563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=697-699&author=J.+S.+J.+Limauthor=N.+C.+Turnerauthor=T.+A.+Yap&title=Cdk4%2F6+inhibitors%3A+Promising+opportunities+beyond+breast+cancer&doi=10.1158%2F2159-8290.CD-16-0563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0563%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%2BS.%2BJ.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DCdk4%252F6%2520inhibitors%253A%2520Promising%2520opportunities%2520beyond%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D697%26epage%3D699%26doi%3D10.1158%2F2159-8290.CD-16-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Treating cancer with selective cdk4/6 inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnrclinonc.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27030077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=417&author=B.+O%E2%80%99Learyauthor=R.+S.+Finnauthor=N.+C.+Turner&title=Treating+cancer+with+selective+cdk4%2F6+inhibitors&doi=10.1038%2Fnrclinonc.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Treating cancer with selective CDK4/6 inhibitors</span></div><div class="casAuthors">O'Leary, Ben; Finn, Richard S.; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-430</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathol. process.  Clin. implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents.  The emergence of a new generation of selective CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has enabled tumor types in which CDK4/6 has a pivotal role in the G1-to-S-phase cell-cycle transition to be targeted with improved effectiveness, and fewer adverse effects.  Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage estrogen receptor (ER)-pos. breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile.  Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified.  Extending the use of CDK4/6 inhibitors beyond ER-pos. breast cancer is challenging, and will likely require biomarkers that are predictive of a response, and the use of combination therapies in order to optimize CDK4/6 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNYw6CRUf17Vg90H21EOLACvtfcHk0lgEH9Oj1YlwjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D&md5=6641dc6ab3cbd70edac46319ce4e6f45</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DB.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DTreating%2520cancer%2520with%2520selective%2520cdk4%252F6%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D13%26spage%3D417%26doi%3D10.1038%2Fnrclinonc.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">Targeting cdk4 and cdk6: From discovery to therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F2159-8290.CD-15-0894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=26658964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlslaqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=353-367&author=C.+J.+Sherrauthor=D.+Beachauthor=G.+I.+Shapiro&title=Targeting+cdk4+and+cdk6%3A+From+discovery+to+therapy&doi=10.1158%2F2159-8290.CD-15-0894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK4 and CDK6: From Discovery to Therapy</span></div><div class="casAuthors">Sherr, Charles J.; Beach, David; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-367</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Biochem. and genetic characterization of D-type cyclins, their cyclin D-dependent kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16INK4 over two decades ago revealed how mammalian cells regulate entry into the DNA synthetic (S) phase of the cell-division cycle in a retinoblastoma protein-dependent manner.  These investigations provided proof-of-principle that CDK4/6 inhibitors, particularly when combined with coinhibition of allied mitogen-dependent signal transduction pathways, might prove valuable in cancer therapy.  FDA approval of the CDK4/6 inhibitor palbociclib used with the aromatase inhibitor letrozole for breast cancer treatment highlights long-sought success.  The newest findings herald clin. trials targeting other cancers.  Significance: Rapidly emerging data with selective inhibitors of CDK4/6 have validated these cell-cycle kinases as anticancer drug targets, corroborating longstanding preclin. predictions.  This review addresses the discovery of these CDKs and their regulators, as well as translation of CDK4/6 biol. to pos. clin. outcomes and development of rational combinatorial therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNk2UjFylJJ7Vg90H21EOLACvtfcHk0lgEH9Oj1YlwjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlslaqu70%253D&md5=f4b1670d4771ca2079fb1eb7ebaef2b2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0894%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DBeach%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DTargeting%2520cdk4%2520and%2520cdk6%253A%2520From%2520discovery%2520to%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D353%26epage%3D367%26doi%3D10.1158%2F2159-8290.CD-15-0894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Giovanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavecchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzaro, G.</span></span> <span> </span><span class="NLM_article-title">Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: An update on recent findings (2013–2016)</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1215</span>– <span class="NLM_lpage">1230</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1234603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1080%2F13543784.2016.1234603" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1215-1230&author=C.+Di+Giovanniauthor=E.+Novellinoauthor=A.+Chilinauthor=A.+Lavecchiaauthor=G.+Marzaro&title=Investigational+drugs+targeting+cyclin-dependent+kinases+for+the+treatment+of+cancer%3A+An+update+on+recent+findings+%282013%E2%80%932016%29&doi=10.1080%2F13543784.2016.1234603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1234603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1234603%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGiovanni%26aufirst%3DC.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DChilin%26aufirst%3DA.%26aulast%3DLavecchia%26aufirst%3DA.%26aulast%3DMarzaro%26aufirst%3DG.%26atitle%3DInvestigational%2520drugs%2520targeting%2520cyclin-dependent%2520kinases%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520An%2520update%2520on%2520recent%2520findings%2520%25282013%25E2%2580%25932016%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1215%26epage%3D1230%26doi%3D10.1080%2F13543784.2016.1234603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span> <span> </span><span class="NLM_article-title">Targeting cdk4/6 in patients with cancer</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.ctrv.2016.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27017286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=129&author=E.+Hamiltonauthor=J.+R.+Infante&title=Targeting+cdk4%2F6+in+patients+with+cancer&doi=10.1016%2Fj.ctrv.2016.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK4/6 in patients with cancer</span></div><div class="casAuthors">Hamilton, Erika; Infante, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway controls cell cycle progression by regulating the G1-S checkpoint.  Dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway results in increased proliferation, and is frequently obsd. in many types of cancer.  Pathway activation can occur through a variety of mechanisms, including gene amplification or rearrangement, loss of neg. regulators, epigenetic alterations, and point mutations in key pathway components.  Due to the importance of CDK4/6 activity in cancer cells, CDK4/6 inhibitors have emerged as promising candidates for cancer treatment.  Moreover, combination of a CDK4/6 inhibitor with other targeted therapies may help overcome acquired or de novo treatment resistance.  Ongoing studies include combinations of CDK4/6 inhibitors with endocrine therapy and phosphatidylinositol 3-kinase (PI3K) pathway inhibitors for hormone receptor-pos. (HR+) breast cancers, and with selective RAF and MEK inhibitors for tumors with alterations in the mitogen activated protein kinase (MAPK) pathway such as melanoma.  In particular, the combination of CDK4/6 inhibitors with endocrine therapy, such as palbociclib's recent first-line approval in combination with letrozole, is expected to transform the treatment of HR+ breast cancer.  Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219).  Here we describe the current preclin. and clin. data for these novel agents and discuss combination strategies with other agents for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6OrwmwegM7Vg90H21EOLACvtfcHk0lgEH9Oj1YlwjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOmu7w%253D&md5=8a88741e40627cb9f5c477b5a106b5ac</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DE.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DTargeting%2520cdk4%252F6%2520in%2520patients%2520with%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2016%26volume%3D45%26spage%3D129%26doi%3D10.1016%2Fj.ctrv.2016.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Gahmen, U.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1021/jm049353p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049353p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFSqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=737-743&author=H.+Luauthor=D.+J.+Changauthor=B.+Baratteauthor=L.+Meijerauthor=U.+Schulze-Gahmen&title=Crystal+structure+of+a+human+cyclin-dependent+kinase+6+complex+with+a+flavonol+inhibitor%2C+fisetin&doi=10.1021%2Fjm049353p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin</span></div><div class="casAuthors">Lu, Heshu; Chang, Debbie J.; Baratte, Blandine; Meijer, Laurent; Schulze-Gahmen, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-743</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play a central role in cell cycle control, apoptosis, transcription, and neuronal functions.  They are important targets for the design of drugs with antimitotic or antineurodegenerative effects.  CDK4 and CDK6 form a subfamily among the CDKs in mammalian cells, as defined by sequence similarities.  Compared to CDK2 and CDK5, structural information on CDK4 and CDK6 is sparse.  We describe here the crystal structure of human CDK6 in complex with a viral cyclin and a flavonol inhibitor, fisetin.  Fisetin binds to the active form of CDK6, forming hydrogen bonds with the side chains of residues in the binding pocket that undergo large conformational changes during CDK activation by cyclin binding.  The 4-keto group and the 3-hydroxyl group of fisetin are hydrogen bonded with the backbone in the hinge region between the N-terminal and C-terminal kinase domain, as has been obsd. for many CDK inhibitors.  However, CDK2 and HCK kinase in complex with other flavone inhibitors such as quercetin and flavopiridol showed a different binding mode with the inhibitor rotated by about 180°.  The structural information of the CDK6-fisetin complex is correlated with the binding affinities of different flavone inhibitors for CDK6.  This complex structure is the first description of an inhibitor complex with a kinase from the CDK4/6 subfamily and can provide a basis for selecting and designing inhibitor compds. with higher affinities and specificities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeJrMaE-wOqrVg90H21EOLACvtfcHk0ljuJBlDZO3Bdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFSqsQ%253D%253D&md5=0c3910ed0310038be241230a633ba840</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm049353p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049353p%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DD.%2BJ.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26atitle%3DCrystal%2520structure%2520of%2520a%2520human%2520cyclin-dependent%2520kinase%25206%2520complex%2520with%2520a%2520flavonol%2520inhibitor%252C%2520fisetin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D737%26epage%3D743%26doi%3D10.1021%2Fjm049353p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase (cdk) inhibitors as anticancer drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2015.05.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3420-3435&author=C.+Sanchez-Martinezauthor=L.+M.+Gelbertauthor=M.+J.+Lallenaauthor=A.+de+Dios&title=Cyclin+dependent+kinase+%28cdk%29+inhibitors+as+anticancer+drugs&doi=10.1016%2Fj.bmcl.2015.05.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%2520%2528cdk%2529%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3420%26epage%3D3435%26doi%3D10.1016%2Fj.bmcl.2015.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diskin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parasuraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnepp, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Dual cdk4/cdk6 inhibition induces cell-cycle arrest and senescence in neuroblastoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6173</span>– <span class="NLM_lpage">6182</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1078-0432.CCR-13-1675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=24045179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyku7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6173-6182&author=J.+Raderauthor=M.+R.+Russellauthor=L.+S.+Hartauthor=M.+S.+Nakazawaauthor=L.+T.+Belcastroauthor=D.+Martinezauthor=Y.+Liauthor=E.+L.+Carpenterauthor=E.+F.+Attiyehauthor=S.+J.+Diskinauthor=S.+Kimauthor=S.+Parasuramanauthor=G.+Caponigroauthor=R.+W.+Schneppauthor=A.+C.+Woodauthor=B.+Pawelauthor=K.+A.+Coleauthor=J.+M.+Maris&title=Dual+cdk4%2Fcdk6+inhibition+induces+cell-cycle+arrest+and+senescence+in+neuroblastoma&doi=10.1158%2F1078-0432.CCR-13-1675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma</span></div><div class="casAuthors">Rader, JulieAnn; Russell, Mike R.; Hart, Lori S.; Nakazawa, Michael S.; Belcastro, Lili T.; Martinez, Daniel; Li, Yimei; Carpenter, Erica L.; Attiyeh, Edward F.; Diskin, Sharon J.; Kim, Sunkyu; Parasuraman, Sudha; Caponigro, Giordano; Schnepp, Robert W.; Wood, Andrew C.; Pawel, Bruce; Cole, Kristina A.; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6173-6182</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Neuroblastoma is a pediatric cancer that continues to exact significant morbidity and mortality.  Recently, a no. of cell-cycle proteins, particularly those within the Cyclin D/CDK4/CDK6/RB network, have been shown to exert oncogenic roles in neuroblastoma, suggesting that their therapeutic exploitation might improve patient outcomes.  Exptl. Procedures: We evaluated the effect of dual CDK4/CDK6 inhibition on neuroblastoma viability using LEE011 (Novartis Oncol.), a highly specific CDK4/6 inhibitor.  Results: Treatment with LEE011 significantly reduced proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis at nanomolar concns. (mean IC50 = 307 ± 68 nmol/L in sensitive lines).  LEE011 caused cell-cycle arrest and cellular senescence that was attributed to dose-dependent decreases in phosphorylated RB and FOXM1, resp.  In addn., responsiveness of neuroblastoma xenografts to LEE011 translated to the in vivo setting in that there was a direct correlation of in vitro IC50 values with degree of s.c. xenograft growth delay.  Although our data indicate that neuroblastomas sensitive to LEE011 were more likely to contain genomic amplification of MYCN (P = 0.01), the identification of addnl. clin. accessible biomarkers is of high importance.  Conclusions: Taken together, our data show that LEE011 is active in a large subset of neuroblastoma cell line and xenograft models, and supports the clin. development of this CDK4/6 inhibitor as a therapy for patients with this disease.  Clin Cancer Res; 19(22); 6173-82. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEpLsvDNwSLVg90H21EOLACvtfcHk0ljuJBlDZO3Bdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyku7rL&md5=5fd1f23125cca7e087d0e14d4c66c3c1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1675%26sid%3Dliteratum%253Aachs%26aulast%3DRader%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%2BR.%26aulast%3DHart%26aufirst%3DL.%2BS.%26aulast%3DNakazawa%26aufirst%3DM.%2BS.%26aulast%3DBelcastro%26aufirst%3DL.%2BT.%26aulast%3DMartinez%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCarpenter%26aufirst%3DE.%2BL.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DDiskin%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DParasuraman%26aufirst%3DS.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DSchnepp%26aufirst%3DR.%2BW.%26aulast%3DWood%26aufirst%3DA.%2BC.%26aulast%3DPawel%26aufirst%3DB.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DDual%2520cdk4%252Fcdk6%2520inhibition%2520induces%2520cell-cycle%2520arrest%2520and%2520senescence%2520in%2520neuroblastoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6173%26epage%3D6182%26doi%3D10.1158%2F1078-0432.CCR-13-1675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostofizadeh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Euw, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkankit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamidi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taschereau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belldegrun, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F. F.</span></span> <span> </span><span class="NLM_article-title">Pd-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2997</span>– <span class="NLM_lpage">3004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=23898052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=2997-3004&author=J.+E.+Loganauthor=N.+Mostofizadehauthor=A.+J.+Desaiauthor=E.+Von+Euwauthor=D.+Conklinauthor=V.+Konkankitauthor=H.+Hamidiauthor=M.+Eckardtauthor=L.+Andersonauthor=H.+W.+Chenauthor=C.+Gintherauthor=E.+Taschereauauthor=P.+H.+Buiauthor=J.+G.+Christensenauthor=A.+S.+Belldegrunauthor=D.+J.+Slamonauthor=F.+F.+Kabbinavar&title=Pd-0332991%2C+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6%2C+demonstrates+inhibition+of+proliferation+in+renal+cell+carcinoma+at+nanomolar+concentrations+and+molecular+markers+predict+for+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity</span></div><div class="casAuthors">Logan, Joshua E.; Mostofizadeh, Nikayeh; Desai, Amrita J.; Von Euw, Erika; Conklin, Dylan; Konkankit, Veerauo; Hamidi, Habib; Eckardt, Mark; Anderson, Lee; Chen, Hsiao-Wang; Ginther, Charles; Taschereau, Eileen; Bui, Peter H.; Christensen, James G.; Belldegrun, Arie S.; Slamon, Dennis J.; Kabbinavar, Fairooz F.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2997-3004</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: PD-0332991 is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and was evaluated to det. its anti-proliferative effects in 25 renal cell carcinoma (RCC) cell lines.  Materials and Methods: Half-maximal inhibitory concns. (IC50) of PD-0332991 were detd. with cell line proliferation assays, as were its effects on the cell cycle, apoptosis, and retinoblastoma (RB) phosphorylation.  Mol. markers for response prediction, including p16, p15, cyclin D1 (CCND1), cyclin E1 (CCNE1), E2F transcription factor 1 (E2F1), RB, CDK4 and CDK6, were studied using array comparative genomic hybridization (CGH) and gene expression.  Results: IC50 values for PD-0332991 ranged from 25.0 nM to 700 nM, and the agent demonstrated G0/G1 cell-cycle arrest, induction of late apoptosis, and blockade of RB phosphorylation.  Through genotype and expression data p16, p15 and E2F1 were identified as having significant assocn. between loss and sensitivity to PD-0332991: p16 (p=0.021), p15 (p=0.047), and E2F1 (p=0.041).  Conclusion: PD-0332991 has antiproliferative activity in RCC cell lines, and mol. markers predict for sensitivity to this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy_nR-af24obVg90H21EOLACvtfcHk0lgUfFpT4_ToDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsLnI&md5=edd3b575a24b999dd3ec69b648a9b11d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLogan%26aufirst%3DJ.%2BE.%26aulast%3DMostofizadeh%26aufirst%3DN.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DVon%2BEuw%26aufirst%3DE.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DKonkankit%26aufirst%3DV.%26aulast%3DHamidi%26aufirst%3DH.%26aulast%3DEckardt%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%2BW.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DTaschereau%26aufirst%3DE.%26aulast%3DBui%26aufirst%3DP.%2BH.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DBelldegrun%26aufirst%3DA.%2BS.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DKabbinavar%26aufirst%3DF.%2BF.%26atitle%3DPd-0332991%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%252C%2520demonstrates%2520inhibition%2520of%2520proliferation%2520in%2520renal%2520cell%2520carcinoma%2520at%2520nanomolar%2520concentrations%2520and%2520molecular%2520markers%2520predict%2520for%2520sensitivity%26jtitle%3DAnticancer%2520Res.%26date%3D2013%26volume%3D33%26spage%3D2997%26epage%3D3004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalous, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowst, C.</span></span> <span> </span><span class="NLM_article-title">Pd 0332991, a selective cyclin d kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1186/bcr2419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1186%2Fbcr2419" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1-13&author=R.+S.+Finnauthor=J.+Deringauthor=D.+Conklinauthor=O.+Kalousauthor=D.+J.+Cohenauthor=A.+J.+Desaiauthor=C.+Gintherauthor=M.+Atefiauthor=I.+Chenauthor=C.+Fowst&title=Pd+0332991%2C+a+selective+cyclin+d+kinase+4%2F6+inhibitor%2C+preferentially+inhibits+proliferation+of+luminal+estrogen+receptor-positive+human+breast+cancer+cell+lines+in+vitro&doi=10.1186%2Fbcr2419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fbcr2419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr2419%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DFowst%26aufirst%3DC.%26atitle%3DPd%25200332991%252C%2520a%2520selective%2520cyclin%2520d%2520kinase%25204%252F6%2520inhibitor%252C%2520preferentially%2520inhibits%2520proliferation%2520of%2520luminal%2520estrogen%2520receptor-positive%2520human%2520breast%2520cancer%2520cell%2520lines%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2009%26volume%3D11%26spage%3D1%26epage%3D13%26doi%3D10.1186%2Fbcr2419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2388</span>– <span class="NLM_lpage">2406</span>, <span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+R.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lgUfFpT4_ToDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%2BR.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baughn, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Liberto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen-Kiang, S.</span></span> <span> </span><span class="NLM_article-title">A novel orally active small molecule potently induces g<sub>1</sub> arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7661</span>– <span class="NLM_lpage">7667</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-1098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F0008-5472.CAN-06-1098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=7661-7667&author=L.+B.+Baughnauthor=M.+Di+Libertoauthor=K.+Wuauthor=P.+L.+Toogoodauthor=T.+Louieauthor=R.+Gottschalkauthor=R.+Niesvizkyauthor=H.+Choauthor=S.+Elyauthor=M.+A.+S.+Mooreauthor=S.+Chen-Kiang&title=A+novel+orally+active+small+molecule+potently+induces+g1+arrest+in+primary+myeloma+cells+and+prevents+tumor+growth+by+specific+inhibition+of+cyclin-dependent+kinase+4%2F6&doi=10.1158%2F0008-5472.CAN-06-1098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-1098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-1098%26sid%3Dliteratum%253Aachs%26aulast%3DBaughn%26aufirst%3DL.%2BB.%26aulast%3DDi%2BLiberto%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DLouie%26aufirst%3DT.%26aulast%3DGottschalk%26aufirst%3DR.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DEly%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DM.%2BA.%2BS.%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DA%2520novel%2520orally%2520active%2520small%2520molecule%2520potently%2520induces%2520g1%2520arrest%2520in%2520primary%2520myeloma%2520cells%2520and%2520prevents%2520tumor%2520growth%2520by%2520specific%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D7661%26epage%3D7667%26doi%3D10.1158%2F0008-5472.CAN-06-1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athuluridivakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallireddigari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallela, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billa, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbaiah, D. R. C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharathi, E. V.</span></span> <span> </span><span class="NLM_article-title">Vasquez-Del Carpio, R.; Padgaonkar, A.; Baker, S. J.; Reddy, E. P. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (cdk4) and ampk-related kinase 5 (arks)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1021/jm401073p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401073p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=578-599&author=M.+V.+R.+Reddyauthor=B.+Akulaauthor=S.+C.+Cosenzaauthor=S.+Athuluridivakarauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=V.+K.+Billaauthor=D.+R.+C.+V.+Subbaiahauthor=E.+V.+Bharathi&title=Vasquez-Del+Carpio%2C+R.%3B+Padgaonkar%2C+A.%3B+Baker%2C+S.+J.%3B+Reddy%2C+E.+P.+Discovery+of+8-cyclopentyl-2-%5B4-%284-methyl-piperazin-1-yl%29-phenylamino%5D-7-oxo-7%2C8-dihydro-pyrido%5B2%2C3-d%5Dpyrimidine-6-carbonitrile+%287x%29+as+a+potent+inhibitor+of+cyclin-dependent+kinase+4+%28cdk4%29+and+ampk-related+kinase+5+%28arks%29&doi=10.1021%2Fjm401073p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm401073p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401073p%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DAkula%26aufirst%3DB.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DAthuluridivakar%26aufirst%3DS.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DBilla%26aufirst%3DV.%2BK.%26aulast%3DSubbaiah%26aufirst%3DD.%2BR.%2BC.%2BV.%26aulast%3DBharathi%26aufirst%3DE.%2BV.%26atitle%3DVasquez-Del%2520Carpio%252C%2520R.%253B%2520Padgaonkar%252C%2520A.%253B%2520Baker%252C%2520S.%2520J.%253B%2520Reddy%252C%2520E.%2520P.%2520Discovery%2520of%25208-cyclopentyl-2-%255B4-%25284-methyl-piperazin-1-yl%2529-phenylamino%255D-7-oxo-7%252C8-dihydro-pyrido%255B2%252C3-d%255Dpyrimidine-6-carbonitrile%2520%25287x%2529%2520as%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%2520%2528cdk4%2529%2520and%2520ampk-related%2520kinase%25205%2520%2528arks%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D578%26epage%3D599%26doi%3D10.1021%2Fjm401073p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolay, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardeesy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, N. J.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 and igf1 receptor inhibitors synergize to suppress the growth of p16ink4a-deficient pancreatic cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3947</span>– <span class="NLM_lpage">3958</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F0008-5472.CAN-13-2923" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3947-3958&author=A.+M.+Heilmannauthor=R.+M.+Pereraauthor=V.+Eckerauthor=B.+N.+Nicolayauthor=N.+Bardeesyauthor=C.+H.+Benesauthor=N.+J.+Dyson&title=Cdk4%2F6+and+igf1+receptor+inhibitors+synergize+to+suppress+the+growth+of+p16ink4a-deficient+pancreatic+cancers&doi=10.1158%2F0008-5472.CAN-13-2923"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2923%26sid%3Dliteratum%253Aachs%26aulast%3DHeilmann%26aufirst%3DA.%2BM.%26aulast%3DPerera%26aufirst%3DR.%2BM.%26aulast%3DEcker%26aufirst%3DV.%26aulast%3DNicolay%26aufirst%3DB.%2BN.%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DDyson%26aufirst%3DN.%2BJ.%26atitle%3DCdk4%252F6%2520and%2520igf1%2520receptor%2520inhibitors%2520synergize%2520to%2520suppress%2520the%2520growth%2520of%2520p16ink4a-deficient%2520pancreatic%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3947%26epage%3D3958%26doi%3D10.1158%2F0008-5472.CAN-13-2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Dort, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nino, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanks, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbán, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (mek1) and phosphatidylinositol 3-kinase (pi3k)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2512</span>– <span class="NLM_lpage">2522</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2512-2522&author=M.+E.+Van+Dortauthor=H.+Hongauthor=H.+Wangauthor=C.+A.+Ninoauthor=R.+L.+Lombardiauthor=A.+E.+Blanksauthor=S.+Galb%C3%A1nauthor=B.+D.+Ross&title=Discovery+of+bifunctional+oncogenic+target+inhibitors+against+allosteric+mitogen-activated+protein+kinase+%28mek1%29+and+phosphatidylinositol+3-kinase+%28pi3k%29&doi=10.1021%2Facs.jmedchem.5b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K)</span></div><div class="casAuthors">Van Dort, Marcian E.; Hong, Hao; Wang, Hanxiao; Nino, Charles A.; Lombardi, Rachel L.; Blanks, Avery E.; Galban, Stefanie; Ross, Brian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2512-2522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a series of single entity, bifunctional MEK1/PI3K inhibitors achieved by covalent linking of structural analogs of the ATP-competitive PI3K inhibitor ZSTK474 and the ATP-noncompetitive MEK inhibitor PD0325901 is described.  Inhibitors displayed potent in vitro inhibition of MEK1 (0.015 < IC50 (nM) < 56.7) and PI3K (54 < IC50 (nM) < 341) in enzymic inhibition assays.  Concurrent MEK1 and PI3K inhibition was demonstrated with inhibitors 9 and 14 in two tumor cell lines (A549, D54).  Inhibitors produced dose-dependent decreased cell viability similar to the combined administration of equiv. doses of ZSTK474 and PD0325901.  In vivo efficacy of 14 following oral administration was demonstrated in D54 glioma and A549 lung tumor bearing mice.  Compd. 14 showed a 95% and 67% inhibition of tumor ERK1/2 and Akt phosphorylation, resp., at 2 h postadministration by Western blot anal., confirming the bioavailability and efficacy of this bifunctional inhibitor strategy toward combined MEK1/PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxtplBF0UZ7bVg90H21EOLACvtfcHk0lgTuCLaKL8BwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yqsL4%253D&md5=1bbc4eef05d0c4bab6a21e7a5db2790e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01655%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDort%26aufirst%3DM.%2BE.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNino%26aufirst%3DC.%2BA.%26aulast%3DLombardi%26aufirst%3DR.%2BL.%26aulast%3DBlanks%26aufirst%3DA.%2BE.%26aulast%3DGalb%25C3%25A1n%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520bifunctional%2520oncogenic%2520target%2520inhibitors%2520against%2520allosteric%2520mitogen-activated%2520protein%2520kinase%2520%2528mek1%2529%2520and%2520phosphatidylinositol%25203-kinase%2520%2528pi3k%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2512%26epage%3D2522%26doi%3D10.1021%2Facs.jmedchem.5b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sestito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrobono, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Maio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapposelli, S.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of pdk1 and aurora kinase a: An effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00251</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00251" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGku7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=100-114&author=S.+Danieleauthor=S.+Sestitoauthor=D.+Pietrobonoauthor=C.+Giacomelliauthor=G.+Chielliniauthor=D.+Di+Maioauthor=L.+Marinelliauthor=E.+Novellinoauthor=C.+Martiniauthor=S.+Rapposelli&title=Dual+inhibition+of+pdk1+and+aurora+kinase+a%3A+An+effective+strategy+to+induce+differentiation+and+apoptosis+of+human+glioblastoma+multiforme+stem+cells&doi=10.1021%2Facschemneuro.6b00251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells</span></div><div class="casAuthors">Daniele, Simona; Sestito, Simona; Pietrobono, Deborah; Giacomelli, Chiara; Chiellini, Grazia; Di Maio, Danilo; Marinelli, Luciana; Novellino, Ettore; Martini, Claudia; Rapposelli, Simona</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-114</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The poor prognosis of Glioblastoma Multiforme (GBM) is mainly attributed to drug resistance mechanisms and to the existence of a subpopulation of glioma stem cells (GSCs).  Multi-target compds. able to both affect different deregulated pathways and the GSC subpopulation could escape tumor resistance, and most importantly, eradicate the stem cell reservoir.  In this respect, the simultaneous inhibition of Phosphoinositide-dependent kinase-1 (PDK1) and Aurora Kinase A (AurA), each one playing a pivotal role in cellular survival/migration/differentiation, could represent an innovative strategy to overcome GBM resistance and recurrence.  Herein, the cross-talk between these pathways was investigated, using the single-target ref. compds. MP7 (PDK1 inhibitor) and Alisertib (AurA inhibitor).  Furthermore, a new ligand, SA16, was identified for its ability to inhibit the PDK1 and the AurA pathways at once, thus proving to be a useful tool for the simultaneous inhibition of the two kinases.  SA16 blocked GBM cell proliferation, reduced tumor invasiveness, and triggered cellular apoptosis.  Most importantly, the AurA/PDK1 blocker showed an increased efficacy against GSCs, inducing their differentiation and apoptosis.  To the best of the authors' knowledge, this is the first report on combined targeting of PDK1 and AurA.  This drug represents an attractive multi-target lead scaffold for the development of new potential treatments for GBM and GSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxUhIyHzkNb7Vg90H21EOLACvtfcHk0lgTuCLaKL8BwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGku7fE&md5=0b560d2d60ed52d45d7d40864b551f1d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00251%26sid%3Dliteratum%253Aachs%26aulast%3DDaniele%26aufirst%3DS.%26aulast%3DSestito%26aufirst%3DS.%26aulast%3DPietrobono%26aufirst%3DD.%26aulast%3DGiacomelli%26aufirst%3DC.%26aulast%3DChiellini%26aufirst%3DG.%26aulast%3DDi%2BMaio%26aufirst%3DD.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DRapposelli%26aufirst%3DS.%26atitle%3DDual%2520inhibition%2520of%2520pdk1%2520and%2520aurora%2520kinase%2520a%253A%2520An%2520effective%2520strategy%2520to%2520induce%2520differentiation%2520and%2520apoptosis%2520of%2520human%2520glioblastoma%2520multiforme%2520stem%2520cells%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D100%26epage%3D114%26doi%3D10.1021%2Facschemneuro.6b00251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konze, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. G.</span></span> <span> </span><span class="NLM_article-title">Targeting ezh2 and prc2 dependence as novel anticancer therapy</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2015.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.exphem.2015.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=26027790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2hsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=698-712&author=B.+W.+Xuauthor=K.+D.+Konzeauthor=J.+Jinauthor=G.+G.+Wang&title=Targeting+ezh2+and+prc2+dependence+as+novel+anticancer+therapy&doi=10.1016%2Fj.exphem.2015.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EZH2 and PRC2 dependence as novel anticancer therapy</span></div><div class="casAuthors">Xu, Bowen; Konze, Kyle D.; Jin, Jian; Wang, Gang Greg</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">698-712</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Distinctive patterns of chromatin modification control gene expression and define cellular identity during development and cell differentiation.  Polycomb repressive complex 2 (PRC2), the sole mammalian enzymic complex capable of establishing gene-repressive high-degree methylation of histone H3 at lysine 27 (H3K27), plays crucial roles in regulation of normal and malignant hematopoiesis.  Recently, increasing evidence has indicated that recurrent gain-of-function mutation and overexpression of EZH2, the catalytic subunit of PRC2, drive and promote malignant transformation such as B-cell lymphomagenesis, providing a rationale for PRC2 inhibition as a novel anticancer strategy.  Here, we summarize the recently developed strategies for inhibition of PRC2, which include a series of highly specific, highly potent, small-mol. inhibitors of EZH2 and EZH1, an EZH2-related methyltransferase.  PRC2 establishes functional crosstalk with numerous epigenetic machineries during dynamic regulation of gene transcription.  Perturbation of such functional crosstalk caused by genetic events obsd. in various hematol. cancers, such as inactivation of SNF5 and somatic mutation of UTX, confers PRC2 dependence, thus rendering an increased sensitivity to PRC2 inhibition.  We discuss our current understanding of EZH2 somatic mutations frequently found in B-cell lymphomas and recurrent mutations in various other epigenetic regulators as novel mol. predictors and determinants of PRC2 sensitivity.  As recent advances have indicated a crit. developmental or tumor-suppressive role for PRC2 and EZH2 in various tissue types, we discuss concerns over potentially toxic or even adverse effects assocd. with EZH2/1 inhibition in certain biol. contexts or on cancer genetic background.  Collectively, inhibition of PRC2 catalytic activity has emerged as a promising therapeutic intervention for the precise treatment of a range of genetically defined hematol. malignancies and can be potentially applied to a broader spectrum of human cancers that bear similar genetic and epigenetic characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdNIFJBGEoLVg90H21EOLACvtfcHk0lhpGd67hsZcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2hsbfO&md5=fa5481ff0ffc5bdc4b57dd7e21bc7fec</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2015.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%2BW.%26aulast%3DKonze%26aufirst%3DK.%2BD.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%2BG.%26atitle%3DTargeting%2520ezh2%2520and%2520prc2%2520dependence%2520as%2520novel%2520anticancer%2520therapy%26jtitle%3DExp.%2520Hematol.%26date%3D2015%26volume%3D43%26spage%3D698%26epage%3D712%26doi%3D10.1016%2Fj.exphem.2015.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peserico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, C.</span></span> <span> </span><span class="NLM_article-title">Physical and functional hat/hdac interplay regulates protein acetylation balance</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2011/371832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1155%2F2011%2F371832" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=1-10&author=A.+Pesericoauthor=C.+Simone&title=Physical+and+functional+hat%2Fhdac+interplay+regulates+protein+acetylation+balance&doi=10.1155%2F2011%2F371832"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1155%2F2011%2F371832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F371832%26sid%3Dliteratum%253Aachs%26aulast%3DPeserico%26aufirst%3DA.%26aulast%3DSimone%26aufirst%3DC.%26atitle%3DPhysical%2520and%2520functional%2520hat%252Fhdac%2520interplay%2520regulates%2520protein%2520acetylation%2520balance%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2011%2F371832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">Hdac family: What are the cancer relevant targets?</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=Hdac+family%3A+What+are+the+cancer+relevant+targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0lhpGd67hsZcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHdac%2520family%253A%2520What%2520are%2520the%2520cancer%2520relevant%2520targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">New and emerging hdac inhibitors for cancer treatment</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+hdac+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0lhpGd67hsZcpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520hdac%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N. B.</span></span> <span> </span><span class="NLM_article-title">Hdac inhibitors in cancer biology: Emerging mechanisms and clinical applications</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/icb.2011.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Ficb.2011.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=22124371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=85-94&author=O.+Khanauthor=N.+B.+La+Thangue&title=Hdac+inhibitors+in+cancer+biology%3A+Emerging+mechanisms+and+clinical+applications&doi=10.1038%2Ficb.2011.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications</span></div><div class="casAuthors">Khan, Omar; La Thangue, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology & Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiol. processes, many of which are aberrantly controlled in tumor cells.  As HDAC inhibition prompts tumor cells to enter apoptosis, small-mol. HDAC inhibitors have been developed as a new class of mechanism-based anti-cancer agent, many of which have entered clin. trials.  Although the clin. picture is evolving and the precise utility of HDAC inhibitors remains to be detd., it is noteworthy that certain tumor types undergo a favorable response, in particular hematol. malignancies.  Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease.  Here, we discuss developments in our understanding of mol. events that underlie the anti-cancer effects of HDAC inhibitors and relate this information to the emerging clin. picture for the application of these inhibitors in the treatment of cancer.  Immunol. and Cell Biol. (2012) 90, 85-94; doi:10.1038/icb.2011.100; published online 29 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvd48xGUlskbVg90H21EOLACvtfcHk0lheSuhHjinKWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D&md5=b9214c008e22696af4ee808b2e2af7f2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Ficb.2011.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ficb.2011.100%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DO.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26atitle%3DHdac%2520inhibitors%2520in%2520cancer%2520biology%253A%2520Emerging%2520mechanisms%2520and%2520clinical%2520applications%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D90%26spage%3D85%26epage%3D94%26doi%3D10.1038%2Ficb.2011.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3645</span>– <span class="NLM_lpage">3655</span>, <span class="refDoi"> DOI: 10.1021/jm400179b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400179b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3645-3655&author=J.+B.+Chenauthor=T.+R.+Chernauthor=T.+T.+Weiauthor=C.+C.+Chenauthor=J.+H.+Linauthor=J.+M.+Fang&title=Design+and+synthesis+of+dual-action+inhibitors+targeting+histone+deacetylases+and+3-hydroxy-3-methylglutaryl+coenzyme+a+reductase+for+cancer+treatment&doi=10.1021%2Fjm400179b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment</span></div><div class="casAuthors">Chen, Jhih-Bin; Chern, Ting-Rong; Wei, Tzu-Tang; Chen, Ching-Chow; Lin, Jung-Hsin; Fang, Jim-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3645-3655</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) such as I (X = bond, CH2; Y = bond, 1,4-benzenediyl; Z = bond, 1,2,3-triazole-4,1-diyl) and II were prepd. by incorporating the hydroxamate moieties of HDAC inhibitors into statins such as lovastatin known as HMGR inhibitors.  Hydroxamic acids such as II derived from ring-opening of the lactone moieties of statins were the most effective of the compds. tested at inhibiting HDAC and HMGR in vitro and in human leukemia cells, with IC50 values of 12-44 nM against HMGR, 63-125 nM against HDAC1, 414-600 nM against HDAC2, and 51-133 nM against HDAC6.  Statin-derived hydroxamic acids such as II inhibited the growth of human cancer cells with IC50 values of 18-20 μM and greater than five-fold selectivity for human cancer cells over normal human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYxyB-8TwI0LVg90H21EOLACvtfcHk0lheSuhHjinKWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D&md5=e212e0f2e9d565b215f69e66dfd8adac</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm400179b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400179b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BB.%26aulast%3DChern%26aufirst%3DT.%2BR.%26aulast%3DWei%26aufirst%3DT.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DFang%26aufirst%3DJ.%2BM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual-action%2520inhibitors%2520targeting%2520histone%2520deacetylases%2520and%25203-hydroxy-3-methylglutaryl%2520coenzyme%2520a%2520reductase%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3645%26epage%3D3655%26doi%3D10.1021%2Fjm400179b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (jak2) and histone deacetlyase (hdac) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28jak2%29+and+histone+deacetlyase+%28hdac%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lheSuhHjinKWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528jak2%2529%2520and%2520histone%2520deacetlyase%2520%2528hdac%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-src kinase and hdac inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-src+kinase+and+hdac+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0ljgpyue93eGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-src%2520kinase%2520and%2520hdac%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual hdac and pi3k inhibitor cudc-907 downregulates myc and suppresses growth of myc-dependent cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&author=K.+M.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+S.+Samsonauthor=A.+W.+Maauthor=G.+X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+hdac+and+pi3k+inhibitor+cudc-907+downregulates+myc+and+suppresses+growth+of+myc-dependent+cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0ljgpyue93eGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%2BM.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%2BS.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520hdac%2520and%2520pi3k%2520inhibitor%2520cudc-907%2520downregulates%2520myc%2520and%2520suppresses%2520growth%2520of%2520myc-dependent%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sposto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keshelava, N.</span></span> <span> </span><span class="NLM_article-title">Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant tp53</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3289</span>– <span class="NLM_lpage">3301</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1535-7163.MCT-10-0562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=21159612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3289-3301&author=J.+M.+Huangauthor=M.+A.+Sheardauthor=L.+Y.+Jiauthor=R.+Spostoauthor=N.+Keshelava&title=Combination+of+vorinostat+and+flavopiridol+is+selectively+cytotoxic+to+multidrug-resistant+neuroblastoma+cell+lines+with+mutant+tp53&doi=10.1158%2F1535-7163.MCT-10-0562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53</span></div><div class="casAuthors">Huang, Jen-Ming; Sheard, Michael A.; Ji, Lingyun; Sposto, Richard; Keshelava, Nino</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3289-3301</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As p53 loss of function (LOF) confers high-level drug resistance in neuroblastoma, p53-independent therapies might have superior activity in recurrent neuroblastoma.  We tested the activity of vorinostat, a histone deacetylase inhibitor, and flavopiridol, a pan-Cdk inhibitor, in a panel of multidrug-resistant neuroblastoma cell lines that included lines with wild-type (wt) and transcriptionally active TP53 (n = 3), mutated (mt), and LOF TP53 (n = 4) or p14ARF deletion (n = 1).  The combination of vorinostat and flavopiridol was synergistic and significantly more cytotoxic (P < 0.001) in cell lines with p53-LOF and in the clones stably transfected with dominant-neg. p53 plasmids.  Cell cycle anal. by flow cytometry showed prominent cell-cycle arrest in G2/M (37%) for a cell line with wt TP53 (SK-N-RA) at 16 to 20 h, while cells with mt TP53 (CHLA-90) slipped into sub-G1 at 6 to 24 h (25%-40% specific cell death).  The morphol. hallmarks of mitotic cell death, including defective spindle formation and abnormal cytokinesis, were detected by confocal microscopy after the treatment with vorinostat + flavopiridol combination in CHLA-90.  The combination caused redn. in the expression of G2/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53.  Plk1 expression was reduced in all treated lines.  Small interfering RNA knockdown of Mad2 and cyclin B1 or Plk1 synergistically reduced the clonogenicity of CHLA-90 cells.  The combination of HDAC inhibitor and flavopiridol may be a unique approach to treating neuroblastomas with p53 LOF, one that evokes induction of mitotic failure.  Mol Cancer Ther; 9(12); 3289-301.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq71Jeo3uw5mLVg90H21EOLACvtfcHk0ljgpyue93eGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsL3K&md5=9b36e48fc11d0e9e836559fd3f7336db</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0562%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%2BM.%26aulast%3DSheard%26aufirst%3DM.%2BA.%26aulast%3DJi%26aufirst%3DL.%2BY.%26aulast%3DSposto%26aufirst%3DR.%26aulast%3DKeshelava%26aufirst%3DN.%26atitle%3DCombination%2520of%2520vorinostat%2520and%2520flavopiridol%2520is%2520selectively%2520cytotoxic%2520to%2520multidrug-resistant%2520neuroblastoma%2520cell%2520lines%2520with%2520mutant%2520tp53%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D3289%26epage%3D3301%26doi%3D10.1158%2F1535-7163.MCT-10-0562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagostin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiscock, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniara, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortenson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benning, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrona, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active cdk4/6 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/ml200241a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200241a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=445-449&author=Y.+S.+Choauthor=H.+Angoveauthor=C.+Brainauthor=C.+H.+T.+Chenauthor=H.+Chengauthor=R.+Chengauthor=R.+Chopraauthor=K.+Chungauthor=M.+Congreveauthor=C.+Dagostinauthor=D.+J.+Davisauthor=R.+Feltenauthor=J.+Giraldesauthor=S.+D.+Hiscockauthor=S.+Kimauthor=S.+Kovatsauthor=B.+Laguauthor=K.+Lewryauthor=A.+Looauthor=Y.+P.+Luauthor=M.+Luzzioauthor=W.+Maniaraauthor=R.+McMenaminauthor=P.+N.+Mortensonauthor=R.+Benningauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=J.+Q.+Shenauthor=T.+Smithauthor=Y.+P.+Wangauthor=G.+Williamsauthor=A.+J.+A.+Woolfordauthor=W.+Wronaauthor=M.+Xuauthor=F.+Yangauthor=S.+Howard&title=Fragment-based+discovery+of+7-azabenzimidazoles+as+potent%2C+highly+selective%2C+and+orally+active+cdk4%2F6+inhibitors&doi=10.1021%2Fml200241a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml200241a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200241a%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DDagostin%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DFelten%26aufirst%3DR.%26aulast%3DGiraldes%26aufirst%3DJ.%26aulast%3DHiscock%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKovats%26aufirst%3DS.%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DLewry%26aufirst%3DK.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DY.%2BP.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DManiara%26aufirst%3DW.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMortenson%26aufirst%3DP.%2BN.%26aulast%3DBenning%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DShen%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26aulast%3DWrona%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHoward%26aufirst%3DS.%26atitle%3DFragment-based%2520discovery%2520of%25207-azabenzimidazoles%2520as%2520potent%252C%2520highly%2520selective%252C%2520and%2520orally%2520active%2520cdk4%252F6%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D445%26epage%3D449%26doi%3D10.1021%2Fml200241a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Contributions of molecular properties to drug promiscuity miniperspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/jm301514n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&author=A.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+molecular+properties+to+drug+promiscuity+miniperspective&doi=10.1021%2Fjm301514n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520molecular%2520properties%2520to%2520drug%2520promiscuity%2520miniperspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1789%26epage%3D1795%26doi%3D10.1021%2Fjm301514n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmi-Smail, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dequiedt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span> <span> </span><span class="NLM_article-title">Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3038</span>– <span class="NLM_lpage">3047</span>, <span class="refDoi"> DOI: 10.1021/jm901358y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901358y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3038-3047&author=C.+Salmi-Smailauthor=A.+Fabreauthor=F.+Dequiedtauthor=A.+Restouinauthor=R.+Castellanoauthor=S.+Garbitauthor=P.+Rocheauthor=X.+Morelliauthor=J.+M.+Brunelauthor=Y.+Collette&title=Modified+cap+group+suberoylanilide+hydroxamic+acid+histone+deacetylase+inhibitor+derivatives+reveal+improved+selective+antileukemic+activity&doi=10.1021%2Fjm901358y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity</span></div><div class="casAuthors">Salmi-Smail, Chanaz; Fabre, Aurelie; Dequiedt, Franck; Restouin, Audrey; Castellano, Remy; Garbit, Slaveia; Roche, Philippe; Morelli, Xavier; Brunel, Jean Michel; Collette, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3038-3047</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of SAHA cap derivs. RNHCO(CH2)6CONHOH (R = Ph, 4-H2NC6H4, 2-BrC6H4, 2-naphthyl, 8-quinolinyl, etc.) was designed and prepd. in good-to-excellent yields that varied from 49% to 95%.  These derivs. were evaluated for their antiproliferative activity in several human cancer cell lines.  Antiproliferative activity was obsd. for concns. varying from 0.12 to >100 μM, and a mol. modeling approach of selected SAHA derivs., based on available structural information of human HDAC8 in complex with SAHA, was performed.  Strikingly, two compds. displayed up to 10-fold improved antileukemic activity with respect to SAHA; however, these compds. displayed antiproliferative activity similar to SAHA when assayed against solid tumor-derived cell lines.  A 10-fold improvement in the leukemic vs peripheral blood mononuclear cell therapeutic ratio, with no evident in vivo toxicity toward blood cells, was also obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnbACulcCkrVg90H21EOLACvtfcHk0ljckQnziMXEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D&md5=70cf706e641add7d1ee6d410b501e075</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901358y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901358y%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi-Smail%26aufirst%3DC.%26aulast%3DFabre%26aufirst%3DA.%26aulast%3DDequiedt%26aufirst%3DF.%26aulast%3DRestouin%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGarbit%26aufirst%3DS.%26aulast%3DRoche%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DX.%26aulast%3DBrunel%26aufirst%3DJ.%2BM.%26aulast%3DCollette%26aufirst%3DY.%26atitle%3DModified%2520cap%2520group%2520suberoylanilide%2520hydroxamic%2520acid%2520histone%2520deacetylase%2520inhibitor%2520derivatives%2520reveal%2520improved%2520selective%2520antileukemic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3038%26epage%3D3047%26doi%3D10.1021%2Fjm901358y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepulveda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, S.</span></span> <span> </span><span class="NLM_article-title">Identification of novel hdac inhibitors through cell based screening and their evaluation as potential anticancer agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4793</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2013.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4790-4793&author=T.+Wangauthor=M.+Sepulvedaauthor=P.+Gonzalesauthor=S.+Gately&title=Identification+of+novel+hdac+inhibitors+through+cell+based+screening+and+their+evaluation+as+potential+anticancer+agents&doi=10.1016%2Fj.bmcl.2013.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSepulveda%26aufirst%3DM.%26aulast%3DGonzales%26aufirst%3DP.%26aulast%3DGately%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520novel%2520hdac%2520inhibitors%2520through%2520cell%2520based%2520screening%2520and%2520their%2520evaluation%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4790%26epage%3D4793%26doi%3D10.1016%2Fj.bmcl.2013.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ougolkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoy, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1021/jm901667k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901667k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1347-1356&author=R.+Heauthor=Y.+F.+Chenauthor=Y.+H.+Chenauthor=A.+V.+Ougolkovauthor=J.+S.+Zhangauthor=D.+N.+Savoyauthor=D.+D.+Billadeauauthor=A.+P.+Kozikowski&title=Synthesis+and+biological+evaluation+of+triazol-4-ylphenyl-bearing+histone+deacetylase+inhibitors+as+anticancer+agents&doi=10.1021%2Fjm901667k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Triazol-4-ylphenyl-Bearing Histone Deacetylase Inhibitors as Anticancer Agents</span></div><div class="casAuthors">He, Rong; Chen, Yufeng; Chen, Yihua; Ougolkov, Andrei V.; Zhang, Jin-San; Savoy, Doris N.; Billadeau, Daniel D.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our triazole-based histone deacetylase inhibitor (HDACI), octanedioic acid hydroxyamide[3-(1-phenyl-1H-[1,2,3]triazol-4-yl)phenyl]amide (4a), suppresses pancreatic cancer cell growth in vitro with the lowest IC50 value of 20 nM against MiaPaca-2 cell.  In this study, we continued our efforts to develop triazol-4-ylphenyl bearing hydroxamate analogs by embellishing the terminal Ph ring of 4a with different substituents.  The isoform inhibitory profile of these hydroxamate analogs was similar to those of 4a.  All of these triazol-4-ylphenyl bearing hydroxamates are pan-HDACIs like SAHA.  Moreover, compds. 4h (I) and 11a were found to be very effective inhibitors of cancer cell growth in the HupT3 (IC50 = 50 nM) and MiaPaca-2 (IC50 = 40 nM) cancer cell lines, resp.  Compd. 4a was found to reactivate the expression of CDK inhibitor proteins and to suppress pancreatic cancer cell growth in vivo.  Taken together, these data further support the value of the triazol-4-ylphenyl bearing hydroxamates in identifying potential pancreatic cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_PmkiG6vTw7Vg90H21EOLACvtfcHk0ljckQnziMXEZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVGqug%253D%253D&md5=80c55a4aa2fd3cb5b440ff34aec02b7c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm901667k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901667k%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DOugolkov%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DJ.%2BS.%26aulast%3DSavoy%26aufirst%3DD.%2BN.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520triazol-4-ylphenyl-bearing%2520histone%2520deacetylase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1347%26epage%3D1356%26doi%3D10.1021%2Fjm901667k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span> <span> </span><span class="NLM_article-title">Preparation and characterization of vorinostat-coated beads for profiling of novel target proteins</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1372</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2014.10.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.chroma.2014.10.098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1372&publication_year=2014&pages=34-41&author=C.+C.+Luauthor=K.+Zhangauthor=Y.+Zhangauthor=M.+J.+Tanauthor=Y.+J.+Liauthor=X.+W.+Heauthor=Y.+K.+Zhang&title=Preparation+and+characterization+of+vorinostat-coated+beads+for+profiling+of+novel+target+proteins&doi=10.1016%2Fj.chroma.2014.10.098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2014.10.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2014.10.098%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DHe%26aufirst%3DX.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26atitle%3DPreparation%2520and%2520characterization%2520of%2520vorinostat-coated%2520beads%2520for%2520profiling%2520of%2520novel%2520target%2520proteins%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2014%26volume%3D1372%26spage%3D34%26epage%3D41%26doi%3D10.1016%2Fj.chroma.2014.10.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Brazidec, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claassen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taveras, A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of 2,6,7-trisubstituted-7h-pyrrolo[2,3-d]pyrimidines as aurora kinases inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4033</span>– <span class="NLM_lpage">4037</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2012.04.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=22607669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlWjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4033-4037&author=J.+Y.+Le+Brazidecauthor=A.+Pasisauthor=B.+Tamauthor=C.+Boykinauthor=D.+P.+Wangauthor=D.+J.+Marcotteauthor=G.+Claassenauthor=J.+H.+Chongauthor=J.+H.+Chaoauthor=J.+H.+Fanauthor=K.+Nguyenauthor=L.+Silvianauthor=L.+Lingauthor=L.+Zhangauthor=M.+Choiauthor=M.+Tengauthor=N.+Pathanauthor=S.+Zhaoauthor=T.+Liauthor=A.+Taveras&title=Structure-based+design+of+2%2C6%2C7-trisubstituted-7h-pyrrolo%5B2%2C3-d%5Dpyrimidines+as+aurora+kinases+inhibitors&doi=10.1016%2Fj.bmcl.2012.04.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors</span></div><div class="casAuthors">Le Brazidec, Jean-Yves; Pasis, Angela; Tam, Betty; Boykin, Christina; Wang, Deping; Marcotte, Douglas J.; Claassen, Gisela; Chong, Jer-Hong; Chao, Jianhua; Fan, Junhua; Nguyen, Khanh; Silvian, Laura; Ling, Leona; Zhang, Lin; Choi, Michael; Teng, Min; Pathan, Nuzhat; Zhao, Shuo; Li, Tony; Taveras, Art</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4033-4037</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This Letter reports the optimization of a pyrrolopyrimidine series as dual inhibitors of Aurora A/B kinases.  This series is derived from a pyrazolopyrimidine series previously reported as inhibitors of aurora kinases and CDKs.  In an effort to improve the selectivity of this chemotype, we switched to the pyrrolopyrimidine core which allowed functionalization on C-2.  In addn., the modeling rationale was based on superimposing the structures of Aurora-A kinase and CDK2 which revealed enough differences leading to a path for selectivity improvement.  The synthesis of the new series of pyrrolopyrimidine analogs relied on the development of a different route for the two key intermediates, which led to analogs with both tunable activity against CDK1 and maintained cell potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogQtFgpCCHObVg90H21EOLACvtfcHk0liFFYhSXTelpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlWjtrg%253D&md5=969903ef4b627f4d6f6306447c08758c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.085%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBrazidec%26aufirst%3DJ.%2BY.%26aulast%3DPasis%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DB.%26aulast%3DBoykin%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%2BP.%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DClaassen%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DJ.%2BH.%26aulast%3DChao%26aufirst%3DJ.%2BH.%26aulast%3DFan%26aufirst%3DJ.%2BH.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DSilvian%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DTaveras%26aufirst%3DA.%26atitle%3DStructure-based%2520design%2520of%25202%252C6%252C7-trisubstituted-7h-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520aurora%2520kinases%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4033%26epage%3D4037%26doi%3D10.1016%2Fj.bmcl.2012.04.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Development of a fluorescence polarization based assay for histone deacetylase ligand discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2809</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2008.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=18430569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2809-2812&author=R.+Mazitschekauthor=V.+Patelauthor=D.+F.+Wirthauthor=J.+Clardy&title=Development+of+a+fluorescence+polarization+based+assay+for+histone+deacetylase+ligand+discovery&doi=10.1016%2Fj.bmcl.2008.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a fluorescence polarization based assay for histone deacetylase ligand discovery</span></div><div class="casAuthors">Mazitschek, Ralph; Patel, Vishal; Wirth, Dyann F.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2809-2812</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate many important physiol. processes and the discovery of small mols. that modulate HDAC activity has both academic and clin. relevance.  HDAC inhibitors, most notably SAHA, have been pursued as cancer chemotherapeutics but may be useful in treating psychiatric disorders, malaria, and other diseases.  Herein, the authors describe an inexpensive and robust assay, based on fluorescence polarization, for HDAC ligand discovery.  The assay is well suited for high-throughput screening and enzyme kinetic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg1gFU5ShKbVg90H21EOLACvtfcHk0liFFYhSXTelpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsrg%253D&md5=662ab74f9839dedd37bbb87f3ea950be</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520fluorescence%2520polarization%2520based%2520assay%2520for%2520histone%2520deacetylase%2520ligand%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2809%26epage%3D2812%26doi%3D10.1016%2Fj.bmcl.2008.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiriy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocharova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiriy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, H. J.</span></span> <span> </span><span class="NLM_article-title">Designing thiophene-based azomethine ligomers with tailored properties: Self-assembly and charge carrier mobility</span>. <i>Chem. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4765</span>– <span class="NLM_lpage">4771</span>, <span class="refDoi"> DOI: 10.1021/cm049688v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cm049688v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=4765-4771&author=N.+Kiriyauthor=V.+Bocharovaauthor=A.+Kiriyauthor=M.+Stammauthor=F.+C.+Krebsauthor=H.+J.+Adler&title=Designing+thiophene-based+azomethine+ligomers+with+tailored+properties%3A+Self-assembly+and+charge+carrier+mobility&doi=10.1021%2Fcm049688v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcm049688v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcm049688v%26sid%3Dliteratum%253Aachs%26aulast%3DKiriy%26aufirst%3DN.%26aulast%3DBocharova%26aufirst%3DV.%26aulast%3DKiriy%26aufirst%3DA.%26aulast%3DStamm%26aufirst%3DM.%26aulast%3DKrebs%26aufirst%3DF.%2BC.%26aulast%3DAdler%26aufirst%3DH.%2BJ.%26atitle%3DDesigning%2520thiophene-based%2520azomethine%2520ligomers%2520with%2520tailored%2520properties%253A%2520Self-assembly%2520and%2520charge%2520carrier%2520mobility%26jtitle%3DChem.%2520Mater.%26date%3D2004%26volume%3D16%26spage%3D4765%26epage%3D4771%26doi%3D10.1021%2Fcm049688v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemoine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Six, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depreux, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1021/jm2013453</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1189-1204&author=A.+Garofaloauthor=A.+Farceauthor=S.+Ravezauthor=A.+Lemoineauthor=P.+Sixauthor=P.+Chavatteauthor=L.+Goossensauthor=P.+Depreux&title=Synthesis+and+structure-activity+relationships+of+%28aryloxy%29quinazoline+ureas+as+novel%2C+potent%2C+and+selective+vascular+endothelial+growth+factor+receptor-2+inhibitors&doi=10.1021%2Fjm2013453"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm2013453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013453%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DSix%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DDepreux%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520%2528aryloxy%2529quinazoline%2520ureas%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1189%26epage%3D1204%26doi%3D10.1021%2Fjm2013453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brain, C. T.</span>; <span class="NLM_string-name">Cho, Y. S.</span>; <span class="NLM_string-name">Giraldes, J. W.</span>; <span class="NLM_string-name">Lagu, B.</span>; <span class="NLM_string-name">Levell, J.</span>; <span class="NLM_string-name">Luzzio, M.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Yang, F.</span></span> <span> </span><span class="NLM_article-title">Pyrrolopyrimidine compounds as inhibitors of cdk4/6</span>. <span class="NLM_patent">WO 2011101409 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+T.+Brain&author=Y.+S.+Cho&author=J.+W.+Giraldes&author=B.+Lagu&author=J.+Levell&author=M.+Luzzio&author=L.+B.+Perez&author=Y.+Wang&author=F.+Yang&title=Pyrrolopyrimidine+compounds+as+inhibitors+of+cdk4%2F6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrain%26aufirst%3DC.%2BT.%26atitle%3DPyrrolopyrimidine%2520compounds%2520as%2520inhibitors%2520of%2520cdk4%252F6%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. F.</span></span> <span> </span><span class="NLM_article-title">Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor t790m mutant</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.09.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.ejmech.2015.09.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=115-126&author=M.+Z.+Qinauthor=T.+T.+Wangauthor=B.+X.+Xuauthor=Z.+H.+Maauthor=N.+Jiangauthor=H.+B.+Xieauthor=P.+Gongauthor=Y.+F.+Zhao&title=Novel+hydrazone+moiety-bearing+aminopyrimidines+as+selective+inhibitors+of+epidermal+growth+factor+receptor+t790m+mutant&doi=10.1016%2Fj.ejmech.2015.09.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.09.031%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%2BZ.%26aulast%3DWang%26aufirst%3DT.%2BT.%26aulast%3DXu%26aufirst%3DB.%2BX.%26aulast%3DMa%26aufirst%3DZ.%2BH.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DH.%2BB.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%2BF.%26atitle%3DNovel%2520hydrazone%2520moiety-bearing%2520aminopyrimidines%2520as%2520selective%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520t790m%2520mutant%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D104%26spage%3D115%26epage%3D126%26doi%3D10.1016%2Fj.ejmech.2015.09.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span>; <span class="NLM_string-name">Dobrusin, E. M.</span>; <span class="NLM_string-name">Kramer, J. B.</span>; <span class="NLM_string-name">McNamara, D. J.</span>; <span class="NLM_string-name">Rewcastle, G. W.</span>; <span class="NLM_string-name">Showalter, H. D. H.</span>; <span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of pteridinones as kinase inhibitors</span>. <span class="NLM_patent">WO 2001019825 A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=W.+A.+Denny&author=E.+M.+Dobrusin&author=J.+B.+Kramer&author=D.+J.+McNamara&author=G.+W.+Rewcastle&author=H.+D.+H.+Showalter&author=P.+L.+Toogood&title=Preparation+of+pteridinones+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DPreparation%2520of%2520pteridinones%2520as%2520kinase%2520inhibitors%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span>; <span class="NLM_string-name">Jones, C. D.</span>; <span class="NLM_string-name">Simpson, I.</span>; <span class="NLM_string-name">Ward, R.
A.</span></span> <span> </span><span class="NLM_article-title">2-Anilnopurin-8-ones as inhibitors of tk/mps1 for the treatment of proliferative disorders</span>. <span class="NLM_patent">WO 2009024824 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=D.+M.+Andrews&author=C.+D.+Jones&author=I.+Simpson&author=R.%0AA.+Ward&title=2-Anilnopurin-8-ones+as+inhibitors+of+tk%2Fmps1+for+the+treatment+of+proliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26atitle%3D2-Anilnopurin-8-ones%2520as%2520inhibitors%2520of%2520tk%252Fmps1%2520for%2520the%2520treatment%2520of%2520proliferative%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of [3]rotaxanes that utilize the catalytic activity of a macrocyclic phenanthroline-Cu complex: remarkable effect of the length of the axle precursor</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1002/chem.201405090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1002%2Fchem.201405090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=25470127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2139-2145&author=Y.+Yamashitaauthor=Y.+Mutohauthor=R.+Yamasakiauthor=T.+Kasamaauthor=S.+Saito&title=Synthesis+of+%5B3%5Drotaxanes+that+utilize+the+catalytic+activity+of+a+macrocyclic+phenanthroline-Cu+complex%3A+remarkable+effect+of+the+length+of+the+axle+precursor&doi=10.1002%2Fchem.201405090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of [3]Rotaxanes that Utilize the Catalytic Activity of a Macrocyclic Phenanthroline-Cu Complex: Remarkable Effect of the Length of the Axle Precursor</span></div><div class="casAuthors">Yamashita, Yoshiaki; Mutoh, Yuichiro; Yamasaki, Ryu; Kasama, Takeshi; Saito, Shinichi</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2139-2145</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of [3]rotaxanes with a benzenediylbis(oxyoctyl)phenanthridine wheel and bis(triarylalkoxyphenyl)butadiyne axles [4-(R3C(CH2)nO)C6H4C≡C]2 (R = 4'-cyclohexyl-1,1'-biphenyl-4-yl; n = 6, 15, 20) were prepd. by oxidative dimerization of alkynes 4-(R3C(CH2)nO)C6H4C≡CH (R = 4'-cyclohexyl-1,1'-biphenyl-4-yl; n = 6, 15, 20) posessing the bulky tris[4'-cyclohexyl-(1,1'-biphenyl)-4-yl]methyl blocking group.  The catalytic activity of macrocyclic phenanthroline-Cu complex was utilized to thread the two axle components inside the ring.  The alkyne compd. with chain of 15 or 20 methylene groups gave [3]rotaxanes in high yields, whereas the axle with a chain of six methylene groups afforded a [3]rotaxane in very poor yield.  The effect of ring size in the synthesis of [3]rotaxanes was also examd.  The [3]rotaxanes were not isolated when a macrocyclic phenanthroline compd. with a smaller ring size was used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolmJ_ztMzNjLVg90H21EOLACvtfcHk0likIYOtx64Ibw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWgsr7I&md5=0e3d4ff257d4ffdfc22a8d90a1dbee62</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fchem.201405090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201405090%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DMutoh%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DR.%26aulast%3DKasama%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520%255B3%255Drotaxanes%2520that%2520utilize%2520the%2520catalytic%2520activity%2520of%2520a%2520macrocyclic%2520phenanthroline-Cu%2520complex%253A%2520remarkable%2520effect%2520of%2520the%2520length%2520of%2520the%2520axle%2520precursor%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D2139%26epage%3D2145%26doi%3D10.1002%2Fchem.201405090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. W.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of trk kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4672</span>– <span class="NLM_lpage">4684</span>, <span class="refDoi"> DOI: 10.1021/jm800343j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800343j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4672-4684&author=T.+Wangauthor=M.+L.+Lambauthor=D.+A.+Scottauthor=H.+Wangauthor=M.+H.+Blockauthor=P.+D.+Lyneauthor=J.+W.+Leeauthor=A.+M.+Daviesauthor=H.+J.+Zhangauthor=Y.+Y.+Zhuauthor=F.+Guauthor=Y.+X.+Hanauthor=B.+Wangauthor=P.+J.+Mohrauthor=R.+J.+Kausauthor=J.+A.+Joseyauthor=E.+Hoffmannauthor=K.+Thressauthor=T.+MacIntyreauthor=H.+Y.+Wangauthor=C.+A.+Omerauthor=D.+W.+Yu&title=Identification+of+4-aminopyrazolylpyrimidines+as+potent+inhibitors+of+trk+kinases&doi=10.1021%2Fjm800343j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases</span></div><div class="casAuthors">Wang, Tao; Lamb, Michelle L.; Scott, David A.; Wang, Haixia; Block, Michael H.; Lyne, Paul D.; Lee, John W.; Davies, Audrey M.; Zhang, Hai-Jun; Zhu, Yanyi; Gu, Fei; Han, Yongxin; Wang, Bin; Mohr, Peter J.; Kaus, Robert J.; Josey, John A.; Hoffmann, Ethan; Thress, Ken; MacIntyre, Terry; Wang, Haiyun; Omer, Charles A.; Yu, Dingwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4672-4684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluation of a series of 4-(pyrazolylamino)pyrimidines I (R1 = H, Me, SMe, cyclopropyl, Me2CHO, n-PrO, Me3C; R2 = H, Br, Cl, F, Me; R3 = H, HOCH2CH2NH, (S)-HOCH2CH(OH)CH2NH, etc.; R4 = Me, CH2OH, CH2CONMe2, CH2CONHMe; R5 = Ph, 2-ClC6H4, 4-FC6H4, 5-fluoro-2-pyridyl, 5-fluoro-2-pyrimidyl) as potent Trk kinase inhibitors is reported.  High-throughput screening identified a promising hit in the 4-(pyrazolylamino)pyrimidine chemotype.  Initial optimization of the series led to more potent Trk inhibitors.  Further optimization using two strategies resulted in significant improvement of phys. properties and led to the discovery of I (R1 = Me2CHO; R2 = Cl; R3 = H; R4 = (S)-Me; R5 = 5-fluoro-2-pyridyl) (AZ-23), a potent, orally bioavailable Trk A/B inhibitor.  The compd. offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ60edpRrhTrVg90H21EOLACvtfcHk0likIYOtx64Ibw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D&md5=16401146aa3860d13a4bc35bc04d5f83</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm800343j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800343j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%2BY.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DKaus%26aufirst%3DR.%2BJ.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DYu%26aufirst%3DD.%2BW.%26atitle%3DIdentification%2520of%25204-aminopyrazolylpyrimidines%2520as%2520potent%2520inhibitors%2520of%2520trk%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4672%26epage%3D4684%26doi%3D10.1021%2Fjm800343j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2387</span>, <span class="refDoi"> DOI: 10.1021/jm049355+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2371-2387&author=S.+N.+VanderWelauthor=P.+J.+Harveyauthor=D.+J.+McNamaraauthor=J.+T.+Repineauthor=P.+R.+Kellerauthor=J.+Quinauthor=R.+J.+Boothauthor=W.+L.+Elliottauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=P.+L.+Toogood&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+specific+inhibitors+of+cyclin-dependent+kinase+4&doi=10.1021%2Fjm049355%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4</span></div><div class="casAuthors">VanderWel, Scott N.; Harvey, Patricia J.; McNamara, Dennis J.; Repine, Joseph T.; Keller, Paul R.; Quin, John, III; Booth, R. John; Elliott, William L.; Dobrusin, Ellen M.; Fry, David W.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2371-2387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer.  The pyrido[2,3-d]pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples.  Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging.  A series of pyrido[2,3-d]pyrimidin-7-ones I (R1 = Me2CH, Et2CH, cyclopentyl; R2 = H, Me, Et, F3C; R3 = H, Me, F, Cl, COMe, MeO2C, etc.; X = HOCH, H2NCH, CH2N, CH2CH2, etc.) was synthesized and investigated as selective inhibitors of Cdk4.  The introduction of a Me substituent at the C-5 position of the pyrido[2,3-d]pyrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases.  Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro.  The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNHZHOwd7c7Vg90H21EOLACvtfcHk0liGVCjphI80WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D&md5=ef3c86bbdfaea0080d1103313d094ccd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DQuin%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520specific%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2371%26epage%3D2387%26doi%3D10.1021%2Fjm049355%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Sanchez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoy, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dow, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and plasmodium falciparum</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3437</span>– <span class="NLM_lpage">3448</span>, <span class="refDoi"> DOI: 10.1021/jm701606b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701606b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2rs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3437-3448&author=Y.+Chenauthor=M.+Lopez-Sanchezauthor=D.+N.+Savoyauthor=D.+D.+Billadeauauthor=G.+S.+Dowauthor=A.+P.+Kozikowski&title=A+series+of+potent+and+selective%2C+triazolylphenyl-based+histone+deacetylases+inhibitors+with+activity+against+pancreatic+cancer+cells+and+plasmodium+falciparum&doi=10.1021%2Fjm701606b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and Plasmodium falciparum</span></div><div class="casAuthors">Chen, Yufeng; Lopez-Sanchez, Miriam; Savoy, Doris N.; Billadeau, Daniel D.; Dow, Geoffrey S.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3437-3448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of the rules governing the inhibition of the various HDAC isoforms is likely to be key to identifying improved therapeutics that act as epigenetic modulators of gene transcription.  Herein we present results on the modification of the CAP region of a set of triazolylphenyl-based HDACIs, and show that the nature of substitution on the Ph ring plays a role in their selectivity for HDAC1 vs. HDAC6, with low to moderate selectivity (2-51-fold) being achieved.  In light of the valuable selectivity and potency that were identified for the triazolylphenyl ligand 6b in the inhibition of HDAC6 (IC50 = 1.9 nM), this compd. represents a valuable research tool and a candidate for further chem. modifications.  Lastly, these new HDACIs were studied for both their anticancer and antimalarial activity, which serve to validate the superior activity of the HDACI 10c.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtC-MXCaqyVLVg90H21EOLACvtfcHk0liGVCjphI80WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2rs7c%253D&md5=5a9e96ed8e268a04d387ca1f60b57837</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm701606b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701606b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLopez-Sanchez%26aufirst%3DM.%26aulast%3DSavoy%26aufirst%3DD.%2BN.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26aulast%3DDow%26aufirst%3DG.%2BS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520series%2520of%2520potent%2520and%2520selective%252C%2520triazolylphenyl-based%2520histone%2520deacetylases%2520inhibitors%2520with%2520activity%2520against%2520pancreatic%2520cancer%2520cells%2520and%2520plasmodium%2520falciparum%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3437%26epage%3D3448%26doi%3D10.1021%2Fjm701606b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cholody, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosakowska-Cholody, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariprakasha, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michejda, C. J.</span></span> <span> </span><span class="NLM_article-title">A new synthetic agent with potent but selective cytotoxic activity against cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4481</span>, <span class="refDoi"> DOI: 10.1021/jm048946x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm048946x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4474-4481&author=W.+M.+Cholodyauthor=T.+Kosakowska-Cholodyauthor=M.+G.+Hollingsheadauthor=H.+K.+Hariprakashaauthor=C.+J.+Michejda&title=A+new+synthetic+agent+with+potent+but+selective+cytotoxic+activity+against+cancer&doi=10.1021%2Fjm048946x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm048946x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm048946x%26sid%3Dliteratum%253Aachs%26aulast%3DCholody%26aufirst%3DW.%2BM.%26aulast%3DKosakowska-Cholody%26aufirst%3DT.%26aulast%3DHollingshead%26aufirst%3DM.%2BG.%26aulast%3DHariprakasha%26aufirst%3DH.%2BK.%26aulast%3DMichejda%26aufirst%3DC.%2BJ.%26atitle%3DA%2520new%2520synthetic%2520agent%2520with%2520potent%2520but%2520selective%2520cytotoxic%2520activity%2520against%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4474%26epage%3D4481%26doi%3D10.1021%2Fjm048946x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanArsdale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Spectrum and degree of cdk drug interactions predicts clinical performance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2273</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1535-7163.MCT-16-0300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27496135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2273-2281&author=P.+Chenauthor=N.+V.+Leeauthor=W.+Y.+Huauthor=M.+R.+Xuauthor=R.+A.+Ferreauthor=H.+Lamauthor=S.+Bergqvistauthor=J.+Solowiejauthor=W.+Diehlauthor=Y.+A.+Heauthor=X.+Yuauthor=A.+Nagataauthor=T.+VanArsdaleauthor=B.+W.+Murray&title=Spectrum+and+degree+of+cdk+drug+interactions+predicts+clinical+performance&doi=10.1158%2F1535-7163.MCT-16-0300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance</span></div><div class="casAuthors">Chen, Ping; Lee, Nathan V.; Hu, Wenyue; Xu, Meirong; Ferre, Rose Ann; Lam, Hieu; Bergqvist, Simon; Solowiej, James; Diehl, Wade; He, You-Ai; Yu, Xiu; Nagata, Asako; Van Arsdale, Todd; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2273-2281</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biol. perspective but drug development is often hindered by toxicities and inadequate efficacy.  Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.  Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clin. activities.  Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacol. while analyses in untransformed cells illuminates significant differences.  To resolve this apparent disconnect, drug behaviors are described at the mol. level.  Nonkinase binding studies and kinome interaction anal. (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacol., may contribute for abemaciclib, and confounds AG-024322 anal.  CDK2 and CDK6 cocrystal structures with the drugs identify the mol. interactions responsible for potency and kinase selectivity.  Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome.  Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket.  Integrating clin. drug exposures into the anal. predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9).  Understanding the mol. components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs.  Mol Cancer Ther; 15(10); 2273-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TbbI98T8v7Vg90H21EOLACvtfcHk0lidccV4_PfKvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK&md5=112e9e46bb33393516fa94620e6383c6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0300%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DN.%2BV.%26aulast%3DHu%26aufirst%3DW.%2BY.%26aulast%3DXu%26aufirst%3DM.%2BR.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DSpectrum%2520and%2520degree%2520of%2520cdk%2520drug%2520interactions%2520predicts%2520clinical%2520performance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2273%26epage%3D2281%26doi%3D10.1158%2F1535-7163.MCT-16-0300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eramian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span> <span> </span><span class="NLM_article-title">Protein structure modeling with modeller</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1007/978-1-60327-058-8_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1007%2F978-1-60327-058-8_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=18542861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlKqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2008&pages=145-159&author=N.+Eswarauthor=D.+Eramianauthor=B.+Webbauthor=M.+Y.+Shenauthor=A.+Sali&title=Protein+structure+modeling+with+modeller&doi=10.1007%2F978-1-60327-058-8_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Protein structure modeling with MODELER</span></div><div class="casAuthors">Eswar, Narayanan; Eramian, David; Webb, Ben; Shen, Min-Yi; Sali, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">Structural Proteomics</span>),
    <span class="NLM_cas:pages">145-159</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Genome sequencing projects have resulted in a rapid increase in the no. of known protein sequences.  In contrast, only about one-hundredth of these sequences have been characterized using exptl. structure detn. methods.  Computational protein structure modeling techniques have the potential to bridge this sequence-structure gap.  This chapter presents an example that illustrates the use of MODELLER to construct a comparative model for a protein with unknown structure.  Automation of similar protocols has resulted in models of useful accuracy for domains in more than half of all known protein sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHl3qSEO3oiLVg90H21EOLACvtfcHk0lidccV4_PfKvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlKqsrg%253D&md5=dfdc94abf280f9f4b316ab9c369c2466</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-058-8_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60327-058-8_8%26sid%3Dliteratum%253Aachs%26aulast%3DEswar%26aufirst%3DN.%26aulast%3DEramian%26aufirst%3DD.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DM.%2BY.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DProtein%2520structure%2520modeling%2520with%2520modeller%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2008%26volume%3D426%26spage%3D145%26epage%3D159%26doi%3D10.1007%2F978-1-60327-058-8_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delano, W. L.</span></span> <i>The Pymol Molecular Graphics System</i>, version 1.7; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+L.+Delano&title=The+Pymol+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDelano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520Pymol%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troso-Sandoval, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8492</span>– <span class="NLM_lpage">8497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8492-8497&author=P.+N.+Munsterauthor=T.+Troso-Sandovalauthor=N.+Rosenauthor=R.+Rifkindauthor=P.+A.+Marksauthor=V.+M.+Richon&title=The+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid+induces+differentiation+of+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DTroso-Sandoval%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DRifkind%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%2520induces%2520differentiation%2520of%2520human%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D8492%26epage%3D8497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolay, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keibler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerdemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">The metabolic function of cyclin d3-cdk6 kinase in cancer cell survival</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature22797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnature22797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=28607489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=426-430&author=H.+Wangauthor=B.+N.+Nicolayauthor=J.+M.+Chickauthor=X.+Gaoauthor=Y.+Gengauthor=H.+Renauthor=H.+Gaoauthor=G.+Yangauthor=J.+A.+Williamsauthor=J.+M.+Suskiauthor=M.+A.+Keiblerauthor=E.+Sicinskaauthor=U.+Gerdemannauthor=W.+N.+Hainingauthor=T.+M.+Robertsauthor=K.+Polyakauthor=S.+P.+Gygiauthor=N.+J.+Dysonauthor=P.+Sicinski&title=The+metabolic+function+of+cyclin+d3-cdk6+kinase+in+cancer+cell+survival&doi=10.1038%2Fnature22797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival</span></div><div class="casAuthors">Wang, Haizhen; Nicolay, Brandon N.; Chick, Joel M.; Gao, Xueliang; Geng, Yan; Ren, Hong; Gao, Hui; Yang, Guizhi; Williams, Juliet A.; Suski, Jan M.; Keibler, Mark A.; Sicinska, Ewa; Gerdemann, Ulrike; Haining, W. Nicholas; Roberts, Thomas M.; Polyak, Kornelia; Gygi, Steven P.; Dyson, Nicholas J.; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7658</span>),
    <span class="NLM_cas:pages">426-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">D-type cyclins (D1, D2 and D3) and their assocd. cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation.  Inhibitors of CDK4 and CDK6 are currently being tested in clin. trials for patients with several cancer types, with promising results.  Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2.  This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways.  Inhibition of cyclin D3-CDK6 in tumor cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione.  This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumor cells.  The pro-survival function of cyclin D-assocd. kinase operates in tumors expressing high levels of cyclin D3-CDK6 complexes.  We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumor subsets that undergo cell death and tumor regression upon inhibition of CDK4 and CDK6.  Cyclin D3-CDK6, through its ability to link cell cycle and cell metab., represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD4-8f9Q8KErVg90H21EOLACvtfcHk0lidccV4_PfKvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb0%253D&md5=f2539399d1c4fb2163fb245d25c07843</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature22797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22797%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNicolay%26aufirst%3DB.%2BN.%26aulast%3DChick%26aufirst%3DJ.%2BM.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26aulast%3DSuski%26aufirst%3DJ.%2BM.%26aulast%3DKeibler%26aufirst%3DM.%2BA.%26aulast%3DSicinska%26aufirst%3DE.%26aulast%3DGerdemann%26aufirst%3DU.%26aulast%3DHaining%26aufirst%3DW.%2BN.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DPolyak%26aufirst%3DK.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DDyson%26aufirst%3DN.%2BJ.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DThe%2520metabolic%2520function%2520of%2520cyclin%2520d3-cdk6%2520kinase%2520in%2520cancer%2520cell%2520survival%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D426%26epage%3D430%26doi%3D10.1038%2Fnature22797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buege, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprowl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilyeva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlatter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarimboli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span> <span> </span><span class="NLM_article-title">Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both cdk4/6 and oct2 functions</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">5231</span>– <span class="NLM_lpage">5236</span>, <span class="refDoi"> DOI: 10.1073/pnas.1424313112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1073%2Fpnas.1424313112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=5231-5236&author=N.+Pablaauthor=A.+A.+Gibsonauthor=M.+Buegeauthor=S.+S.+Ongauthor=L.+Liauthor=S.+Huauthor=G.+Duauthor=J.+A.+Sprowlauthor=A.+Vasilyevaauthor=L.+J.+Jankeauthor=E.+Schlatterauthor=T.+Chenauthor=G.+Ciarimboliauthor=A.+Sparreboom&title=Mitigation+of+acute+kidney+injury+by+cell-cycle+inhibitors+that+suppress+both+cdk4%2F6+and+oct2+functions&doi=10.1073%2Fpnas.1424313112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1424313112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1424313112%26sid%3Dliteratum%253Aachs%26aulast%3DPabla%26aufirst%3DN.%26aulast%3DGibson%26aufirst%3DA.%2BA.%26aulast%3DBuege%26aufirst%3DM.%26aulast%3DOng%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DSprowl%26aufirst%3DJ.%2BA.%26aulast%3DVasilyeva%26aufirst%3DA.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DSchlatter%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DCiarimboli%26aufirst%3DG.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DMitigation%2520of%2520acute%2520kidney%2520injury%2520by%2520cell-cycle%2520inhibitors%2520that%2520suppress%2520both%2520cdk4%252F6%2520and%2520oct2%2520functions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D5231%26epage%3D5236%26doi%3D10.1073%2Fpnas.1424313112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eschbach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierczak, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimer, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirner-Eppeneder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keinrath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solyanik, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyran, C. C.</span></span> <span> </span><span class="NLM_article-title">(18)f-fdg-pet/ct and diffusion-weighted mri for monitoring a braf and cdk 4/6 inhibitor combination therapy in a murine model of human melanoma</span>. <i>Cancer imaging: the official publication of the International Cancer Imaging Society</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.1186/s40644-018-0135-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1186%2Fs40644-018-0135-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=29347968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A280%3ADC%252BC1MvitFajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=2&author=R.+S.+Eschbachauthor=P.+M.+Kazmierczakauthor=M.+M.+Heimerauthor=A.+Todicaauthor=H.+Hirner-Eppenederauthor=M.+J.+Schneiderauthor=G.+Keinrathauthor=O.+Solyanikauthor=J.+Olivierauthor=W.+G.+Kunzauthor=M.+F.+Reiserauthor=P.+Bartensteinauthor=J.+Rickeauthor=C.+C.+Cyran&title=%2818%29f-fdg-pet%2Fct+and+diffusion-weighted+mri+for+monitoring+a+braf+and+cdk+4%2F6+inhibitor+combination+therapy+in+a+murine+model+of+human+melanoma&doi=10.1186%2Fs40644-018-0135-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">(18)F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma</span></div><div class="casAuthors">Eschbach Ralf S; Kazmierczak Philipp M; Heimer Maurice M; Hirner-Eppeneder Heidrun; Schneider Moritz J; Keinrath Georg; Solyanik Olga; Kunz Wolfgang G; Reiser Maximilian F; Ricke Jens; Cyran Clemens C; Todica Andrei; Olivier Jessica; Bartenstein Peter; Schneider Moritz J</div><div class="citationInfo"><span class="NLM_cas:title">Cancer imaging : the official publication of the International Cancer Imaging Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of BRAF-V600-mutant human melanoma monitored by (18)F-FDG-PET/CT and diffusion-weighted MRI (DW-MRI).  METHODS:  Human BRAF-V600-mutant melanoma (A375) xenograft-bearing balb/c nude mice (n = 21) were imaged by (18)F-FDG-PET/CT and DW-MRI before (day 0) and after (day 7) a 1-week BRAF and CDK 4/6 inhibitor combination therapy (n = 12; dabrafenib, 20 mg/kg/d; ribociclib, 100 mg/kg/d) or placebo (n = 9).  Animals were scanned on a small animal PET after intravenous administration of 20 MBq (18)F-FDG.  Tumor glucose uptake was calculated as the tumor-to-liver-ratio (TTL).  Unenhanced CT data sets were subsequently acquired for anatomic coregistration.  Tumor diffusivity was assessed by DW-MRI using the apparent diffusion coefficient (ADC).  Anti-tumor therapy effects were assessed by ex vivo immunohistochemistry for validation purposes (microvascular density - CD31; tumor cell proliferation - Ki-67).  RESULTS:  Tumor glucose uptake was significantly suppressed under therapy (αTTLTherapy - 1.00 ± 0.53 vs. αTTLControl 0.85 ± 1.21; p < 0.001).  In addition, tumor diffusivity was significantly elevated following the BRAF and CDK 4/6 inhibitor combination therapy (αADCTherapy 0.12 ± 0.14 × 10(-3) mm(2)/s; αADCControl - 0.12 ± 0.06 × 10(-3) mm(2)/s; p < 0.001).  Immunohistochemistry revealed a significant suppression of microvascular density (CD31, 147 ± 48 vs. 287 ± 92; p = 0.001) and proliferation (Ki-67, 3718 ± 998 vs. 5389 ± 1332; p = 0.007) in the therapy compared to the control group.  CONCLUSION:  A novel BRAF and CDK 4/6 inhibitor combination therapy exhibited significant anti-angiogenic and anti-proliferative effects in experimental human melanomas, monitored by (18)F-FDG-PET/CT and DW-MRI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBjd8AjXu4mJ6KlWarZTAzfW6udTcc2eZ7kuoaLNVCr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvitFajsw%253D%253D&md5=188448387b42004292c567ce4a2b1065</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1186%2Fs40644-018-0135-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40644-018-0135-y%26sid%3Dliteratum%253Aachs%26aulast%3DEschbach%26aufirst%3DR.%2BS.%26aulast%3DKazmierczak%26aufirst%3DP.%2BM.%26aulast%3DHeimer%26aufirst%3DM.%2BM.%26aulast%3DTodica%26aufirst%3DA.%26aulast%3DHirner-Eppeneder%26aufirst%3DH.%26aulast%3DSchneider%26aufirst%3DM.%2BJ.%26aulast%3DKeinrath%26aufirst%3DG.%26aulast%3DSolyanik%26aufirst%3DO.%26aulast%3DOlivier%26aufirst%3DJ.%26aulast%3DKunz%26aufirst%3DW.%2BG.%26aulast%3DReiser%26aufirst%3DM.%2BF.%26aulast%3DBartenstein%26aufirst%3DP.%26aulast%3DRicke%26aufirst%3DJ.%26aulast%3DCyran%26aufirst%3DC.%2BC.%26atitle%3D%252818%2529f-fdg-pet%252Fct%2520and%2520diffusion-weighted%2520mri%2520for%2520monitoring%2520a%2520braf%2520and%2520cdk%25204%252F6%2520inhibitor%2520combination%2520therapy%2520in%2520a%2520murine%2520model%2520of%2520human%2520melanoma%26jtitle%3DCancer%2520imaging%253A%2520the%2520official%2520publication%2520of%2520the%2520International%2520Cancer%2520Imaging%2520Society%26date%3D2018%26volume%3D18%26spage%3D2%26doi%3D10.1186%2Fs40644-018-0135-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chartier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najmanovich, R.</span></span> <span> </span><span class="NLM_article-title">Kinome render: A stand-alone and web-accessible tool to annotate the human protein kinome tree</span>. <i>PeerJ</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e126</span>, <span class="refDoi"> DOI: 10.7717/peerj.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.7717%2Fpeerj.126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=23940838" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=e126&author=M.+Chartierauthor=T.+Chenardauthor=J.+Barkerauthor=R.+Najmanovich&title=Kinome+render%3A+A+stand-alone+and+web-accessible+tool+to+annotate+the+human+protein+kinome+tree&doi=10.7717%2Fpeerj.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.126%26sid%3Dliteratum%253Aachs%26aulast%3DChartier%26aufirst%3DM.%26aulast%3DChenard%26aufirst%3DT.%26aulast%3DBarker%26aufirst%3DJ.%26aulast%3DNajmanovich%26aufirst%3DR.%26atitle%3DKinome%2520render%253A%2520A%2520stand-alone%2520and%2520web-accessible%2520tool%2520to%2520annotate%2520the%2520human%2520protein%2520kinome%2520tree%26jtitle%3DPeerJ%26date%3D2013%26volume%3D1%26spage%3De126%26doi%3D10.7717%2Fpeerj.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 34 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tizhi Wu, Zhen Qin, Yucheng Tian, Jubo Wang, Chenxi Xu, Zhiyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Jinlei Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13228-13257. <a href="https://doi.org/10.1021/acs.jmedchem.0c00744" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00744%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BDevelopments%252Bin%252Bthe%252BBiology%252Band%252BMedicinal%252BChemistry%252Bof%252BCDK9%252BInhibitors%25253A%252BAn%252BUpdate%26aulast%3DWu%26aufirst%3DTizhi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D17092020%26date%3D31082020%26volume%3D63%26issue%3D22%26spage%3D13228%26epage%3D13257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yang Wang, Xing Chen, Yaoyao Yan, Xiaochen Zhu, Mingming Liu, <span class="NLM_string-name hlFld-ContribAuthor">Xinhua Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3327-3347. <a href="https://doi.org/10.1021/acs.jmedchem.9b02121" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02121%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BSARs%252Bof%252B5-Chloro-N4-phenyl-N2-%252528pyridin-2-yl%252529pyrimidine-2%25252C4-diamine%252BDerivatives%252Bas%252BOral%252BAvailable%252Band%252BDual%252BCDK%252B6%252Band%252B9%252BInhibitors%252Bwith%252BPotent%252BAntitumor%252BActivity%26aulast%3DWang%26aufirst%3DYang%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20122019%26date%3D12032020%26date%3D04032020%26volume%3D63%26issue%3D6%26spage%3D3327%26epage%3D3347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Pan</span>, <span class="hlFld-ContribAuthor ">Yanrong  Dan</span>, <span class="hlFld-ContribAuthor ">Dafeng  Guo</span>, <span class="hlFld-ContribAuthor ">Junhao  Jiang</span>, <span class="hlFld-ContribAuthor ">Dongzhi  Ran</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Binghua  Tian</span>, <span class="hlFld-ContribAuthor ">Jianyong  Yuan</span>, <span class="hlFld-ContribAuthor ">Yu  Yu</span>, <span class="hlFld-ContribAuthor ">Zongjie  Gan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113672. <a href="https://doi.org/10.1016/j.ejmech.2021.113672" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113672</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113672%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4-pyrimidinediamine%252Bderivatives%252Bas%252Bpotent%252Bdual%252Binhibitors%252Bof%252BALK%252Band%252BHDAC%26aulast%3DPan%26aufirst%3DTao%26date%3D2021%26volume%3D224%26spage%3D113672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eclair Venturini  Filho</span>, <span class="hlFld-ContribAuthor ">Erick M.C.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sergio  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sandro J.  Greco</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidines: Recent synthetic procedures and anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132256. <a href="https://doi.org/10.1016/j.tet.2021.132256" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132256%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAminopyrimidines%25253A%252BRecent%252Bsynthetic%252Bprocedures%252Band%252Banticancer%252Bactivities%26aulast%3DFilho%26aufirst%3DEclair%2BVenturini%26date%3D2021%26volume%3D92%26spage%3D132256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amr K.A.  Bass</span>, <span class="hlFld-ContribAuthor ">Mona S.  El-Zoghbi</span>, <span class="hlFld-ContribAuthor ">El-Shimaa M.  Nageeb</span>, <span class="hlFld-ContribAuthor ">Mamdouh F.A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Gamal El-Din A.  Abuo-Rahma</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112904. <a href="https://doi.org/10.1016/j.ejmech.2020.112904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComprehensive%252Breview%252Bfor%252Banticancer%252Bhybridized%252Bmultitargeting%252BHDAC%252Binhibitors%26aulast%3DBass%26aufirst%3DAmr%2BK.A.%26date%3D2021%26volume%3D209%26spage%3D112904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keying  Liu</span>, <span class="hlFld-ContribAuthor ">Biyun  Xue</span>, <span class="hlFld-ContribAuthor ">Guiqin  Bai</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Downregulation of Diacylglycerol kinase zeta (DGKZ) suppresses tumorigenesis and progression of cervical cancer by facilitating cell apoptosis and cell cycle arrest. </span><span class="cited-content_cbyCitation_journal-name">Bioengineered</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 1517-1529. <a href="https://doi.org/10.1080/21655979.2021.1918505" title="DOI URL">https://doi.org/10.1080/21655979.2021.1918505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/21655979.2021.1918505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F21655979.2021.1918505%26sid%3Dliteratum%253Aachs%26jtitle%3DBioengineered%26atitle%3DDownregulation%252Bof%252BDiacylglycerol%252Bkinase%252Bzeta%252B%252528DGKZ%252529%252Bsuppresses%252Btumorigenesis%252Band%252Bprogression%252Bof%252Bcervical%252Bcancer%252Bby%252Bfacilitating%252Bcell%252Bapoptosis%252Band%252Bcell%252Bcycle%252Barrest%26aulast%3DLiu%26aufirst%3DKeying%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1%26spage%3D1517%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivan P  Mosiagin</span>, <span class="hlFld-ContribAuthor ">Olesya A  Tomashenko</span>, <span class="hlFld-ContribAuthor ">Dar’ya V  Spiridonova</span>, <span class="hlFld-ContribAuthor ">Mikhail S  Novikov</span>, <span class="hlFld-ContribAuthor ">Sergey P  Tunik</span>, <span class="hlFld-ContribAuthor ">Alexander F  Khlebnikov</span>. </span><span class="cited-content_cbyCitation_article-title">Free-radical cyclization approach to polyheterocycles containing pyrrole and pyridine rings. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>17 </em>, 1490-1498. <a href="https://doi.org/10.3762/bjoc.17.105" title="DOI URL">https://doi.org/10.3762/bjoc.17.105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.17.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.17.105%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFree-radical%252Bcyclization%252Bapproach%252Bto%252Bpolyheterocycles%252Bcontaining%252Bpyrrole%252Band%252Bpyridine%252Brings%26aulast%3DMosiagin%26aufirst%3DIvan%2BP%26date%3D2021%26date%3D2021%26volume%3D17%26spage%3D1490%26epage%3D1498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Gao</span>, <span class="hlFld-ContribAuthor ">Hang  Zhang</span>, <span class="hlFld-ContribAuthor ">Frédéric  Lirussi</span>, <span class="hlFld-ContribAuthor ">Carmen  Garrido</span>, <span class="hlFld-ContribAuthor ">Xiang-Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Tian  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2020,</strong> <em>182 </em>, 114224. <a href="https://doi.org/10.1016/j.bcp.2020.114224" title="DOI URL">https://doi.org/10.1016/j.bcp.2020.114224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2020.114224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2020.114224%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DDual%252Binhibitors%252Bof%252Bhistone%252Bdeacetylases%252Band%252Bother%252Bcancer-related%252Btargets%25253A%252BA%252Bpharmacological%252Bperspective%26aulast%3DGao%26aufirst%3DYuan%26date%3D2020%26volume%3D182%26spage%3D114224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Fan</span>, <span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoshuang  Wang</span>, <span class="hlFld-ContribAuthor ">Yakun  Ma</span>, <span class="hlFld-ContribAuthor ">Yongtao  Li</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 12O—A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (21)
                                     , 5199. <a href="https://doi.org/10.3390/molecules25215199" title="DOI URL">https://doi.org/10.3390/molecules25215199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25215199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25215199%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252B12O%2525E2%252580%252594A%252BNovel%252BOral%252BMulti-Kinase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumor%26aulast%3DFan%26aufirst%3DYan%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D21%26spage%3D5199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Yun  He</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 – 2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (10)
                                     , 795-805. <a href="https://doi.org/10.1080/13543776.2020.1825686" title="DOI URL">https://doi.org/10.1080/13543776.2020.1825686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1825686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1825686%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DCyclin-dependent%252Bkinase%252B4%25252F6%252Binhibitors%252Bfor%252Bcancer%252Btherapy%25253A%252Ba%252Bpatent%252Breview%252B%2525282015%252B%2525E2%252580%252593%252B2019%252529%26aulast%3DWang%26aufirst%3DPeng-Fei%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D10%26spage%3D795%26epage%3D805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qilin  Xu</span>, <span class="hlFld-ContribAuthor ">Huachun  Fan</span>, <span class="hlFld-ContribAuthor ">Hongmiao  Yao</span>, <span class="hlFld-ContribAuthor ">Duoheng  Wang</span>, <span class="hlFld-ContribAuthor ">Hangwei  Yu</span>, <span class="hlFld-ContribAuthor ">Bingbing  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiqun  Yu</span>, <span class="hlFld-ContribAuthor ">Weike  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding monoacylation of symmetrical diamines: A kinetic study of acylation reaction of m-phenylenediamine and benzoic anhydride in microreactor. </span><span class="cited-content_cbyCitation_journal-name">Chemical Engineering Journal</span><span> <strong>2020,</strong> <em>398 </em>, 125584. <a href="https://doi.org/10.1016/j.cej.2020.125584" title="DOI URL">https://doi.org/10.1016/j.cej.2020.125584</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cej.2020.125584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cej.2020.125584%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Engineering%2520Journal%26atitle%3DUnderstanding%252Bmonoacylation%252Bof%252Bsymmetrical%252Bdiamines%25253A%252BA%252Bkinetic%252Bstudy%252Bof%252Bacylation%252Breaction%252Bof%252Bm-phenylenediamine%252Band%252Bbenzoic%252Banhydride%252Bin%252Bmicroreactor%26aulast%3DXu%26aufirst%3DQilin%26date%3D2020%26volume%3D398%26spage%3D125584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brilliant N.  Marak</span>, <span class="hlFld-ContribAuthor ">Jayanta  Dowarah</span>, <span class="hlFld-ContribAuthor ">Laldingluaia  Khiangte</span>, <span class="hlFld-ContribAuthor ">Ved Prakash  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112571. <a href="https://doi.org/10.1016/j.ejmech.2020.112571" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112571%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Binsight%252Bon%252Bthe%252Brecent%252Bdevelopment%252Bof%252BCyclic%252BDependent%252BKinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DMarak%26aufirst%3DBrilliant%2BN.%26date%3D2020%26volume%3D203%26spage%3D112571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingfei  Wu</span>, <span class="hlFld-ContribAuthor ">Jianfei  Han</span>, <span class="hlFld-ContribAuthor ">Zhicheng  Liu</span>, <span class="hlFld-ContribAuthor ">Yilong  Zhang</span>, <span class="hlFld-ContribAuthor ">Cheng  Huang</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Zeng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>258 </em>, 118228. <a href="https://doi.org/10.1016/j.lfs.2020.118228" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.118228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.118228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.118228%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DIdentification%252Bof%252Bnovel%252BCDK%252B9%252Binhibitors%252Bbased%252Bon%252Bvirtual%252Bscreening%25252C%252Bmolecular%252Bdynamics%252Bsimulation%25252C%252Band%252Bbiological%252Bevaluation%26aulast%3DWu%26aufirst%3DMingfei%26date%3D2020%26volume%3D258%26spage%3D118228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biao  Wang</span>, <span class="hlFld-ContribAuthor ">Fu  Peng</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Jin  Zhou</span>, <span class="hlFld-ContribAuthor ">Nan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jia  Sheng</span>, <span class="hlFld-ContribAuthor ">Phensinee  Haruehanroengra</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>, <span class="hlFld-ContribAuthor ">Bo  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (8)
                                     , 1492-1510. <a href="https://doi.org/10.1016/j.apsb.2019.12.013" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.12.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.12.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.12.013%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DRational%252Bdrug%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bchiral%252Btetrahydronaphthalene-fused%252Bspirooxindole%252Bas%252BMDM2-CDK4%252Bdual%252Binhibitor%252Bagainst%252Bglioblastoma%26aulast%3DWang%26aufirst%3DBiao%26date%3D2020%26volume%3D10%26issue%3D8%26spage%3D1492%26epage%3D1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angel R.  de Lera</span>, <span class="hlFld-ContribAuthor ">A.  Ganesan</span>. </span><span class="cited-content_cbyCitation_article-title">Two-hit wonders: The expanding universe of multitargeting epigenetic agents. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2020,</strong> <em>57 </em>, 135-154. <a href="https://doi.org/10.1016/j.cbpa.2020.05.009" title="DOI URL">https://doi.org/10.1016/j.cbpa.2020.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DTwo-hit%252Bwonders%25253A%252BThe%252Bexpanding%252Buniverse%252Bof%252Bmultitargeting%252Bepigenetic%252Bagents%26aulast%3Dde%2BLera%26aufirst%3DAngel%2BR.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fan  Yun</span>, <span class="hlFld-ContribAuthor ">Chunhui  Cheng</span>, <span class="hlFld-ContribAuthor ">Sadeeq  Ullah</span>, <span class="hlFld-ContribAuthor ">Qipeng  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>198 </em>, 112322. <a href="https://doi.org/10.1016/j.ejmech.2020.112322" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112322%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bhistone%252Bdeacetylase1%25252F2%252B%252528HDAC1%25252F2%252529%252Band%252Bcyclin-dependent%252BKinase2%252B%252528CDK2%252529%252Bdual%252Binhibitors%252Bagainst%252Bmalignant%252Bcancer%26aulast%3DYun%26aufirst%3DFan%26date%3D2020%26volume%3D198%26spage%3D112322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunhui  Cheng</span>, <span class="hlFld-ContribAuthor ">Fan  Yun</span>, <span class="hlFld-ContribAuthor ">Sadeeq  Ullah</span>, <span class="hlFld-ContribAuthor ">Qipeng  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112073. <a href="https://doi.org/10.1016/j.ejmech.2020.112073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bcyclin-dependent%252Bkinase%252B%252528CDK%252529%252Band%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Bdual%252Binhibitors%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Banticancer%252Bactivity%26aulast%3DCheng%26aufirst%3DChunhui%26date%3D2020%26volume%3D189%26spage%3D112073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Tomaselli</span>, <span class="hlFld-ContribAuthor ">Alessia  Lucidi</span>, <span class="hlFld-ContribAuthor ">Dante  Rotili</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic polypharmacology: A new frontier for epi‐drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (1)
                                     , 190-244. <a href="https://doi.org/10.1002/med.21600" title="DOI URL">https://doi.org/10.1002/med.21600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21600%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEpigenetic%252Bpolypharmacology%25253A%252BA%252Bnew%252Bfrontier%252Bfor%252Bepi%2525E2%252580%252590drug%252Bdiscovery%26aulast%3DTomaselli%26aufirst%3DDaniela%26date%3D2020%26date%3D2019%26volume%3D40%26issue%3D1%26spage%3D190%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Barker</span>, <span class="hlFld-ContribAuthor ">Lisa  Pilkington</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems—Five Heteroatoms 2:3 or 3:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14895-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14895-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14895-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14895-4%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%2525E2%252580%252594Five%252BHeteroatoms%252B2%25253A3%252Bor%252B3%25253A2%26aulast%3DBarker%26aufirst%3DDavid%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Kaiyuan  Deng</span>, <span class="hlFld-ContribAuthor ">Cheng  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Li</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Yakun  Ma</span>, <span class="hlFld-ContribAuthor ">Peiqing  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Shi</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Yan  Fan</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 414-423. <a href="https://doi.org/10.1080/14756366.2019.1705290" title="DOI URL">https://doi.org/10.1080/14756366.2019.1705290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1705290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1705290%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BCDKs%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bsolid%252Btumour%252Bby%252Bsimultaneously%252Bregulating%252Bthe%252Bcell%252Bcycle%252Band%252Btranscription%252Bcontrol%26aulast%3DWang%26aufirst%3DXin%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D414%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Chenhua  Yu</span>, <span class="hlFld-ContribAuthor ">Cheng  Wang</span>, <span class="hlFld-ContribAuthor ">Yakun  Ma</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Li</span>, <span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Manqian  Zhou</span>, <span class="hlFld-ContribAuthor ">Peiqing  Sun</span>, <span class="hlFld-ContribAuthor ">Jianyu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Yan  Fan</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111535. <a href="https://doi.org/10.1016/j.ejmech.2019.07.038" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.038%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bcyclin-dependent%252Bkinase%252B9%252B%252528CDK9%252529%252Binhibitor%252Bwith%252Bsuppression%252Bof%252Bcancer%252Bstemness%252Bactivity%252Bagainst%252Bnon-small-cell%252Blung%252Bcancer%26aulast%3DWang%26aufirst%3DXin%26date%3D2019%26volume%3D181%26spage%3D111535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi  Huang</span>, <span class="hlFld-ContribAuthor ">Borui  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhongxiang  Qin</span>, <span class="hlFld-ContribAuthor ">Yongtao  Li</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>, <span class="hlFld-ContribAuthor ">Jianyu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Yi  Shi</span>, <span class="hlFld-ContribAuthor ">Yan  Fan</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>181 </em>, 111541. <a href="https://doi.org/10.1016/j.ejmech.2019.07.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bdual%252Binhibitors%252Btargeting%252BCDK4%252Band%252BVEGFR2%252Bsynergistically%252Bsuppressed%252Bcancer%252Bprogression%252Band%252Bangiogenesis%26aulast%3DHuang%26aufirst%3DZhi%26date%3D2019%26volume%3D181%26spage%3D111541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavithra K.  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Yeongjoon  Lee</span>, <span class="hlFld-ContribAuthor ">Yangmee  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Ligand‐binding Hotspot Residues of CDK4 Using Molecular Docking and Molecular Dynamics Simulation. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2019,</strong> <em>40 </em>
                                    (10)
                                     , 1025-1032. <a href="https://doi.org/10.1002/bkcs.11873" title="DOI URL">https://doi.org/10.1002/bkcs.11873</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.11873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.11873%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DIdentification%252Bof%252BLigand%2525E2%252580%252590binding%252BHotspot%252BResidues%252Bof%252BCDK4%252BUsing%252BMolecular%252BDocking%252Band%252BMolecular%252BDynamics%252BSimulation%26aulast%3DBalasubramanian%26aufirst%3DPavithra%2BK.%26date%3D2019%26date%3D2019%26volume%3D40%26issue%3D10%26spage%3D1025%26epage%3D1032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Yu</span>, <span class="hlFld-ContribAuthor ">Dongzhi  Ran</span>, <span class="hlFld-ContribAuthor ">Junhao  Jiang</span>, <span class="hlFld-ContribAuthor ">Tao  Pan</span>, <span class="hlFld-ContribAuthor ">Yanrong  Dan</span>, <span class="hlFld-ContribAuthor ">Qiang  Tang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">LinLing  Gan</span>, <span class="hlFld-ContribAuthor ">Zongjie  Gan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2136-2140. <a href="https://doi.org/10.1016/j.bmcl.2019.06.059" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.06.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.06.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.06.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252B9H-purin%252Bderivatives%252Bas%252Bdual%252Binhibitors%252Bof%252BHDAC1%252Band%252BCDK2%26aulast%3DYu%26aufirst%3DYu%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2136%26epage%3D2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Nihar  Kinarivala</span>, <span class="hlFld-ContribAuthor ">Sahil  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship. </span><span class="cited-content_cbyCitation_journal-name">Anti-Cancer Agents in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 842-874. <a href="https://doi.org/10.2174/1871520619666190118120708" title="DOI URL">https://doi.org/10.2174/1871520619666190118120708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1871520619666190118120708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1871520619666190118120708%26sid%3Dliteratum%253Aachs%26jtitle%3DAnti-Cancer%2520Agents%2520in%2520Medicinal%2520Chemistry%26atitle%3DMulti-Targeting%252BAnticancer%252BAgents%25253A%252BRational%252BApproaches%25252C%252BSynthetic%252BRoutes%252Band%252BStructure%252BActivity%252BRelationship%26aulast%3DSingh%26aufirst%3DHarbinder%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D842%26epage%3D874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Hu</span>, <span class="hlFld-ContribAuthor ">Chu  Wang</span>, <span class="hlFld-ContribAuthor ">Xin  Xin</span>, <span class="hlFld-ContribAuthor ">Shuaikang  Li</span>, <span class="hlFld-ContribAuthor ">Zefei  Li</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2,4-diaminopyrimidine derivatives as potent antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2019,</strong> <em>43 </em>
                                    (25)
                                     , 10190-10202. <a href="https://doi.org/10.1039/C9NJ02154J" title="DOI URL">https://doi.org/10.1039/C9NJ02154J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ02154J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ02154J%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidine%252Bderivatives%252Bas%252Bpotent%252Bantitumor%252Bagents%26aulast%3DHu%26aufirst%3DGang%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D25%26spage%3D10190%26epage%3D10202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Stazi</span>, <span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>, <span class="hlFld-ContribAuthor ">Andrea  Mattevi</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2019,</strong> <em>50 </em>, 89-100. <a href="https://doi.org/10.1016/j.cbpa.2019.03.002" title="DOI URL">https://doi.org/10.1016/j.cbpa.2019.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DHistone%252Bdeacetylases%252Bas%252Ban%252Bepigenetic%252Bpillar%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bhybrid%252Binhibitors%252Bin%252Bcancer%26aulast%3DStazi%26aufirst%3DGiulia%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melania  Poratti</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>. </span><span class="cited-content_cbyCitation_article-title">Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>172 </em>, 143-153. <a href="https://doi.org/10.1016/j.ejmech.2019.03.064" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.064%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThird-generation%252BCDK%252Binhibitors%25253A%252BA%252Breview%252Bon%252Bthe%252Bsynthesis%252Band%252Bbinding%252Bmodes%252Bof%252BPalbociclib%25252C%252BRibociclib%252Band%252BAbemaciclib%26aulast%3DPoratti%26aufirst%3DMelania%26date%3D2019%26volume%3D172%26spage%3D143%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Liangyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Li</span>, <span class="hlFld-ContribAuthor ">Qi  Shen</span>, <span class="hlFld-ContribAuthor ">Qiaoling  Xu</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 7-amino-[1,2,4]triazolo[4,3-f]pteridinone, and 7-aminotetrazolo[1,5-f]pteridinone derivative as potent antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 690-709. <a href="https://doi.org/10.1016/j.ejmech.2018.12.009" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B7-amino-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-f%25255Dpteridinone%25252C%252Band%252B7-aminotetrazolo%25255B1%25252C5-f%25255Dpteridinone%252Bderivative%252Bas%252Bpotent%252Bantitumor%252Bagents%26aulast%3DHou%26aufirst%3DYunlei%26date%3D2019%26volume%3D163%26spage%3D690%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Schiedel</span>, <span class="hlFld-ContribAuthor ">Stuart J  Conway</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules as tools to study the chemical epigenetics of lysine acetylation. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2018,</strong> <em>45 </em>, 166-178. <a href="https://doi.org/10.1016/j.cbpa.2018.06.015" title="DOI URL">https://doi.org/10.1016/j.cbpa.2018.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2018.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DSmall%252Bmolecules%252Bas%252Btools%252Bto%252Bstudy%252Bthe%252Bchemical%252Bepigenetics%252Bof%252Blysine%252Bacetylation%26aulast%3DSchiedel%26aufirst%3DMatthias%26date%3D2018%26volume%3D45%26spage%3D166%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahmud  Hasan</span>, <span class="hlFld-ContribAuthor ">Rehana K.  Leak</span>, <span class="hlFld-ContribAuthor ">Robert E.  Stratford</span>, <span class="hlFld-ContribAuthor ">Darius P.  Zlotos</span>, <span class="hlFld-ContribAuthor ">Paula A.  Witt-Enderby</span>. </span><span class="cited-content_cbyCitation_article-title">Drug conjugates-an emerging approach to treat breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2018,</strong> <em>6 </em>
                                    (4)
                                     , e00417. <a href="https://doi.org/10.1002/prp2.417" title="DOI URL">https://doi.org/10.1002/prp2.417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.417%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DDrug%252Bconjugates-an%252Bemerging%252Bapproach%252Bto%252Btreat%252Bbreast%252Bcancer%26aulast%3DHasan%26aufirst%3DMahmud%26date%3D2018%26date%3D2018%26volume%3D6%26issue%3D4%26spage%3De00417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic showing design for merged CDK-HDAC pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Derivatives of <b>5a–5f</b>, <b>6a–6f</b>, <b>10a–10d</b>, <b>11a–11d</b>, <b>14a–14d</b>, <b>17</b>, and <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) EDCI, HOBt, DIEA, rt, 12 h, 39–80% yield for <b>3a</b>–<b>3f</b>, 63–87% yield for <b>9a</b>–<b>9d</b>, 40–82% yield for <b>13a</b>–<b>13d</b>; (b) Pd(OAc)<sub>2</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 12 h, 73–89% yield for <b>5a</b>–<b>5f</b>, 76-84% yield for <b>10a</b>–<b>10d</b>, 80–84% yield for <b>14a</b>–<b>14d</b>, 45% yield for <b>17</b>; (c) NH<sub>2</sub>OH, CH<sub>3</sub>OH, reflux, 18 h, 48–76% yield for <b>6a</b>–<b>6f</b>, 58–71% yield for <b>11a</b>–<b>11d</b>, 68% yield for <b>18</b>; (d) triphosgene, Et<sub>3</sub>N, DCM; (e) Et<sub>3</sub>N, DMF, 78% yield over two steps.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Derivatives of <b>22–25</b>, <b>27</b>, <b>28</b>, <b>31–32</b>, and <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 12 h, 79% yield for <b>27</b>, 46% yield for <b>31</b>, 77% yield for <b>35</b>; (b) conc. HCl, THF, 84% yield for <b>20</b> over two steps, 66% yield for <b>30</b>; (c) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O (80%), EtOH, 80°C, 6 h, 79% yield; (d) EDCI, HOBt, DIEA, rt, 12 h, 72% yield for <b>22</b>, 32% yield for <b>23</b>, 49% yield for <b>24</b>, 67% yield for <b>26</b>; (e) NH<sub>2</sub>OH, CH<sub>3</sub>OH, reflux, 18 h, 67% yield for <b>25</b>, 49% yield for <b>28</b>, 64% yield for <b>32</b>; (f) 5-nitropyridin-2-amine, SOCl<sub>2</sub>, pyridine, THF, 80°C, 6 h, 10% yield; (g) Pd/C, HCOONH<sub>4</sub>, EtOH, 80°C, 12 h, 88% yield.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Derivatives of <b>41–42</b>, <b>44–45</b>, and <b>46–48</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) DIEA, EA, −40°C to rt, 2 h, 99% yield; (b) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH, reflux, 2 h, 85% yield; (c) triethylorthoformate, MgSO<sub>4,</sub> DMF, 130°C, 2 h, 47% yield; (d) Pd(OAc)<sub>2</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 100 °C, 12 h, 77% yield for <b>41</b>, 45% yield for <b>44</b>; (e) NaNO<sub>2,</sub> conc. HCl, 0 °C to rt, 3.25 h, 65% yield; (f) NH<sub>2</sub>OH, CH<sub>3</sub>OH, reflux, 18 h, 45% yield for <b>42</b>, 32% yield for <b>45</b>; (g) LiAlH<sub>4</sub>, THF, 0°C to rt, 4 h, 57% yield; (h) NaOH, THF/CH<sub>3</sub>OH/H<sub>2</sub>O, rt, 12 h, 93% yield; (i) HN(CH<sub>3</sub>)<sub>2</sub>, EDCI, HOBt, DIEA, rt, 12 h, 61% yield.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase binding selectivity for compound <b>6e</b> shown on the human kinome dendrogram. The inhibition rates were determined using the KinaseProfiler of Eurofins. The figure was generated by using an online Kinome Render program (<a href="http://www.biophys.umontreal.ca/nrg/NRG/KinomeRender.html" class="extLink">http://www.biophys.umontreal.ca/nrg/NRG/KinomeRender.html</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Representation of the predicted binding modes of compound <b>6e</b> (purple) and ribociclib (yellow) in the ATP pocket of CDK4, which employed CDK6 (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EZ5">4EZ5</a>) as the template for homology modeling. Dashed lines indicate the H-bond interaction between compounds and CDK4. (B) Predicted binding mode of compound <b>6e</b> (yellow) and vorinostat (green) with HDAC1. The crystal structure of HDAC1 was taken from the RCSB Protein Data Bank (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>). (C) Proposed binding mode of compound <b>6e</b> (orange) and ribociclib (cyan) within the active site of CDK9 (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF">4BCF</a>). The dashed lines represent the H-bond interaction between compounds and CDK9.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compound <b>6e</b> on cell cycle progression of human tumor cell lines. Compound <b>6e</b> induces G2 arrest in high concentration and induces G1 arrest in low concentration. (A) MDA-MB-231 and T47D cell lines; (B) H460 and A549 cell lines; (C) HepG2 and Hep3B cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>6e</b> induces cell apoptosis in vitro. (A) Hoechst 33342 nuclear staining of T47D cell line, showing the basal level of cells with apoptotic bodies in untreated control (left) and a dose-dependent increase in the number of apoptotic cells after treatment with compound <b>6e</b>. Representative pictures, scale bar 20 μm. (B) Flow cytometry and (C) quantitative analysis of apoptotic cells. Cells were incubated with the indicated concentrations of compound <b>6e</b> or vorinostat for 48 h and were stained with FITC-Annexin V/PI, followed by flow cytometry analysis. Data are expressed as means ± SD of the percentages of apoptotic cells from three independent experiments, ***<i>P</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Western blotting analysis for inhibition of (A) CDK4 and (B) histone acetylation pathway. Breast cell lines (MDA-MB-231 and T47D), lung cancer cell lines (H460 and A549), and liver cancer cell lines (HepG2 and Hep3B) were treated with 1 and 5 μM compound <b>6e</b> and vorinostat for 48 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Immunofluorescence staining of (A) CDK4 in untreated cells (control, upper panel) or treated with compound <b>6e</b> (lower panel) at 100 nM and (B) acetyl-histone H3 in untreated cells (control, upper panel) or treated with compound <b>6e</b> (lower panel) at 1 μM. Nuclei were counterstained with DAPI. The merged images are shown in the right column. Representative images, scale bar is 10 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. In vivo antitumor efficacy of compound <b>6e</b> against 4T1 tumor xenograft models with IP administration. (A) Effects of compound <b>6e</b>, ribociclib, and vorinostat on toxicity and animal survival. (B) Representative animals injected with 5 × 10<sup>4</sup> Fluc-4T1 shows significant bioluminescence activity at day 8 and day 25. (C) Quantitative analysis of tumor inhibitory responses by bioluminescence imaging signals at day 25 demonstrated that compound <b>6e</b> showed significantly better inhibitory. (D,E) Tumor volumes were recorded. Animals were treated with solvent control, compound <b>6e</b> at doses of 90 and 130 mg/kg/day, and ribociclib and vorinostat at a dose of 130 mg/kg/day through IP injection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/medium/jm-2018-00209z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo antitumor efficacy of compound <b>6e</b> against 4T1 tumor xenograft models with oral administration. (A) Antitumor efficacy of <b>6e</b>, ribociclib, and vorinostat treated 4T1 xenograft tumor. (B) Average body weights for <b>6e</b>, ribociclib, and vorinostat treated mice groups. (C) p-Rb and Bcl-2 staining of tumor tissues showing the down-regulation in <b>6e</b> groups compared to other groups. Scale bar, 50 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.8b00209/20180406/images/large/jm-2018-00209z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00209&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i122">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 59 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+history+and+future+of+targeting+cyclin-dependent+kinases+in+cancer+therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lhi16forb5UCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520history%2520and%2520future%2520of%2520targeting%2520cyclin-dependent%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grana, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (cdks), growth suppressor genes and cyclin-dependent kinase inhibitors (ckis)</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">219</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1995&pages=211-219&author=X.+Granaauthor=E.+P.+Reddy&title=Cell+cycle+control+in+mammalian+cells%3A+Role+of+cyclins%2C+cyclin+dependent+kinases+%28cdks%29%2C+growth+suppressor+genes+and+cyclin-dependent+kinase+inhibitors+%28ckis%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrana%26aufirst%3DX.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCell%2520cycle%2520control%2520in%2520mammalian%2520cells%253A%2520Role%2520of%2520cyclins%252C%2520cyclin%2520dependent%2520kinases%2520%2528cdks%2529%252C%2520growth%2520suppressor%2520genes%2520and%2520cyclin-dependent%2520kinase%2520inhibitors%2520%2528ckis%2529%26jtitle%3DOncogene%26date%3D1995%26volume%3D11%26spage%3D211%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">To cycle or not to cycle: A critical decision in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=To+cycle+or+not+to+cycle%3A+A+critical+decision+in+cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0lhi16forb5UCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DTo%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520A%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, cdks and cancer: A changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+cdks+and+cancer%3A+A+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lh0lOvmmAHp5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520cdks%2520and%2520cancer%253A%2520A%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Cdk4: A key player in the cell cycle, development, and cancer</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1177/1947601913478972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1177%2F1947601913478972" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=23634254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1Wls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=658-669&author=S.+J.+Bakerauthor=E.+P.+Reddy&title=Cdk4%3A+A+key+player+in+the+cell+cycle%2C+development%2C+and+cancer&doi=10.1177%2F1947601913478972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4: a key player in the cell cycle, development, and cancer</span></div><div class="casAuthors">Baker, Stacey J.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">658-669, 12</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  The cell cycle is regulated in part by cyclins and their assocd. serine/threonine cyclin-dependent kinases, or CDKs.  CDK4, in conjunction with the D-type cyclins, mediates progression through the G1 phase when the cell preps. to initiate DNA synthesis.  Although CDK4-null mutant mice are viable and cell proliferation is not significantly affected in vitro due to compensatory roles played by other CDKs, this gene plays a key role in mammalian development and cancer.  This review discusses the role that CDK4 plays in cell cycle control, normal development, and tumorigenesis as well as how small mol. inhibitors of CDK4 can be used to treat disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrm4MktbeTP7Vg90H21EOLACvtfcHk0lh0lOvmmAHp5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1Wls7g%253D&md5=a9b5bbdff7e0c4bc6c350f210bc483b0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1177%2F1947601913478972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601913478972%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DCdk4%253A%2520A%2520key%2520player%2520in%2520the%2520cell%2520cycle%252C%2520development%252C%2520and%2520cancer%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D658%26epage%3D669%26doi%3D10.1177%2F1947601913478972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M. A.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: Cdk4 inhibitors for cancer therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3379</span>– <span class="NLM_lpage">3383</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1078-0432.CCR-13-1551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=24795392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKksr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=3379-3383&author=M.+A.+Dickson&title=Molecular+pathways%3A+Cdk4+inhibitors+for+cancer+therapy&doi=10.1158%2F1078-0432.CCR-13-1551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: CDK4 Inhibitors for Cancer Therapy</span></div><div class="casAuthors">Dickson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3379-3383</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common.  CDK4 is the key regulator of the G1-S transition.  In complex with cyclin D, CDK4 phosphorylates retinoblastoma protein (Rb) and drives cell-cycle progression, a process inhibited by p16.  The p16-CDK4-cyclin D-Rb is aberrant in the majority of cancers and is, thus, a logical target for anticancer therapy.  Previous attempts to block CDK4 with nonselective cyclin-dependent kinase (CDK) inhibitors led to toxicity and little efficacy.  However, the recent development of selective CDK4 inhibitors launched the first successful efforts to target the pathway for cancer therapy.  Three oral selective CDK4 inhibitors have entered clin. trials: palbociclib (PD0332991), LEE011, and LY2835219.  CDK4 inhibitors have in vitro activity against a broad range of cancers and in patients have shown antitumor activity in breast cancer, lymphoma, sarcoma, and other tumors.  Major efforts are under way to develop biomarkers of response, understand potential mechanisms of resistance, and develop rational combinations of CDK4 inhibitors with chemotherapy and other targeted drugs.  Clin Cancer Res; 20(13); 3379-83. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMbU-VJN7oubVg90H21EOLACvtfcHk0lh0lOvmmAHp5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKksr3O&md5=90a6fdde00acbc1b4bbe69472859176a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1551%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26atitle%3DMolecular%2520pathways%253A%2520Cdk4%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D3379%26epage%3D3383%26doi%3D10.1158%2F1078-0432.CCR-13-1551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 inhibitors: Promising opportunities beyond breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F2159-8290.CD-16-0563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=697-699&author=J.+S.+J.+Limauthor=N.+C.+Turnerauthor=T.+A.+Yap&title=Cdk4%2F6+inhibitors%3A+Promising+opportunities+beyond+breast+cancer&doi=10.1158%2F2159-8290.CD-16-0563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0563%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%2BS.%2BJ.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DCdk4%252F6%2520inhibitors%253A%2520Promising%2520opportunities%2520beyond%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D697%26epage%3D699%26doi%3D10.1158%2F2159-8290.CD-16-0563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Treating cancer with selective cdk4/6 inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnrclinonc.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27030077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=417&author=B.+O%E2%80%99Learyauthor=R.+S.+Finnauthor=N.+C.+Turner&title=Treating+cancer+with+selective+cdk4%2F6+inhibitors&doi=10.1038%2Fnrclinonc.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Treating cancer with selective CDK4/6 inhibitors</span></div><div class="casAuthors">O'Leary, Ben; Finn, Richard S.; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-430</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathol. process.  Clin. implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents.  The emergence of a new generation of selective CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has enabled tumor types in which CDK4/6 has a pivotal role in the G1-to-S-phase cell-cycle transition to be targeted with improved effectiveness, and fewer adverse effects.  Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage estrogen receptor (ER)-pos. breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile.  Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified.  Extending the use of CDK4/6 inhibitors beyond ER-pos. breast cancer is challenging, and will likely require biomarkers that are predictive of a response, and the use of combination therapies in order to optimize CDK4/6 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNYw6CRUf17Vg90H21EOLACvtfcHk0lhQ4JBH9LUqGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D&md5=6641dc6ab3cbd70edac46319ce4e6f45</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DB.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DTreating%2520cancer%2520with%2520selective%2520cdk4%252F6%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D13%26spage%3D417%26doi%3D10.1038%2Fnrclinonc.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherr, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">Targeting cdk4 and cdk6: From discovery to therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0894</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F2159-8290.CD-15-0894" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=26658964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlslaqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=353-367&author=C.+J.+Sherrauthor=D.+Beachauthor=G.+I.+Shapiro&title=Targeting+cdk4+and+cdk6%3A+From+discovery+to+therapy&doi=10.1158%2F2159-8290.CD-15-0894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK4 and CDK6: From Discovery to Therapy</span></div><div class="casAuthors">Sherr, Charles J.; Beach, David; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-367</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Biochem. and genetic characterization of D-type cyclins, their cyclin D-dependent kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16INK4 over two decades ago revealed how mammalian cells regulate entry into the DNA synthetic (S) phase of the cell-division cycle in a retinoblastoma protein-dependent manner.  These investigations provided proof-of-principle that CDK4/6 inhibitors, particularly when combined with coinhibition of allied mitogen-dependent signal transduction pathways, might prove valuable in cancer therapy.  FDA approval of the CDK4/6 inhibitor palbociclib used with the aromatase inhibitor letrozole for breast cancer treatment highlights long-sought success.  The newest findings herald clin. trials targeting other cancers.  Significance: Rapidly emerging data with selective inhibitors of CDK4/6 have validated these cell-cycle kinases as anticancer drug targets, corroborating longstanding preclin. predictions.  This review addresses the discovery of these CDKs and their regulators, as well as translation of CDK4/6 biol. to pos. clin. outcomes and development of rational combinatorial therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNk2UjFylJJ7Vg90H21EOLACvtfcHk0lhQ4JBH9LUqGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlslaqu70%253D&md5=f4b1670d4771ca2079fb1eb7ebaef2b2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0894%26sid%3Dliteratum%253Aachs%26aulast%3DSherr%26aufirst%3DC.%2BJ.%26aulast%3DBeach%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DTargeting%2520cdk4%2520and%2520cdk6%253A%2520From%2520discovery%2520to%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D353%26epage%3D367%26doi%3D10.1158%2F2159-8290.CD-15-0894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Giovanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavecchia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzaro, G.</span></span> <span> </span><span class="NLM_article-title">Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: An update on recent findings (2013–2016)</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1215</span>– <span class="NLM_lpage">1230</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1234603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1080%2F13543784.2016.1234603" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1215-1230&author=C.+Di+Giovanniauthor=E.+Novellinoauthor=A.+Chilinauthor=A.+Lavecchiaauthor=G.+Marzaro&title=Investigational+drugs+targeting+cyclin-dependent+kinases+for+the+treatment+of+cancer%3A+An+update+on+recent+findings+%282013%E2%80%932016%29&doi=10.1080%2F13543784.2016.1234603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1234603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1234603%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGiovanni%26aufirst%3DC.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DChilin%26aufirst%3DA.%26aulast%3DLavecchia%26aufirst%3DA.%26aulast%3DMarzaro%26aufirst%3DG.%26atitle%3DInvestigational%2520drugs%2520targeting%2520cyclin-dependent%2520kinases%2520for%2520the%2520treatment%2520of%2520cancer%253A%2520An%2520update%2520on%2520recent%2520findings%2520%25282013%25E2%2580%25932016%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1215%26epage%3D1230%26doi%3D10.1080%2F13543784.2016.1234603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span> <span> </span><span class="NLM_article-title">Targeting cdk4/6 in patients with cancer</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2016.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.ctrv.2016.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27017286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOmu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=129&author=E.+Hamiltonauthor=J.+R.+Infante&title=Targeting+cdk4%2F6+in+patients+with+cancer&doi=10.1016%2Fj.ctrv.2016.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK4/6 in patients with cancer</span></div><div class="casAuthors">Hamilton, Erika; Infante, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway controls cell cycle progression by regulating the G1-S checkpoint.  Dysregulation of the cyclin D-CDK4/6-INK4-Rb pathway results in increased proliferation, and is frequently obsd. in many types of cancer.  Pathway activation can occur through a variety of mechanisms, including gene amplification or rearrangement, loss of neg. regulators, epigenetic alterations, and point mutations in key pathway components.  Due to the importance of CDK4/6 activity in cancer cells, CDK4/6 inhibitors have emerged as promising candidates for cancer treatment.  Moreover, combination of a CDK4/6 inhibitor with other targeted therapies may help overcome acquired or de novo treatment resistance.  Ongoing studies include combinations of CDK4/6 inhibitors with endocrine therapy and phosphatidylinositol 3-kinase (PI3K) pathway inhibitors for hormone receptor-pos. (HR+) breast cancers, and with selective RAF and MEK inhibitors for tumors with alterations in the mitogen activated protein kinase (MAPK) pathway such as melanoma.  In particular, the combination of CDK4/6 inhibitors with endocrine therapy, such as palbociclib's recent first-line approval in combination with letrozole, is expected to transform the treatment of HR+ breast cancer.  Currently, three selective CDK4/6 inhibitors have been approved or are in late-stage development: palbociclib (PD-0332991), ribociclib (LEE011), and abemaciclib (LY2835219).  Here we describe the current preclin. and clin. data for these novel agents and discuss combination strategies with other agents for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri6OrwmwegM7Vg90H21EOLACvtfcHk0lhQ4JBH9LUqGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOmu7w%253D&md5=8a88741e40627cb9f5c477b5a106b5ac</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2016.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2016.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DE.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DTargeting%2520cdk4%252F6%2520in%2520patients%2520with%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2016%26volume%3D45%26spage%3D129%26doi%3D10.1016%2Fj.ctrv.2016.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baratte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Gahmen, U.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1021/jm049353p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049353p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFSqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=737-743&author=H.+Luauthor=D.+J.+Changauthor=B.+Baratteauthor=L.+Meijerauthor=U.+Schulze-Gahmen&title=Crystal+structure+of+a+human+cyclin-dependent+kinase+6+complex+with+a+flavonol+inhibitor%2C+fisetin&doi=10.1021%2Fjm049353p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of a Human Cyclin-Dependent Kinase 6 Complex with a Flavonol Inhibitor, Fisetin</span></div><div class="casAuthors">Lu, Heshu; Chang, Debbie J.; Baratte, Blandine; Meijer, Laurent; Schulze-Gahmen, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">737-743</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play a central role in cell cycle control, apoptosis, transcription, and neuronal functions.  They are important targets for the design of drugs with antimitotic or antineurodegenerative effects.  CDK4 and CDK6 form a subfamily among the CDKs in mammalian cells, as defined by sequence similarities.  Compared to CDK2 and CDK5, structural information on CDK4 and CDK6 is sparse.  We describe here the crystal structure of human CDK6 in complex with a viral cyclin and a flavonol inhibitor, fisetin.  Fisetin binds to the active form of CDK6, forming hydrogen bonds with the side chains of residues in the binding pocket that undergo large conformational changes during CDK activation by cyclin binding.  The 4-keto group and the 3-hydroxyl group of fisetin are hydrogen bonded with the backbone in the hinge region between the N-terminal and C-terminal kinase domain, as has been obsd. for many CDK inhibitors.  However, CDK2 and HCK kinase in complex with other flavone inhibitors such as quercetin and flavopiridol showed a different binding mode with the inhibitor rotated by about 180°.  The structural information of the CDK6-fisetin complex is correlated with the binding affinities of different flavone inhibitors for CDK6.  This complex structure is the first description of an inhibitor complex with a kinase from the CDK4/6 subfamily and can provide a basis for selecting and designing inhibitor compds. with higher affinities and specificities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeJrMaE-wOqrVg90H21EOLACvtfcHk0ljvsVzuRhqqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFSqsQ%253D%253D&md5=0c3910ed0310038be241230a633ba840</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm049353p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049353p%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DD.%2BJ.%26aulast%3DBaratte%26aufirst%3DB.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26atitle%3DCrystal%2520structure%2520of%2520a%2520human%2520cyclin-dependent%2520kinase%25206%2520complex%2520with%2520a%2520flavonol%2520inhibitor%252C%2520fisetin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D737%26epage%3D743%26doi%3D10.1021%2Fjm049353p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Martinez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbert, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin dependent kinase (cdk) inhibitors as anticancer drugs</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3435</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.05.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2015.05.100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3420-3435&author=C.+Sanchez-Martinezauthor=L.+M.+Gelbertauthor=M.+J.+Lallenaauthor=A.+de+Dios&title=Cyclin+dependent+kinase+%28cdk%29+inhibitors+as+anticancer+drugs&doi=10.1016%2Fj.bmcl.2015.05.100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.05.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.05.100%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Martinez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520dependent%2520kinase%2520%2528cdk%2529%2520inhibitors%2520as%2520anticancer%2520drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D3420%26epage%3D3435%26doi%3D10.1016%2Fj.bmcl.2015.05.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attiyeh, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diskin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parasuraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnepp, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span> <span> </span><span class="NLM_article-title">Dual cdk4/cdk6 inhibition induces cell-cycle arrest and senescence in neuroblastoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6173</span>– <span class="NLM_lpage">6182</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1078-0432.CCR-13-1675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=24045179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslyku7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6173-6182&author=J.+Raderauthor=M.+R.+Russellauthor=L.+S.+Hartauthor=M.+S.+Nakazawaauthor=L.+T.+Belcastroauthor=D.+Martinezauthor=Y.+Liauthor=E.+L.+Carpenterauthor=E.+F.+Attiyehauthor=S.+J.+Diskinauthor=S.+Kimauthor=S.+Parasuramanauthor=G.+Caponigroauthor=R.+W.+Schneppauthor=A.+C.+Woodauthor=B.+Pawelauthor=K.+A.+Coleauthor=J.+M.+Maris&title=Dual+cdk4%2Fcdk6+inhibition+induces+cell-cycle+arrest+and+senescence+in+neuroblastoma&doi=10.1158%2F1078-0432.CCR-13-1675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma</span></div><div class="casAuthors">Rader, JulieAnn; Russell, Mike R.; Hart, Lori S.; Nakazawa, Michael S.; Belcastro, Lili T.; Martinez, Daniel; Li, Yimei; Carpenter, Erica L.; Attiyeh, Edward F.; Diskin, Sharon J.; Kim, Sunkyu; Parasuraman, Sudha; Caponigro, Giordano; Schnepp, Robert W.; Wood, Andrew C.; Pawel, Bruce; Cole, Kristina A.; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6173-6182</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Neuroblastoma is a pediatric cancer that continues to exact significant morbidity and mortality.  Recently, a no. of cell-cycle proteins, particularly those within the Cyclin D/CDK4/CDK6/RB network, have been shown to exert oncogenic roles in neuroblastoma, suggesting that their therapeutic exploitation might improve patient outcomes.  Exptl. Procedures: We evaluated the effect of dual CDK4/CDK6 inhibition on neuroblastoma viability using LEE011 (Novartis Oncol.), a highly specific CDK4/6 inhibitor.  Results: Treatment with LEE011 significantly reduced proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis at nanomolar concns. (mean IC50 = 307 ± 68 nmol/L in sensitive lines).  LEE011 caused cell-cycle arrest and cellular senescence that was attributed to dose-dependent decreases in phosphorylated RB and FOXM1, resp.  In addn., responsiveness of neuroblastoma xenografts to LEE011 translated to the in vivo setting in that there was a direct correlation of in vitro IC50 values with degree of s.c. xenograft growth delay.  Although our data indicate that neuroblastomas sensitive to LEE011 were more likely to contain genomic amplification of MYCN (P = 0.01), the identification of addnl. clin. accessible biomarkers is of high importance.  Conclusions: Taken together, our data show that LEE011 is active in a large subset of neuroblastoma cell line and xenograft models, and supports the clin. development of this CDK4/6 inhibitor as a therapy for patients with this disease.  Clin Cancer Res; 19(22); 6173-82. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowEpLsvDNwSLVg90H21EOLACvtfcHk0ljvsVzuRhqqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslyku7rL&md5=5fd1f23125cca7e087d0e14d4c66c3c1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1675%26sid%3Dliteratum%253Aachs%26aulast%3DRader%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%2BR.%26aulast%3DHart%26aufirst%3DL.%2BS.%26aulast%3DNakazawa%26aufirst%3DM.%2BS.%26aulast%3DBelcastro%26aufirst%3DL.%2BT.%26aulast%3DMartinez%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCarpenter%26aufirst%3DE.%2BL.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DDiskin%26aufirst%3DS.%2BJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DParasuraman%26aufirst%3DS.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DSchnepp%26aufirst%3DR.%2BW.%26aulast%3DWood%26aufirst%3DA.%2BC.%26aulast%3DPawel%26aufirst%3DB.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DDual%2520cdk4%252Fcdk6%2520inhibition%2520induces%2520cell-cycle%2520arrest%2520and%2520senescence%2520in%2520neuroblastoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6173%26epage%3D6182%26doi%3D10.1158%2F1078-0432.CCR-13-1675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostofizadeh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Euw, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konkankit, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamidi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taschereau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belldegrun, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabbinavar, F. F.</span></span> <span> </span><span class="NLM_article-title">Pd-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2997</span>– <span class="NLM_lpage">3004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=23898052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=2997-3004&author=J.+E.+Loganauthor=N.+Mostofizadehauthor=A.+J.+Desaiauthor=E.+Von+Euwauthor=D.+Conklinauthor=V.+Konkankitauthor=H.+Hamidiauthor=M.+Eckardtauthor=L.+Andersonauthor=H.+W.+Chenauthor=C.+Gintherauthor=E.+Taschereauauthor=P.+H.+Buiauthor=J.+G.+Christensenauthor=A.+S.+Belldegrunauthor=D.+J.+Slamonauthor=F.+F.+Kabbinavar&title=Pd-0332991%2C+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6%2C+demonstrates+inhibition+of+proliferation+in+renal+cell+carcinoma+at+nanomolar+concentrations+and+molecular+markers+predict+for+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity</span></div><div class="casAuthors">Logan, Joshua E.; Mostofizadeh, Nikayeh; Desai, Amrita J.; Von Euw, Erika; Conklin, Dylan; Konkankit, Veerauo; Hamidi, Habib; Eckardt, Mark; Anderson, Lee; Chen, Hsiao-Wang; Ginther, Charles; Taschereau, Eileen; Bui, Peter H.; Christensen, James G.; Belldegrun, Arie S.; Slamon, Dennis J.; Kabbinavar, Fairooz F.</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2997-3004</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: PD-0332991 is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and was evaluated to det. its anti-proliferative effects in 25 renal cell carcinoma (RCC) cell lines.  Materials and Methods: Half-maximal inhibitory concns. (IC50) of PD-0332991 were detd. with cell line proliferation assays, as were its effects on the cell cycle, apoptosis, and retinoblastoma (RB) phosphorylation.  Mol. markers for response prediction, including p16, p15, cyclin D1 (CCND1), cyclin E1 (CCNE1), E2F transcription factor 1 (E2F1), RB, CDK4 and CDK6, were studied using array comparative genomic hybridization (CGH) and gene expression.  Results: IC50 values for PD-0332991 ranged from 25.0 nM to 700 nM, and the agent demonstrated G0/G1 cell-cycle arrest, induction of late apoptosis, and blockade of RB phosphorylation.  Through genotype and expression data p16, p15 and E2F1 were identified as having significant assocn. between loss and sensitivity to PD-0332991: p16 (p=0.021), p15 (p=0.047), and E2F1 (p=0.041).  Conclusion: PD-0332991 has antiproliferative activity in RCC cell lines, and mol. markers predict for sensitivity to this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy_nR-af24obVg90H21EOLACvtfcHk0lj9TznwiKe0xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVaqsLnI&md5=edd3b575a24b999dd3ec69b648a9b11d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLogan%26aufirst%3DJ.%2BE.%26aulast%3DMostofizadeh%26aufirst%3DN.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DVon%2BEuw%26aufirst%3DE.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DKonkankit%26aufirst%3DV.%26aulast%3DHamidi%26aufirst%3DH.%26aulast%3DEckardt%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DH.%2BW.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DTaschereau%26aufirst%3DE.%26aulast%3DBui%26aufirst%3DP.%2BH.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DBelldegrun%26aufirst%3DA.%2BS.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DKabbinavar%26aufirst%3DF.%2BF.%26atitle%3DPd-0332991%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%252C%2520demonstrates%2520inhibition%2520of%2520proliferation%2520in%2520renal%2520cell%2520carcinoma%2520at%2520nanomolar%2520concentrations%2520and%2520molecular%2520markers%2520predict%2520for%2520sensitivity%26jtitle%3DAnticancer%2520Res.%26date%3D2013%26volume%3D33%26spage%3D2997%26epage%3D3004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalous, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginther, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowst, C.</span></span> <span> </span><span class="NLM_article-title">Pd 0332991, a selective cyclin d kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1186/bcr2419</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1186%2Fbcr2419" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1-13&author=R.+S.+Finnauthor=J.+Deringauthor=D.+Conklinauthor=O.+Kalousauthor=D.+J.+Cohenauthor=A.+J.+Desaiauthor=C.+Gintherauthor=M.+Atefiauthor=I.+Chenauthor=C.+Fowst&title=Pd+0332991%2C+a+selective+cyclin+d+kinase+4%2F6+inhibitor%2C+preferentially+inhibits+proliferation+of+luminal+estrogen+receptor-positive+human+breast+cancer+cell+lines+in+vitro&doi=10.1186%2Fbcr2419"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fbcr2419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr2419%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DFowst%26aufirst%3DC.%26atitle%3DPd%25200332991%252C%2520a%2520selective%2520cyclin%2520d%2520kinase%25204%252F6%2520inhibitor%252C%2520preferentially%2520inhibits%2520proliferation%2520of%2520luminal%2520estrogen%2520receptor-positive%2520human%2520breast%2520cancer%2520cell%2520lines%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2009%26volume%3D11%26spage%3D1%26epage%3D13%26doi%3D10.1186%2Fbcr2419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodfuehrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2388</span>– <span class="NLM_lpage">2406</span>, <span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+R.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lj9TznwiKe0xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%2BR.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baughn, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Liberto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niesvizky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen-Kiang, S.</span></span> <span> </span><span class="NLM_article-title">A novel orally active small molecule potently induces g<sub>1</sub> arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7661</span>– <span class="NLM_lpage">7667</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-1098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F0008-5472.CAN-06-1098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=7661-7667&author=L.+B.+Baughnauthor=M.+Di+Libertoauthor=K.+Wuauthor=P.+L.+Toogoodauthor=T.+Louieauthor=R.+Gottschalkauthor=R.+Niesvizkyauthor=H.+Choauthor=S.+Elyauthor=M.+A.+S.+Mooreauthor=S.+Chen-Kiang&title=A+novel+orally+active+small+molecule+potently+induces+g1+arrest+in+primary+myeloma+cells+and+prevents+tumor+growth+by+specific+inhibition+of+cyclin-dependent+kinase+4%2F6&doi=10.1158%2F0008-5472.CAN-06-1098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-1098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-1098%26sid%3Dliteratum%253Aachs%26aulast%3DBaughn%26aufirst%3DL.%2BB.%26aulast%3DDi%2BLiberto%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DLouie%26aufirst%3DT.%26aulast%3DGottschalk%26aufirst%3DR.%26aulast%3DNiesvizky%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DEly%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DM.%2BA.%2BS.%26aulast%3DChen-Kiang%26aufirst%3DS.%26atitle%3DA%2520novel%2520orally%2520active%2520small%2520molecule%2520potently%2520induces%2520g1%2520arrest%2520in%2520primary%2520myeloma%2520cells%2520and%2520prevents%2520tumor%2520growth%2520by%2520specific%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D7661%26epage%3D7667%26doi%3D10.1158%2F0008-5472.CAN-06-1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akula, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athuluridivakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallireddigari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallela, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billa, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbaiah, D. R. C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharathi, E. V.</span></span> <span> </span><span class="NLM_article-title">Vasquez-Del Carpio, R.; Padgaonkar, A.; Baker, S. J.; Reddy, E. P. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (cdk4) and ampk-related kinase 5 (arks)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1021/jm401073p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401073p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=578-599&author=M.+V.+R.+Reddyauthor=B.+Akulaauthor=S.+C.+Cosenzaauthor=S.+Athuluridivakarauthor=M.+R.+Mallireddigariauthor=V.+R.+Pallelaauthor=V.+K.+Billaauthor=D.+R.+C.+V.+Subbaiahauthor=E.+V.+Bharathi&title=Vasquez-Del+Carpio%2C+R.%3B+Padgaonkar%2C+A.%3B+Baker%2C+S.+J.%3B+Reddy%2C+E.+P.+Discovery+of+8-cyclopentyl-2-%5B4-%284-methyl-piperazin-1-yl%29-phenylamino%5D-7-oxo-7%2C8-dihydro-pyrido%5B2%2C3-d%5Dpyrimidine-6-carbonitrile+%287x%29+as+a+potent+inhibitor+of+cyclin-dependent+kinase+4+%28cdk4%29+and+ampk-related+kinase+5+%28arks%29&doi=10.1021%2Fjm401073p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm401073p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401073p%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DAkula%26aufirst%3DB.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DAthuluridivakar%26aufirst%3DS.%26aulast%3DMallireddigari%26aufirst%3DM.%2BR.%26aulast%3DPallela%26aufirst%3DV.%2BR.%26aulast%3DBilla%26aufirst%3DV.%2BK.%26aulast%3DSubbaiah%26aufirst%3DD.%2BR.%2BC.%2BV.%26aulast%3DBharathi%26aufirst%3DE.%2BV.%26atitle%3DVasquez-Del%2520Carpio%252C%2520R.%253B%2520Padgaonkar%252C%2520A.%253B%2520Baker%252C%2520S.%2520J.%253B%2520Reddy%252C%2520E.%2520P.%2520Discovery%2520of%25208-cyclopentyl-2-%255B4-%25284-methyl-piperazin-1-yl%2529-phenylamino%255D-7-oxo-7%252C8-dihydro-pyrido%255B2%252C3-d%255Dpyrimidine-6-carbonitrile%2520%25287x%2529%2520as%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%2520%2528cdk4%2529%2520and%2520ampk-related%2520kinase%25205%2520%2528arks%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D578%26epage%3D599%26doi%3D10.1021%2Fjm401073p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolay, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardeesy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, N. J.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 and igf1 receptor inhibitors synergize to suppress the growth of p16ink4a-deficient pancreatic cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">3947</span>– <span class="NLM_lpage">3958</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-2923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F0008-5472.CAN-13-2923" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=3947-3958&author=A.+M.+Heilmannauthor=R.+M.+Pereraauthor=V.+Eckerauthor=B.+N.+Nicolayauthor=N.+Bardeesyauthor=C.+H.+Benesauthor=N.+J.+Dyson&title=Cdk4%2F6+and+igf1+receptor+inhibitors+synergize+to+suppress+the+growth+of+p16ink4a-deficient+pancreatic+cancers&doi=10.1158%2F0008-5472.CAN-13-2923"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-2923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-2923%26sid%3Dliteratum%253Aachs%26aulast%3DHeilmann%26aufirst%3DA.%2BM.%26aulast%3DPerera%26aufirst%3DR.%2BM.%26aulast%3DEcker%26aufirst%3DV.%26aulast%3DNicolay%26aufirst%3DB.%2BN.%26aulast%3DBardeesy%26aufirst%3DN.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DDyson%26aufirst%3DN.%2BJ.%26atitle%3DCdk4%252F6%2520and%2520igf1%2520receptor%2520inhibitors%2520synergize%2520to%2520suppress%2520the%2520growth%2520of%2520p16ink4a-deficient%2520pancreatic%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D3947%26epage%3D3958%26doi%3D10.1158%2F0008-5472.CAN-13-2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Dort, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nino, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanks, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbán, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (mek1) and phosphatidylinositol 3-kinase (pi3k)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2512</span>– <span class="NLM_lpage">2522</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01655</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01655" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2512-2522&author=M.+E.+Van+Dortauthor=H.+Hongauthor=H.+Wangauthor=C.+A.+Ninoauthor=R.+L.+Lombardiauthor=A.+E.+Blanksauthor=S.+Galb%C3%A1nauthor=B.+D.+Ross&title=Discovery+of+bifunctional+oncogenic+target+inhibitors+against+allosteric+mitogen-activated+protein+kinase+%28mek1%29+and+phosphatidylinositol+3-kinase+%28pi3k%29&doi=10.1021%2Facs.jmedchem.5b01655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K)</span></div><div class="casAuthors">Van Dort, Marcian E.; Hong, Hao; Wang, Hanxiao; Nino, Charles A.; Lombardi, Rachel L.; Blanks, Avery E.; Galban, Stefanie; Ross, Brian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2512-2522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a series of single entity, bifunctional MEK1/PI3K inhibitors achieved by covalent linking of structural analogs of the ATP-competitive PI3K inhibitor ZSTK474 and the ATP-noncompetitive MEK inhibitor PD0325901 is described.  Inhibitors displayed potent in vitro inhibition of MEK1 (0.015 < IC50 (nM) < 56.7) and PI3K (54 < IC50 (nM) < 341) in enzymic inhibition assays.  Concurrent MEK1 and PI3K inhibition was demonstrated with inhibitors 9 and 14 in two tumor cell lines (A549, D54).  Inhibitors produced dose-dependent decreased cell viability similar to the combined administration of equiv. doses of ZSTK474 and PD0325901.  In vivo efficacy of 14 following oral administration was demonstrated in D54 glioma and A549 lung tumor bearing mice.  Compd. 14 showed a 95% and 67% inhibition of tumor ERK1/2 and Akt phosphorylation, resp., at 2 h postadministration by Western blot anal., confirming the bioavailability and efficacy of this bifunctional inhibitor strategy toward combined MEK1/PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxtplBF0UZ7bVg90H21EOLACvtfcHk0lgOGEkI7jR5Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yqsL4%253D&md5=1bbc4eef05d0c4bab6a21e7a5db2790e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01655%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDort%26aufirst%3DM.%2BE.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNino%26aufirst%3DC.%2BA.%26aulast%3DLombardi%26aufirst%3DR.%2BL.%26aulast%3DBlanks%26aufirst%3DA.%2BE.%26aulast%3DGalb%25C3%25A1n%26aufirst%3DS.%26aulast%3DRoss%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520bifunctional%2520oncogenic%2520target%2520inhibitors%2520against%2520allosteric%2520mitogen-activated%2520protein%2520kinase%2520%2528mek1%2529%2520and%2520phosphatidylinositol%25203-kinase%2520%2528pi3k%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2512%26epage%3D2522%26doi%3D10.1021%2Facs.jmedchem.5b01655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daniele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sestito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrobono, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Maio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapposelli, S.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of pdk1 and aurora kinase a: An effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00251</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00251" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGku7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=100-114&author=S.+Danieleauthor=S.+Sestitoauthor=D.+Pietrobonoauthor=C.+Giacomelliauthor=G.+Chielliniauthor=D.+Di+Maioauthor=L.+Marinelliauthor=E.+Novellinoauthor=C.+Martiniauthor=S.+Rapposelli&title=Dual+inhibition+of+pdk1+and+aurora+kinase+a%3A+An+effective+strategy+to+induce+differentiation+and+apoptosis+of+human+glioblastoma+multiforme+stem+cells&doi=10.1021%2Facschemneuro.6b00251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells</span></div><div class="casAuthors">Daniele, Simona; Sestito, Simona; Pietrobono, Deborah; Giacomelli, Chiara; Chiellini, Grazia; Di Maio, Danilo; Marinelli, Luciana; Novellino, Ettore; Martini, Claudia; Rapposelli, Simona</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-114</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The poor prognosis of Glioblastoma Multiforme (GBM) is mainly attributed to drug resistance mechanisms and to the existence of a subpopulation of glioma stem cells (GSCs).  Multi-target compds. able to both affect different deregulated pathways and the GSC subpopulation could escape tumor resistance, and most importantly, eradicate the stem cell reservoir.  In this respect, the simultaneous inhibition of Phosphoinositide-dependent kinase-1 (PDK1) and Aurora Kinase A (AurA), each one playing a pivotal role in cellular survival/migration/differentiation, could represent an innovative strategy to overcome GBM resistance and recurrence.  Herein, the cross-talk between these pathways was investigated, using the single-target ref. compds. MP7 (PDK1 inhibitor) and Alisertib (AurA inhibitor).  Furthermore, a new ligand, SA16, was identified for its ability to inhibit the PDK1 and the AurA pathways at once, thus proving to be a useful tool for the simultaneous inhibition of the two kinases.  SA16 blocked GBM cell proliferation, reduced tumor invasiveness, and triggered cellular apoptosis.  Most importantly, the AurA/PDK1 blocker showed an increased efficacy against GSCs, inducing their differentiation and apoptosis.  To the best of the authors' knowledge, this is the first report on combined targeting of PDK1 and AurA.  This drug represents an attractive multi-target lead scaffold for the development of new potential treatments for GBM and GSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxUhIyHzkNb7Vg90H21EOLACvtfcHk0lgOGEkI7jR5Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGku7fE&md5=0b560d2d60ed52d45d7d40864b551f1d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00251%26sid%3Dliteratum%253Aachs%26aulast%3DDaniele%26aufirst%3DS.%26aulast%3DSestito%26aufirst%3DS.%26aulast%3DPietrobono%26aufirst%3DD.%26aulast%3DGiacomelli%26aufirst%3DC.%26aulast%3DChiellini%26aufirst%3DG.%26aulast%3DDi%2BMaio%26aufirst%3DD.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DRapposelli%26aufirst%3DS.%26atitle%3DDual%2520inhibition%2520of%2520pdk1%2520and%2520aurora%2520kinase%2520a%253A%2520An%2520effective%2520strategy%2520to%2520induce%2520differentiation%2520and%2520apoptosis%2520of%2520human%2520glioblastoma%2520multiforme%2520stem%2520cells%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D100%26epage%3D114%26doi%3D10.1021%2Facschemneuro.6b00251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konze, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. G.</span></span> <span> </span><span class="NLM_article-title">Targeting ezh2 and prc2 dependence as novel anticancer therapy</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2015.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.exphem.2015.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=26027790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2hsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=698-712&author=B.+W.+Xuauthor=K.+D.+Konzeauthor=J.+Jinauthor=G.+G.+Wang&title=Targeting+ezh2+and+prc2+dependence+as+novel+anticancer+therapy&doi=10.1016%2Fj.exphem.2015.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting EZH2 and PRC2 dependence as novel anticancer therapy</span></div><div class="casAuthors">Xu, Bowen; Konze, Kyle D.; Jin, Jian; Wang, Gang Greg</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">698-712</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Distinctive patterns of chromatin modification control gene expression and define cellular identity during development and cell differentiation.  Polycomb repressive complex 2 (PRC2), the sole mammalian enzymic complex capable of establishing gene-repressive high-degree methylation of histone H3 at lysine 27 (H3K27), plays crucial roles in regulation of normal and malignant hematopoiesis.  Recently, increasing evidence has indicated that recurrent gain-of-function mutation and overexpression of EZH2, the catalytic subunit of PRC2, drive and promote malignant transformation such as B-cell lymphomagenesis, providing a rationale for PRC2 inhibition as a novel anticancer strategy.  Here, we summarize the recently developed strategies for inhibition of PRC2, which include a series of highly specific, highly potent, small-mol. inhibitors of EZH2 and EZH1, an EZH2-related methyltransferase.  PRC2 establishes functional crosstalk with numerous epigenetic machineries during dynamic regulation of gene transcription.  Perturbation of such functional crosstalk caused by genetic events obsd. in various hematol. cancers, such as inactivation of SNF5 and somatic mutation of UTX, confers PRC2 dependence, thus rendering an increased sensitivity to PRC2 inhibition.  We discuss our current understanding of EZH2 somatic mutations frequently found in B-cell lymphomas and recurrent mutations in various other epigenetic regulators as novel mol. predictors and determinants of PRC2 sensitivity.  As recent advances have indicated a crit. developmental or tumor-suppressive role for PRC2 and EZH2 in various tissue types, we discuss concerns over potentially toxic or even adverse effects assocd. with EZH2/1 inhibition in certain biol. contexts or on cancer genetic background.  Collectively, inhibition of PRC2 catalytic activity has emerged as a promising therapeutic intervention for the precise treatment of a range of genetically defined hematol. malignancies and can be potentially applied to a broader spectrum of human cancers that bear similar genetic and epigenetic characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSdNIFJBGEoLVg90H21EOLACvtfcHk0lgF7fT7NG8_2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2hsbfO&md5=fa5481ff0ffc5bdc4b57dd7e21bc7fec</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2015.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2015.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DB.%2BW.%26aulast%3DKonze%26aufirst%3DK.%2BD.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%2BG.%26atitle%3DTargeting%2520ezh2%2520and%2520prc2%2520dependence%2520as%2520novel%2520anticancer%2520therapy%26jtitle%3DExp.%2520Hematol.%26date%3D2015%26volume%3D43%26spage%3D698%26epage%3D712%26doi%3D10.1016%2Fj.exphem.2015.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peserico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, C.</span></span> <span> </span><span class="NLM_article-title">Physical and functional hat/hdac interplay regulates protein acetylation balance</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2011/371832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1155%2F2011%2F371832" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=1-10&author=A.+Pesericoauthor=C.+Simone&title=Physical+and+functional+hat%2Fhdac+interplay+regulates+protein+acetylation+balance&doi=10.1155%2F2011%2F371832"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1155%2F2011%2F371832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F371832%26sid%3Dliteratum%253Aachs%26aulast%3DPeserico%26aufirst%3DA.%26aulast%3DSimone%26aufirst%3DC.%26atitle%3DPhysical%2520and%2520functional%2520hat%252Fhdac%2520interplay%2520regulates%2520protein%2520acetylation%2520balance%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2011%2F371832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">Hdac family: What are the cancer relevant targets?</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=Hdac+family%3A+What+are+the+cancer+relevant+targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0lgF7fT7NG8_2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHdac%2520family%253A%2520What%2520are%2520the%2520cancer%2520relevant%2520targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">New and emerging hdac inhibitors for cancer treatment</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1172/JCI69738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1172%2FJCI69738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=24382387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=30-39&author=A.+C.+Westauthor=R.+W.+Johnstone&title=New+and+emerging+hdac+inhibitors+for+cancer+treatment&doi=10.1172%2FJCI69738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging HDAC inhibitors for cancer treatment</span></div><div class="casAuthors">West, Alison C.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci.  The identification of these enzymes and their partner proteins has driven the rapid development of small-mol. inhibitors that target the cancer epigenome.  Herein, the authors discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis.  The authors examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpELUU7P0B_grVg90H21EOLACvtfcHk0lgF7fT7NG8_2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFejtg%253D%253D&md5=ab59960223b33e89725f6539b031f531</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1172%2FJCI69738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69738%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DA.%2BC.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520hdac%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D30%26epage%3D39%26doi%3D10.1172%2FJCI69738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N. B.</span></span> <span> </span><span class="NLM_article-title">Hdac inhibitors in cancer biology: Emerging mechanisms and clinical applications</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/icb.2011.100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Ficb.2011.100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=22124371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=85-94&author=O.+Khanauthor=N.+B.+La+Thangue&title=Hdac+inhibitors+in+cancer+biology%3A+Emerging+mechanisms+and+clinical+applications&doi=10.1038%2Ficb.2011.100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications</span></div><div class="casAuthors">Khan, Omar; La Thangue, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology & Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-94</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Reversible acetylation mediated by histone deacetylases (HDACs) influences a broad repertoire of physiol. processes, many of which are aberrantly controlled in tumor cells.  As HDAC inhibition prompts tumor cells to enter apoptosis, small-mol. HDAC inhibitors have been developed as a new class of mechanism-based anti-cancer agent, many of which have entered clin. trials.  Although the clin. picture is evolving and the precise utility of HDAC inhibitors remains to be detd., it is noteworthy that certain tumor types undergo a favorable response, in particular hematol. malignancies.  Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease.  Here, we discuss developments in our understanding of mol. events that underlie the anti-cancer effects of HDAC inhibitors and relate this information to the emerging clin. picture for the application of these inhibitors in the treatment of cancer.  Immunol. and Cell Biol. (2012) 90, 85-94; doi:10.1038/icb.2011.100; published online 29 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvd48xGUlskbVg90H21EOLACvtfcHk0lgjmB98EgS9FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslykuw%253D%253D&md5=b9214c008e22696af4ee808b2e2af7f2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Ficb.2011.100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ficb.2011.100%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DO.%26aulast%3DLa%2BThangue%26aufirst%3DN.%2BB.%26atitle%3DHdac%2520inhibitors%2520in%2520cancer%2520biology%253A%2520Emerging%2520mechanisms%2520and%2520clinical%2520applications%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D90%26spage%3D85%26epage%3D94%26doi%3D10.1038%2Ficb.2011.100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J. M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase for cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3645</span>– <span class="NLM_lpage">3655</span>, <span class="refDoi"> DOI: 10.1021/jm400179b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400179b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3645-3655&author=J.+B.+Chenauthor=T.+R.+Chernauthor=T.+T.+Weiauthor=C.+C.+Chenauthor=J.+H.+Linauthor=J.+M.+Fang&title=Design+and+synthesis+of+dual-action+inhibitors+targeting+histone+deacetylases+and+3-hydroxy-3-methylglutaryl+coenzyme+a+reductase+for+cancer+treatment&doi=10.1021%2Fjm400179b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase for Cancer Treatment</span></div><div class="casAuthors">Chen, Jhih-Bin; Chern, Ting-Rong; Wei, Tzu-Tang; Chen, Ching-Chow; Lin, Jung-Hsin; Fang, Jim-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3645-3655</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of histone deacetylase (HDAC) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) such as I (X = bond, CH2; Y = bond, 1,4-benzenediyl; Z = bond, 1,2,3-triazole-4,1-diyl) and II were prepd. by incorporating the hydroxamate moieties of HDAC inhibitors into statins such as lovastatin known as HMGR inhibitors.  Hydroxamic acids such as II derived from ring-opening of the lactone moieties of statins were the most effective of the compds. tested at inhibiting HDAC and HMGR in vitro and in human leukemia cells, with IC50 values of 12-44 nM against HMGR, 63-125 nM against HDAC1, 414-600 nM against HDAC2, and 51-133 nM against HDAC6.  Statin-derived hydroxamic acids such as II inhibited the growth of human cancer cells with IC50 values of 18-20 μM and greater than five-fold selectivity for human cancer cells over normal human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYxyB-8TwI0LVg90H21EOLACvtfcHk0lgjmB98EgS9FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gt7c%253D&md5=e212e0f2e9d565b215f69e66dfd8adac</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm400179b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400179b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BB.%26aulast%3DChern%26aufirst%3DT.%2BR.%26aulast%3DWei%26aufirst%3DT.%2BT.%26aulast%3DChen%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DFang%26aufirst%3DJ.%2BM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520dual-action%2520inhibitors%2520targeting%2520histone%2520deacetylases%2520and%25203-hydroxy-3-methylglutaryl%2520coenzyme%2520a%2520reductase%2520for%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3645%26epage%3D3655%26doi%3D10.1021%2Fjm400179b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of janus kinase 2 (jak2) and histone deacetlyase (hdac) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Y.+Yenauthor=B.+W.+Dymock&title=Design+and+synthesis+of+janus+kinase+2+%28jak2%29+and+histone+deacetlyase+%28hdac%29+bispecific+inhibitors+based+on+pacritinib+and+evidence+of+dual+pathway+inhibition+in+hematological+cell+lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lgjmB98EgS9FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520janus%2520kinase%25202%2520%2528jak2%2529%2520and%2520histone%2520deacetlyase%2520%2528hdac%2529%2520bispecific%2520inhibitors%2520based%2520on%2520pacritinib%2520and%2520evidence%2520of%2520dual%2520pathway%2520inhibition%2520in%2520hematological%2520cell%2520lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffey, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandvold, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soellner, M. B.</span></span> <span> </span><span class="NLM_article-title">Development of a chimeric c-src kinase and hdac inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">783</span>, <span class="refDoi"> DOI: 10.1021/ml400175d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400175d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=779-783&author=K.+S.+Koauthor=M.+E.+Steffeyauthor=K.+R.+Brandvoldauthor=M.+B.+Soellner&title=Development+of+a+chimeric+c-src+kinase+and+hdac+inhibitor&doi=10.1021%2Fml400175d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Chimeric c-Src Kinase and HDAC Inhibitor</span></div><div class="casAuthors">Ko, Kristin S.; Steffey, Michael E.; Brandvold, Kristoffer R.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">779-783</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of synergism obsd. between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described.  The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor.  Chimeric inhibitor (I) is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzi2suGn-7ErVg90H21EOLACvtfcHk0lgjmB98EgS9FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKit7rL&md5=5f34ce3b1f65a8ac1a4341f563a5e1d9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fml400175d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400175d%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DK.%2BS.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DBrandvold%26aufirst%3DK.%2BR.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520chimeric%2520c-src%2520kinase%2520and%2520hdac%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D779%26epage%3D783%26doi%3D10.1021%2Fml400175d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellarocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M. E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattaey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Dual hdac and pi3k inhibitor cudc-907 downregulates myc and suppresses growth of myc-dependent cancers</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1535-7163.MCT-16-0390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27980108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=285-299&author=K.+M.+Sunauthor=R.+Atoyanauthor=M.+A.+Borekauthor=S.+Dellaroccaauthor=M.+E.+S.+Samsonauthor=A.+W.+Maauthor=G.+X.+Xuauthor=T.+Pattersonauthor=D.+P.+Tuckauthor=J.+L.+Vinerauthor=A.+Fattaeyauthor=J.+Wang&title=Dual+hdac+and+pi3k+inhibitor+cudc-907+downregulates+myc+and+suppresses+growth+of+myc-dependent+cancers&doi=10.1158%2F1535-7163.MCT-16-0390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers</span></div><div class="casAuthors">Sun, Kaiming; Atoyan, Ruzanna; Borek, Mylissa A.; Dellarocca, Steven; Samson, Maria Elena S.; Ma, Anna W.; Xu, Guang-Xin; Patterson, Troy; Tuck, David P.; Viner, Jaye L.; Fattaey, Ali; Wang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs that promote cell growth and proliferation.  Preclin. studies have suggested that individually targeting upstream regulators of MYC, such as histone deacetylases (HDAC) and phosphoinositide 3-kinases (PI3K), can reduce MYC protein levels and suppress the growth of MYC-driven cancers.  Synergy between HDAC and PI3K inhibition in inducing cancer cell death has also been reported, but the involvement of MYC regulation is unclear.  In this study, we demonstrated that HDAC and PI3K inhibition synergistically downregulates MYC protein levels and induces apoptosis in "double-hit" (DH) diffuse large B-cell lymphoma (DLBCL) cells.  Furthermore, CUDC-907, a small-mol. dual-acting inhibitor of both class I and II HDACs and class I PI3Ks, effectively suppresses the growth and survival of MYC-altered or MYC-dependent cancer cells, such as DH DLBCL and BRD-NUT fusion-pos. NUT midline carcinoma (NMC) cells, and MYC protein downregulation is an early event induced by CUDC-907 treatment.  Consistently, the antitumor activity of CUDC-907 against multiple MYC-driven cancer types was also demonstrated in animal models, including DLBCL and NMC xenograft models, Myc transgenic tumor syngeneic models, and MYC-amplified solid tumor patient-derived xenograft (PDX) models.  Our findings suggest that dual function HDAC and PI3K inhibitor CUDC-907 is an effective agent targeting MYC and thus may be developed as potential therapy for MYC-dependent cancers.  Mol Cancer Ther; 16(2); 285-99. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo82AzF-jV397Vg90H21EOLACvtfcHk0lhEVTB9HXbP7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVertro%253D&md5=d4ffd5f39546fa076448dbfb36406183</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0390%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DK.%2BM.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DBorek%26aufirst%3DM.%2BA.%26aulast%3DDellarocca%26aufirst%3DS.%26aulast%3DSamson%26aufirst%3DM.%2BE.%2BS.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DTuck%26aufirst%3DD.%2BP.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DFattaey%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDual%2520hdac%2520and%2520pi3k%2520inhibitor%2520cudc-907%2520downregulates%2520myc%2520and%2520suppresses%2520growth%2520of%2520myc-dependent%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D285%26epage%3D299%26doi%3D10.1158%2F1535-7163.MCT-16-0390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sposto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keshelava, N.</span></span> <span> </span><span class="NLM_article-title">Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant tp53</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3289</span>– <span class="NLM_lpage">3301</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1535-7163.MCT-10-0562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=21159612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=3289-3301&author=J.+M.+Huangauthor=M.+A.+Sheardauthor=L.+Y.+Jiauthor=R.+Spostoauthor=N.+Keshelava&title=Combination+of+vorinostat+and+flavopiridol+is+selectively+cytotoxic+to+multidrug-resistant+neuroblastoma+cell+lines+with+mutant+tp53&doi=10.1158%2F1535-7163.MCT-10-0562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53</span></div><div class="casAuthors">Huang, Jen-Ming; Sheard, Michael A.; Ji, Lingyun; Sposto, Richard; Keshelava, Nino</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3289-3301</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">As p53 loss of function (LOF) confers high-level drug resistance in neuroblastoma, p53-independent therapies might have superior activity in recurrent neuroblastoma.  We tested the activity of vorinostat, a histone deacetylase inhibitor, and flavopiridol, a pan-Cdk inhibitor, in a panel of multidrug-resistant neuroblastoma cell lines that included lines with wild-type (wt) and transcriptionally active TP53 (n = 3), mutated (mt), and LOF TP53 (n = 4) or p14ARF deletion (n = 1).  The combination of vorinostat and flavopiridol was synergistic and significantly more cytotoxic (P < 0.001) in cell lines with p53-LOF and in the clones stably transfected with dominant-neg. p53 plasmids.  Cell cycle anal. by flow cytometry showed prominent cell-cycle arrest in G2/M (37%) for a cell line with wt TP53 (SK-N-RA) at 16 to 20 h, while cells with mt TP53 (CHLA-90) slipped into sub-G1 at 6 to 24 h (25%-40% specific cell death).  The morphol. hallmarks of mitotic cell death, including defective spindle formation and abnormal cytokinesis, were detected by confocal microscopy after the treatment with vorinostat + flavopiridol combination in CHLA-90.  The combination caused redn. in the expression of G2/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53.  Plk1 expression was reduced in all treated lines.  Small interfering RNA knockdown of Mad2 and cyclin B1 or Plk1 synergistically reduced the clonogenicity of CHLA-90 cells.  The combination of HDAC inhibitor and flavopiridol may be a unique approach to treating neuroblastomas with p53 LOF, one that evokes induction of mitotic failure.  Mol Cancer Ther; 9(12); 3289-301.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq71Jeo3uw5mLVg90H21EOLACvtfcHk0lhEVTB9HXbP7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrsL3K&md5=9b36e48fc11d0e9e836559fd3f7336db</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0562%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%2BM.%26aulast%3DSheard%26aufirst%3DM.%2BA.%26aulast%3DJi%26aufirst%3DL.%2BY.%26aulast%3DSposto%26aufirst%3DR.%26aulast%3DKeshelava%26aufirst%3DN.%26atitle%3DCombination%2520of%2520vorinostat%2520and%2520flavopiridol%2520is%2520selectively%2520cytotoxic%2520to%2520multidrug-resistant%2520neuroblastoma%2520cell%2520lines%2520with%2520mutant%2520tp53%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D3289%26epage%3D3301%26doi%3D10.1158%2F1535-7163.MCT-10-0562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagostin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraldes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiscock, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniara, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortenson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benning, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrona, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S.</span></span> <span> </span><span class="NLM_article-title">Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active cdk4/6 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">445</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/ml200241a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200241a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=445-449&author=Y.+S.+Choauthor=H.+Angoveauthor=C.+Brainauthor=C.+H.+T.+Chenauthor=H.+Chengauthor=R.+Chengauthor=R.+Chopraauthor=K.+Chungauthor=M.+Congreveauthor=C.+Dagostinauthor=D.+J.+Davisauthor=R.+Feltenauthor=J.+Giraldesauthor=S.+D.+Hiscockauthor=S.+Kimauthor=S.+Kovatsauthor=B.+Laguauthor=K.+Lewryauthor=A.+Looauthor=Y.+P.+Luauthor=M.+Luzzioauthor=W.+Maniaraauthor=R.+McMenaminauthor=P.+N.+Mortensonauthor=R.+Benningauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=J.+Q.+Shenauthor=T.+Smithauthor=Y.+P.+Wangauthor=G.+Williamsauthor=A.+J.+A.+Woolfordauthor=W.+Wronaauthor=M.+Xuauthor=F.+Yangauthor=S.+Howard&title=Fragment-based+discovery+of+7-azabenzimidazoles+as+potent%2C+highly+selective%2C+and+orally+active+cdk4%2F6+inhibitors&doi=10.1021%2Fml200241a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml200241a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200241a%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DDagostin%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DFelten%26aufirst%3DR.%26aulast%3DGiraldes%26aufirst%3DJ.%26aulast%3DHiscock%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKovats%26aufirst%3DS.%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DLewry%26aufirst%3DK.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DY.%2BP.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DManiara%26aufirst%3DW.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMortenson%26aufirst%3DP.%2BN.%26aulast%3DBenning%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DShen%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%2BP.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26aulast%3DWrona%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHoward%26aufirst%3DS.%26atitle%3DFragment-based%2520discovery%2520of%25207-azabenzimidazoles%2520as%2520potent%252C%2520highly%2520selective%252C%2520and%2520orally%2520active%2520cdk4%252F6%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D445%26epage%3D449%26doi%3D10.1021%2Fml200241a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Contributions of molecular properties to drug promiscuity miniperspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/jm301514n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&author=A.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+molecular+properties+to+drug+promiscuity+miniperspective&doi=10.1021%2Fjm301514n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520molecular%2520properties%2520to%2520drug%2520promiscuity%2520miniperspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1789%26epage%3D1795%26doi%3D10.1021%2Fjm301514n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salmi-Smail, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dequiedt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restouin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collette, Y.</span></span> <span> </span><span class="NLM_article-title">Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3038</span>– <span class="NLM_lpage">3047</span>, <span class="refDoi"> DOI: 10.1021/jm901358y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901358y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3038-3047&author=C.+Salmi-Smailauthor=A.+Fabreauthor=F.+Dequiedtauthor=A.+Restouinauthor=R.+Castellanoauthor=S.+Garbitauthor=P.+Rocheauthor=X.+Morelliauthor=J.+M.+Brunelauthor=Y.+Collette&title=Modified+cap+group+suberoylanilide+hydroxamic+acid+histone+deacetylase+inhibitor+derivatives+reveal+improved+selective+antileukemic+activity&doi=10.1021%2Fjm901358y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity</span></div><div class="casAuthors">Salmi-Smail, Chanaz; Fabre, Aurelie; Dequiedt, Franck; Restouin, Audrey; Castellano, Remy; Garbit, Slaveia; Roche, Philippe; Morelli, Xavier; Brunel, Jean Michel; Collette, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3038-3047</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of SAHA cap derivs. RNHCO(CH2)6CONHOH (R = Ph, 4-H2NC6H4, 2-BrC6H4, 2-naphthyl, 8-quinolinyl, etc.) was designed and prepd. in good-to-excellent yields that varied from 49% to 95%.  These derivs. were evaluated for their antiproliferative activity in several human cancer cell lines.  Antiproliferative activity was obsd. for concns. varying from 0.12 to >100 μM, and a mol. modeling approach of selected SAHA derivs., based on available structural information of human HDAC8 in complex with SAHA, was performed.  Strikingly, two compds. displayed up to 10-fold improved antileukemic activity with respect to SAHA; however, these compds. displayed antiproliferative activity similar to SAHA when assayed against solid tumor-derived cell lines.  A 10-fold improvement in the leukemic vs peripheral blood mononuclear cell therapeutic ratio, with no evident in vivo toxicity toward blood cells, was also obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjnbACulcCkrVg90H21EOLACvtfcHk0lhyfDXLh2GdFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVOqtrY%253D&md5=70cf706e641add7d1ee6d410b501e075</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm901358y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901358y%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi-Smail%26aufirst%3DC.%26aulast%3DFabre%26aufirst%3DA.%26aulast%3DDequiedt%26aufirst%3DF.%26aulast%3DRestouin%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DR.%26aulast%3DGarbit%26aufirst%3DS.%26aulast%3DRoche%26aufirst%3DP.%26aulast%3DMorelli%26aufirst%3DX.%26aulast%3DBrunel%26aufirst%3DJ.%2BM.%26aulast%3DCollette%26aufirst%3DY.%26atitle%3DModified%2520cap%2520group%2520suberoylanilide%2520hydroxamic%2520acid%2520histone%2520deacetylase%2520inhibitor%2520derivatives%2520reveal%2520improved%2520selective%2520antileukemic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3038%26epage%3D3047%26doi%3D10.1021%2Fjm901358y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepulveda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gately, S.</span></span> <span> </span><span class="NLM_article-title">Identification of novel hdac inhibitors through cell based screening and their evaluation as potential anticancer agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4793</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2013.07.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4790-4793&author=T.+Wangauthor=M.+Sepulvedaauthor=P.+Gonzalesauthor=S.+Gately&title=Identification+of+novel+hdac+inhibitors+through+cell+based+screening+and+their+evaluation+as+potential+anticancer+agents&doi=10.1016%2Fj.bmcl.2013.07.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSepulveda%26aufirst%3DM.%26aulast%3DGonzales%26aufirst%3DP.%26aulast%3DGately%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520novel%2520hdac%2520inhibitors%2520through%2520cell%2520based%2520screening%2520and%2520their%2520evaluation%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4790%26epage%3D4793%26doi%3D10.1016%2Fj.bmcl.2013.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ougolkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoy, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1021/jm901667k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901667k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1347-1356&author=R.+Heauthor=Y.+F.+Chenauthor=Y.+H.+Chenauthor=A.+V.+Ougolkovauthor=J.+S.+Zhangauthor=D.+N.+Savoyauthor=D.+D.+Billadeauauthor=A.+P.+Kozikowski&title=Synthesis+and+biological+evaluation+of+triazol-4-ylphenyl-bearing+histone+deacetylase+inhibitors+as+anticancer+agents&doi=10.1021%2Fjm901667k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of Triazol-4-ylphenyl-Bearing Histone Deacetylase Inhibitors as Anticancer Agents</span></div><div class="casAuthors">He, Rong; Chen, Yufeng; Chen, Yihua; Ougolkov, Andrei V.; Zhang, Jin-San; Savoy, Doris N.; Billadeau, Daniel D.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1347-1356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our triazole-based histone deacetylase inhibitor (HDACI), octanedioic acid hydroxyamide[3-(1-phenyl-1H-[1,2,3]triazol-4-yl)phenyl]amide (4a), suppresses pancreatic cancer cell growth in vitro with the lowest IC50 value of 20 nM against MiaPaca-2 cell.  In this study, we continued our efforts to develop triazol-4-ylphenyl bearing hydroxamate analogs by embellishing the terminal Ph ring of 4a with different substituents.  The isoform inhibitory profile of these hydroxamate analogs was similar to those of 4a.  All of these triazol-4-ylphenyl bearing hydroxamates are pan-HDACIs like SAHA.  Moreover, compds. 4h (I) and 11a were found to be very effective inhibitors of cancer cell growth in the HupT3 (IC50 = 50 nM) and MiaPaca-2 (IC50 = 40 nM) cancer cell lines, resp.  Compd. 4a was found to reactivate the expression of CDK inhibitor proteins and to suppress pancreatic cancer cell growth in vivo.  Taken together, these data further support the value of the triazol-4-ylphenyl bearing hydroxamates in identifying potential pancreatic cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_PmkiG6vTw7Vg90H21EOLACvtfcHk0lhyfDXLh2GdFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVGqug%253D%253D&md5=80c55a4aa2fd3cb5b440ff34aec02b7c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm901667k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901667k%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DOugolkov%26aufirst%3DA.%2BV.%26aulast%3DZhang%26aufirst%3DJ.%2BS.%26aulast%3DSavoy%26aufirst%3DD.%2BN.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520triazol-4-ylphenyl-bearing%2520histone%2520deacetylase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1347%26epage%3D1356%26doi%3D10.1021%2Fjm901667k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span> <span> </span><span class="NLM_article-title">Preparation and characterization of vorinostat-coated beads for profiling of novel target proteins</span>. <i>J. Chromatogr. A</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>1372</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/j.chroma.2014.10.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.chroma.2014.10.098" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1372&publication_year=2014&pages=34-41&author=C.+C.+Luauthor=K.+Zhangauthor=Y.+Zhangauthor=M.+J.+Tanauthor=Y.+J.+Liauthor=X.+W.+Heauthor=Y.+K.+Zhang&title=Preparation+and+characterization+of+vorinostat-coated+beads+for+profiling+of+novel+target+proteins&doi=10.1016%2Fj.chroma.2014.10.098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.chroma.2014.10.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chroma.2014.10.098%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BJ.%26aulast%3DHe%26aufirst%3DX.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26atitle%3DPreparation%2520and%2520characterization%2520of%2520vorinostat-coated%2520beads%2520for%2520profiling%2520of%2520novel%2520target%2520proteins%26jtitle%3DJ.%2520Chromatogr.%2520A%26date%3D2014%26volume%3D1372%26spage%3D34%26epage%3D41%26doi%3D10.1016%2Fj.chroma.2014.10.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Brazidec, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claassen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taveras, A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of 2,6,7-trisubstituted-7h-pyrrolo[2,3-d]pyrimidines as aurora kinases inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4033</span>– <span class="NLM_lpage">4037</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2012.04.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=22607669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC38XntlWjtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4033-4037&author=J.+Y.+Le+Brazidecauthor=A.+Pasisauthor=B.+Tamauthor=C.+Boykinauthor=D.+P.+Wangauthor=D.+J.+Marcotteauthor=G.+Claassenauthor=J.+H.+Chongauthor=J.+H.+Chaoauthor=J.+H.+Fanauthor=K.+Nguyenauthor=L.+Silvianauthor=L.+Lingauthor=L.+Zhangauthor=M.+Choiauthor=M.+Tengauthor=N.+Pathanauthor=S.+Zhaoauthor=T.+Liauthor=A.+Taveras&title=Structure-based+design+of+2%2C6%2C7-trisubstituted-7h-pyrrolo%5B2%2C3-d%5Dpyrimidines+as+aurora+kinases+inhibitors&doi=10.1016%2Fj.bmcl.2012.04.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors</span></div><div class="casAuthors">Le Brazidec, Jean-Yves; Pasis, Angela; Tam, Betty; Boykin, Christina; Wang, Deping; Marcotte, Douglas J.; Claassen, Gisela; Chong, Jer-Hong; Chao, Jianhua; Fan, Junhua; Nguyen, Khanh; Silvian, Laura; Ling, Leona; Zhang, Lin; Choi, Michael; Teng, Min; Pathan, Nuzhat; Zhao, Shuo; Li, Tony; Taveras, Art</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4033-4037</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This Letter reports the optimization of a pyrrolopyrimidine series as dual inhibitors of Aurora A/B kinases.  This series is derived from a pyrazolopyrimidine series previously reported as inhibitors of aurora kinases and CDKs.  In an effort to improve the selectivity of this chemotype, we switched to the pyrrolopyrimidine core which allowed functionalization on C-2.  In addn., the modeling rationale was based on superimposing the structures of Aurora-A kinase and CDK2 which revealed enough differences leading to a path for selectivity improvement.  The synthesis of the new series of pyrrolopyrimidine analogs relied on the development of a different route for the two key intermediates, which led to analogs with both tunable activity against CDK1 and maintained cell potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogQtFgpCCHObVg90H21EOLACvtfcHk0lgipErbyP8vNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntlWjtrg%253D&md5=969903ef4b627f4d6f6306447c08758c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.085%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBrazidec%26aufirst%3DJ.%2BY.%26aulast%3DPasis%26aufirst%3DA.%26aulast%3DTam%26aufirst%3DB.%26aulast%3DBoykin%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%2BP.%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DClaassen%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DJ.%2BH.%26aulast%3DChao%26aufirst%3DJ.%2BH.%26aulast%3DFan%26aufirst%3DJ.%2BH.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DSilvian%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChoi%26aufirst%3DM.%26aulast%3DTeng%26aufirst%3DM.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DTaveras%26aufirst%3DA.%26atitle%3DStructure-based%2520design%2520of%25202%252C6%252C7-trisubstituted-7h-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520aurora%2520kinases%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4033%26epage%3D4037%26doi%3D10.1016%2Fj.bmcl.2012.04.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Development of a fluorescence polarization based assay for histone deacetylase ligand discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2809</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.bmcl.2008.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=18430569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=2809-2812&author=R.+Mazitschekauthor=V.+Patelauthor=D.+F.+Wirthauthor=J.+Clardy&title=Development+of+a+fluorescence+polarization+based+assay+for+histone+deacetylase+ligand+discovery&doi=10.1016%2Fj.bmcl.2008.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a fluorescence polarization based assay for histone deacetylase ligand discovery</span></div><div class="casAuthors">Mazitschek, Ralph; Patel, Vishal; Wirth, Dyann F.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2809-2812</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate many important physiol. processes and the discovery of small mols. that modulate HDAC activity has both academic and clin. relevance.  HDAC inhibitors, most notably SAHA, have been pursued as cancer chemotherapeutics but may be useful in treating psychiatric disorders, malaria, and other diseases.  Herein, the authors describe an inexpensive and robust assay, based on fluorescence polarization, for HDAC ligand discovery.  The assay is well suited for high-throughput screening and enzyme kinetic studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDg1gFU5ShKbVg90H21EOLACvtfcHk0lgipErbyP8vNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWjsrg%253D&md5=662ab74f9839dedd37bbb87f3ea950be</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DWirth%26aufirst%3DD.%2BF.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520fluorescence%2520polarization%2520based%2520assay%2520for%2520histone%2520deacetylase%2520ligand%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D2809%26epage%3D2812%26doi%3D10.1016%2Fj.bmcl.2008.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiriy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocharova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiriy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adler, H. J.</span></span> <span> </span><span class="NLM_article-title">Designing thiophene-based azomethine ligomers with tailored properties: Self-assembly and charge carrier mobility</span>. <i>Chem. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4765</span>– <span class="NLM_lpage">4771</span>, <span class="refDoi"> DOI: 10.1021/cm049688v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cm049688v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=4765-4771&author=N.+Kiriyauthor=V.+Bocharovaauthor=A.+Kiriyauthor=M.+Stammauthor=F.+C.+Krebsauthor=H.+J.+Adler&title=Designing+thiophene-based+azomethine+ligomers+with+tailored+properties%3A+Self-assembly+and+charge+carrier+mobility&doi=10.1021%2Fcm049688v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fcm049688v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcm049688v%26sid%3Dliteratum%253Aachs%26aulast%3DKiriy%26aufirst%3DN.%26aulast%3DBocharova%26aufirst%3DV.%26aulast%3DKiriy%26aufirst%3DA.%26aulast%3DStamm%26aufirst%3DM.%26aulast%3DKrebs%26aufirst%3DF.%2BC.%26aulast%3DAdler%26aufirst%3DH.%2BJ.%26atitle%3DDesigning%2520thiophene-based%2520azomethine%2520ligomers%2520with%2520tailored%2520properties%253A%2520Self-assembly%2520and%2520charge%2520carrier%2520mobility%26jtitle%3DChem.%2520Mater.%26date%3D2004%26volume%3D16%26spage%3D4765%26epage%3D4771%26doi%3D10.1021%2Fcm049688v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemoine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Six, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depreux, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1021/jm2013453</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1189-1204&author=A.+Garofaloauthor=A.+Farceauthor=S.+Ravezauthor=A.+Lemoineauthor=P.+Sixauthor=P.+Chavatteauthor=L.+Goossensauthor=P.+Depreux&title=Synthesis+and+structure-activity+relationships+of+%28aryloxy%29quinazoline+ureas+as+novel%2C+potent%2C+and+selective+vascular+endothelial+growth+factor+receptor-2+inhibitors&doi=10.1021%2Fjm2013453"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm2013453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013453%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DSix%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DDepreux%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520%2528aryloxy%2529quinazoline%2520ureas%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1189%26epage%3D1204%26doi%3D10.1021%2Fjm2013453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brain, C. T.</span>; <span class="NLM_string-name">Cho, Y. S.</span>; <span class="NLM_string-name">Giraldes, J. W.</span>; <span class="NLM_string-name">Lagu, B.</span>; <span class="NLM_string-name">Levell, J.</span>; <span class="NLM_string-name">Luzzio, M.</span>; <span class="NLM_string-name">Perez, L. B.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Yang, F.</span></span> <span> </span><span class="NLM_article-title">Pyrrolopyrimidine compounds as inhibitors of cdk4/6</span>. <span class="NLM_patent">WO 2011101409 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=C.+T.+Brain&author=Y.+S.+Cho&author=J.+W.+Giraldes&author=B.+Lagu&author=J.+Levell&author=M.+Luzzio&author=L.+B.+Perez&author=Y.+Wang&author=F.+Yang&title=Pyrrolopyrimidine+compounds+as+inhibitors+of+cdk4%2F6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrain%26aufirst%3DC.%2BT.%26atitle%3DPyrrolopyrimidine%2520compounds%2520as%2520inhibitors%2520of%2520cdk4%252F6%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. F.</span></span> <span> </span><span class="NLM_article-title">Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor t790m mutant</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.09.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1016%2Fj.ejmech.2015.09.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2015&pages=115-126&author=M.+Z.+Qinauthor=T.+T.+Wangauthor=B.+X.+Xuauthor=Z.+H.+Maauthor=N.+Jiangauthor=H.+B.+Xieauthor=P.+Gongauthor=Y.+F.+Zhao&title=Novel+hydrazone+moiety-bearing+aminopyrimidines+as+selective+inhibitors+of+epidermal+growth+factor+receptor+t790m+mutant&doi=10.1016%2Fj.ejmech.2015.09.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.09.031%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%2BZ.%26aulast%3DWang%26aufirst%3DT.%2BT.%26aulast%3DXu%26aufirst%3DB.%2BX.%26aulast%3DMa%26aufirst%3DZ.%2BH.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DH.%2BB.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DZhao%26aufirst%3DY.%2BF.%26atitle%3DNovel%2520hydrazone%2520moiety-bearing%2520aminopyrimidines%2520as%2520selective%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520t790m%2520mutant%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D104%26spage%3D115%26epage%3D126%26doi%3D10.1016%2Fj.ejmech.2015.09.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span>; <span class="NLM_string-name">Dobrusin, E. M.</span>; <span class="NLM_string-name">Kramer, J. B.</span>; <span class="NLM_string-name">McNamara, D. J.</span>; <span class="NLM_string-name">Rewcastle, G. W.</span>; <span class="NLM_string-name">Showalter, H. D. H.</span>; <span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of pteridinones as kinase inhibitors</span>. <span class="NLM_patent">WO 2001019825 A1</span>, <span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=W.+A.+Denny&author=E.+M.+Dobrusin&author=J.+B.+Kramer&author=D.+J.+McNamara&author=G.+W.+Rewcastle&author=H.+D.+H.+Showalter&author=P.+L.+Toogood&title=Preparation+of+pteridinones+as+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DPreparation%2520of%2520pteridinones%2520as%2520kinase%2520inhibitors%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span>; <span class="NLM_string-name">Jones, C. D.</span>; <span class="NLM_string-name">Simpson, I.</span>; <span class="NLM_string-name">Ward, R.
A.</span></span> <span> </span><span class="NLM_article-title">2-Anilnopurin-8-ones as inhibitors of tk/mps1 for the treatment of proliferative disorders</span>. <span class="NLM_patent">WO 2009024824 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=D.+M.+Andrews&author=C.+D.+Jones&author=I.+Simpson&author=R.%0AA.+Ward&title=2-Anilnopurin-8-ones+as+inhibitors+of+tk%2Fmps1+for+the+treatment+of+proliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26atitle%3D2-Anilnopurin-8-ones%2520as%2520inhibitors%2520of%2520tk%252Fmps1%2520for%2520the%2520treatment%2520of%2520proliferative%2520disorders%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamasaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis of [3]rotaxanes that utilize the catalytic activity of a macrocyclic phenanthroline-Cu complex: remarkable effect of the length of the axle precursor</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1002/chem.201405090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1002%2Fchem.201405090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=25470127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWgsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2139-2145&author=Y.+Yamashitaauthor=Y.+Mutohauthor=R.+Yamasakiauthor=T.+Kasamaauthor=S.+Saito&title=Synthesis+of+%5B3%5Drotaxanes+that+utilize+the+catalytic+activity+of+a+macrocyclic+phenanthroline-Cu+complex%3A+remarkable+effect+of+the+length+of+the+axle+precursor&doi=10.1002%2Fchem.201405090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of [3]Rotaxanes that Utilize the Catalytic Activity of a Macrocyclic Phenanthroline-Cu Complex: Remarkable Effect of the Length of the Axle Precursor</span></div><div class="casAuthors">Yamashita, Yoshiaki; Mutoh, Yuichiro; Yamasaki, Ryu; Kasama, Takeshi; Saito, Shinichi</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2139-2145</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of [3]rotaxanes with a benzenediylbis(oxyoctyl)phenanthridine wheel and bis(triarylalkoxyphenyl)butadiyne axles [4-(R3C(CH2)nO)C6H4C≡C]2 (R = 4'-cyclohexyl-1,1'-biphenyl-4-yl; n = 6, 15, 20) were prepd. by oxidative dimerization of alkynes 4-(R3C(CH2)nO)C6H4C≡CH (R = 4'-cyclohexyl-1,1'-biphenyl-4-yl; n = 6, 15, 20) posessing the bulky tris[4'-cyclohexyl-(1,1'-biphenyl)-4-yl]methyl blocking group.  The catalytic activity of macrocyclic phenanthroline-Cu complex was utilized to thread the two axle components inside the ring.  The alkyne compd. with chain of 15 or 20 methylene groups gave [3]rotaxanes in high yields, whereas the axle with a chain of six methylene groups afforded a [3]rotaxane in very poor yield.  The effect of ring size in the synthesis of [3]rotaxanes was also examd.  The [3]rotaxanes were not isolated when a macrocyclic phenanthroline compd. with a smaller ring size was used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolmJ_ztMzNjLVg90H21EOLACvtfcHk0lgUS41yd5o9dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWgsr7I&md5=0e3d4ff257d4ffdfc22a8d90a1dbee62</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fchem.201405090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201405090%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DMutoh%26aufirst%3DY.%26aulast%3DYamasaki%26aufirst%3DR.%26aulast%3DKasama%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DS.%26atitle%3DSynthesis%2520of%2520%255B3%255Drotaxanes%2520that%2520utilize%2520the%2520catalytic%2520activity%2520of%2520a%2520macrocyclic%2520phenanthroline-Cu%2520complex%253A%2520remarkable%2520effect%2520of%2520the%2520length%2520of%2520the%2520axle%2520precursor%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D2139%26epage%3D2145%26doi%3D10.1002%2Fchem.201405090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaus, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. W.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of trk kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4672</span>– <span class="NLM_lpage">4684</span>, <span class="refDoi"> DOI: 10.1021/jm800343j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800343j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4672-4684&author=T.+Wangauthor=M.+L.+Lambauthor=D.+A.+Scottauthor=H.+Wangauthor=M.+H.+Blockauthor=P.+D.+Lyneauthor=J.+W.+Leeauthor=A.+M.+Daviesauthor=H.+J.+Zhangauthor=Y.+Y.+Zhuauthor=F.+Guauthor=Y.+X.+Hanauthor=B.+Wangauthor=P.+J.+Mohrauthor=R.+J.+Kausauthor=J.+A.+Joseyauthor=E.+Hoffmannauthor=K.+Thressauthor=T.+MacIntyreauthor=H.+Y.+Wangauthor=C.+A.+Omerauthor=D.+W.+Yu&title=Identification+of+4-aminopyrazolylpyrimidines+as+potent+inhibitors+of+trk+kinases&doi=10.1021%2Fjm800343j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases</span></div><div class="casAuthors">Wang, Tao; Lamb, Michelle L.; Scott, David A.; Wang, Haixia; Block, Michael H.; Lyne, Paul D.; Lee, John W.; Davies, Audrey M.; Zhang, Hai-Jun; Zhu, Yanyi; Gu, Fei; Han, Yongxin; Wang, Bin; Mohr, Peter J.; Kaus, Robert J.; Josey, John A.; Hoffmann, Ethan; Thress, Ken; MacIntyre, Terry; Wang, Haiyun; Omer, Charles A.; Yu, Dingwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4672-4684</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis and biol. evaluation of a series of 4-(pyrazolylamino)pyrimidines I (R1 = H, Me, SMe, cyclopropyl, Me2CHO, n-PrO, Me3C; R2 = H, Br, Cl, F, Me; R3 = H, HOCH2CH2NH, (S)-HOCH2CH(OH)CH2NH, etc.; R4 = Me, CH2OH, CH2CONMe2, CH2CONHMe; R5 = Ph, 2-ClC6H4, 4-FC6H4, 5-fluoro-2-pyridyl, 5-fluoro-2-pyrimidyl) as potent Trk kinase inhibitors is reported.  High-throughput screening identified a promising hit in the 4-(pyrazolylamino)pyrimidine chemotype.  Initial optimization of the series led to more potent Trk inhibitors.  Further optimization using two strategies resulted in significant improvement of phys. properties and led to the discovery of I (R1 = Me2CHO; R2 = Cl; R3 = H; R4 = (S)-Me; R5 = 5-fluoro-2-pyridyl) (AZ-23), a potent, orally bioavailable Trk A/B inhibitor.  The compd. offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ60edpRrhTrVg90H21EOLACvtfcHk0lgUS41yd5o9dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVWju7s%253D&md5=16401146aa3860d13a4bc35bc04d5f83</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm800343j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800343j%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BW.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%2BY.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DY.%2BX.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DP.%2BJ.%26aulast%3DKaus%26aufirst%3DR.%2BJ.%26aulast%3DJosey%26aufirst%3DJ.%2BA.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DYu%26aufirst%3DD.%2BW.%26atitle%3DIdentification%2520of%25204-aminopyrazolylpyrimidines%2520as%2520potent%2520inhibitors%2520of%2520trk%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4672%26epage%3D4684%26doi%3D10.1021%2Fjm800343j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">VanderWel, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repine, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2387</span>, <span class="refDoi"> DOI: 10.1021/jm049355+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2371-2387&author=S.+N.+VanderWelauthor=P.+J.+Harveyauthor=D.+J.+McNamaraauthor=J.+T.+Repineauthor=P.+R.+Kellerauthor=J.+Quinauthor=R.+J.+Boothauthor=W.+L.+Elliottauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=P.+L.+Toogood&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+specific+inhibitors+of+cyclin-dependent+kinase+4&doi=10.1021%2Fjm049355%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4</span></div><div class="casAuthors">VanderWel, Scott N.; Harvey, Patricia J.; McNamara, Dennis J.; Repine, Joseph T.; Keller, Paul R.; Quin, John, III; Booth, R. John; Elliott, William L.; Dobrusin, Ellen M.; Fry, David W.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2371-2387</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide an effective method for the treatment of proliferative diseases such as cancer.  The pyrido[2,3-d]pyrimidin-7-one template has been identified previously as a privileged structure for the inhibition of ATP-dependent kinases, and good potency against Cdks has been reported for representative examples.  Obtaining selectivity for individual Cdk enzymes, particularly Cdk4, has been challenging.  A series of pyrido[2,3-d]pyrimidin-7-ones I (R1 = Me2CH, Et2CH, cyclopentyl; R2 = H, Me, Et, F3C; R3 = H, Me, F, Cl, COMe, MeO2C, etc.; X = HOCH, H2NCH, CH2N, CH2CH2, etc.) was synthesized and investigated as selective inhibitors of Cdk4.  The introduction of a Me substituent at the C-5 position of the pyrido[2,3-d]pyrimidin-7-one template is sufficient to confer excellent selectivity for Cdk4 vs other Cdks and representative tyrosine kinases.  Further optimization led to the identification of highly potent and selective inhibitors of Cdk4 that exhibit potent antiproliferative activity against human tumor cells in vitro.  The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKNHZHOwd7c7Vg90H21EOLACvtfcHk0lhMn-sVQqQ8cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisLo%253D&md5=ef3c86bbdfaea0080d1103313d094ccd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm049355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DQuin%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520specific%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2371%26epage%3D2387%26doi%3D10.1021%2Fjm049355%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Sanchez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoy, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dow, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and plasmodium falciparum</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3437</span>– <span class="NLM_lpage">3448</span>, <span class="refDoi"> DOI: 10.1021/jm701606b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701606b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2rs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3437-3448&author=Y.+Chenauthor=M.+Lopez-Sanchezauthor=D.+N.+Savoyauthor=D.+D.+Billadeauauthor=G.+S.+Dowauthor=A.+P.+Kozikowski&title=A+series+of+potent+and+selective%2C+triazolylphenyl-based+histone+deacetylases+inhibitors+with+activity+against+pancreatic+cancer+cells+and+plasmodium+falciparum&doi=10.1021%2Fjm701606b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Series of Potent and Selective, Triazolylphenyl-Based Histone Deacetylases Inhibitors with Activity against Pancreatic Cancer Cells and Plasmodium falciparum</span></div><div class="casAuthors">Chen, Yufeng; Lopez-Sanchez, Miriam; Savoy, Doris N.; Billadeau, Daniel D.; Dow, Geoffrey S.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3437-3448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of the rules governing the inhibition of the various HDAC isoforms is likely to be key to identifying improved therapeutics that act as epigenetic modulators of gene transcription.  Herein we present results on the modification of the CAP region of a set of triazolylphenyl-based HDACIs, and show that the nature of substitution on the Ph ring plays a role in their selectivity for HDAC1 vs. HDAC6, with low to moderate selectivity (2-51-fold) being achieved.  In light of the valuable selectivity and potency that were identified for the triazolylphenyl ligand 6b in the inhibition of HDAC6 (IC50 = 1.9 nM), this compd. represents a valuable research tool and a candidate for further chem. modifications.  Lastly, these new HDACIs were studied for both their anticancer and antimalarial activity, which serve to validate the superior activity of the HDACI 10c.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtC-MXCaqyVLVg90H21EOLACvtfcHk0lhMn-sVQqQ8cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2rs7c%253D&md5=5a9e96ed8e268a04d387ca1f60b57837</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm701606b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701606b%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLopez-Sanchez%26aufirst%3DM.%26aulast%3DSavoy%26aufirst%3DD.%2BN.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26aulast%3DDow%26aufirst%3DG.%2BS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520series%2520of%2520potent%2520and%2520selective%252C%2520triazolylphenyl-based%2520histone%2520deacetylases%2520inhibitors%2520with%2520activity%2520against%2520pancreatic%2520cancer%2520cells%2520and%2520plasmodium%2520falciparum%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3437%26epage%3D3448%26doi%3D10.1021%2Fjm701606b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cholody, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosakowska-Cholody, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hariprakasha, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michejda, C. J.</span></span> <span> </span><span class="NLM_article-title">A new synthetic agent with potent but selective cytotoxic activity against cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4481</span>, <span class="refDoi"> DOI: 10.1021/jm048946x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm048946x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4474-4481&author=W.+M.+Cholodyauthor=T.+Kosakowska-Cholodyauthor=M.+G.+Hollingsheadauthor=H.+K.+Hariprakashaauthor=C.+J.+Michejda&title=A+new+synthetic+agent+with+potent+but+selective+cytotoxic+activity+against+cancer&doi=10.1021%2Fjm048946x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm048946x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm048946x%26sid%3Dliteratum%253Aachs%26aulast%3DCholody%26aufirst%3DW.%2BM.%26aulast%3DKosakowska-Cholody%26aufirst%3DT.%26aulast%3DHollingshead%26aufirst%3DM.%2BG.%26aulast%3DHariprakasha%26aufirst%3DH.%2BK.%26aulast%3DMichejda%26aufirst%3DC.%2BJ.%26atitle%3DA%2520new%2520synthetic%2520agent%2520with%2520potent%2520but%2520selective%2520cytotoxic%2520activity%2520against%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4474%26epage%3D4481%26doi%3D10.1021%2Fjm048946x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanArsdale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Spectrum and degree of cdk drug interactions predicts clinical performance</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2273</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1158%2F1535-7163.MCT-16-0300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=27496135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2273-2281&author=P.+Chenauthor=N.+V.+Leeauthor=W.+Y.+Huauthor=M.+R.+Xuauthor=R.+A.+Ferreauthor=H.+Lamauthor=S.+Bergqvistauthor=J.+Solowiejauthor=W.+Diehlauthor=Y.+A.+Heauthor=X.+Yuauthor=A.+Nagataauthor=T.+VanArsdaleauthor=B.+W.+Murray&title=Spectrum+and+degree+of+cdk+drug+interactions+predicts+clinical+performance&doi=10.1158%2F1535-7163.MCT-16-0300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance</span></div><div class="casAuthors">Chen, Ping; Lee, Nathan V.; Hu, Wenyue; Xu, Meirong; Ferre, Rose Ann; Lam, Hieu; Bergqvist, Simon; Solowiej, James; Diehl, Wade; He, You-Ai; Yu, Xiu; Nagata, Asako; Van Arsdale, Todd; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2273-2281</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biol. perspective but drug development is often hindered by toxicities and inadequate efficacy.  Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.  Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clin. activities.  Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacol. while analyses in untransformed cells illuminates significant differences.  To resolve this apparent disconnect, drug behaviors are described at the mol. level.  Nonkinase binding studies and kinome interaction anal. (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacol., may contribute for abemaciclib, and confounds AG-024322 anal.  CDK2 and CDK6 cocrystal structures with the drugs identify the mol. interactions responsible for potency and kinase selectivity.  Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome.  Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket.  Integrating clin. drug exposures into the anal. predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9).  Understanding the mol. components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs.  Mol Cancer Ther; 15(10); 2273-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TbbI98T8v7Vg90H21EOLACvtfcHk0lhMn-sVQqQ8cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK&md5=112e9e46bb33393516fa94620e6383c6</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0300%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DN.%2BV.%26aulast%3DHu%26aufirst%3DW.%2BY.%26aulast%3DXu%26aufirst%3DM.%2BR.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DSpectrum%2520and%2520degree%2520of%2520cdk%2520drug%2520interactions%2520predicts%2520clinical%2520performance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2273%26epage%3D2281%26doi%3D10.1158%2F1535-7163.MCT-16-0300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eswar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eramian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span> <span> </span><span class="NLM_article-title">Protein structure modeling with modeller</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1007/978-1-60327-058-8_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1007%2F978-1-60327-058-8_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=18542861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlKqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2008&pages=145-159&author=N.+Eswarauthor=D.+Eramianauthor=B.+Webbauthor=M.+Y.+Shenauthor=A.+Sali&title=Protein+structure+modeling+with+modeller&doi=10.1007%2F978-1-60327-058-8_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Protein structure modeling with MODELER</span></div><div class="casAuthors">Eswar, Narayanan; Eramian, David; Webb, Ben; Shen, Min-Yi; Sali, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (Totowa, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">Structural Proteomics</span>),
    <span class="NLM_cas:pages">145-159</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">Genome sequencing projects have resulted in a rapid increase in the no. of known protein sequences.  In contrast, only about one-hundredth of these sequences have been characterized using exptl. structure detn. methods.  Computational protein structure modeling techniques have the potential to bridge this sequence-structure gap.  This chapter presents an example that illustrates the use of MODELLER to construct a comparative model for a protein with unknown structure.  Automation of similar protocols has resulted in models of useful accuracy for domains in more than half of all known protein sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHl3qSEO3oiLVg90H21EOLACvtfcHk0lgH2gy7KUcVYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlKqsrg%253D&md5=dfdc94abf280f9f4b316ab9c369c2466</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-058-8_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-60327-058-8_8%26sid%3Dliteratum%253Aachs%26aulast%3DEswar%26aufirst%3DN.%26aulast%3DEramian%26aufirst%3DD.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DM.%2BY.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DProtein%2520structure%2520modeling%2520with%2520modeller%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2008%26volume%3D426%26spage%3D145%26epage%3D159%26doi%3D10.1007%2F978-1-60327-058-8_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delano, W. L.</span></span> <i>The Pymol Molecular Graphics System</i>, version 1.7; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+L.+Delano&title=The+Pymol+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDelano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520Pymol%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troso-Sandoval, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span> <span> </span><span class="NLM_article-title">The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8492</span>– <span class="NLM_lpage">8497</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=8492-8497&author=P.+N.+Munsterauthor=T.+Troso-Sandovalauthor=N.+Rosenauthor=R.+Rifkindauthor=P.+A.+Marksauthor=V.+M.+Richon&title=The+histone+deacetylase+inhibitor+suberoylanilide+hydroxamic+acid+induces+differentiation+of+human+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DTroso-Sandoval%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DRifkind%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520suberoylanilide%2520hydroxamic%2520acid%2520induces%2520differentiation%2520of%2520human%2520breast%2520cancer%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D8492%26epage%3D8497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolay, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keibler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerdemann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicinski, P.</span></span> <span> </span><span class="NLM_article-title">The metabolic function of cyclin d3-cdk6 kinase in cancer cell survival</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature22797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1038%2Fnature22797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=28607489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=426-430&author=H.+Wangauthor=B.+N.+Nicolayauthor=J.+M.+Chickauthor=X.+Gaoauthor=Y.+Gengauthor=H.+Renauthor=H.+Gaoauthor=G.+Yangauthor=J.+A.+Williamsauthor=J.+M.+Suskiauthor=M.+A.+Keiblerauthor=E.+Sicinskaauthor=U.+Gerdemannauthor=W.+N.+Hainingauthor=T.+M.+Robertsauthor=K.+Polyakauthor=S.+P.+Gygiauthor=N.+J.+Dysonauthor=P.+Sicinski&title=The+metabolic+function+of+cyclin+d3-cdk6+kinase+in+cancer+cell+survival&doi=10.1038%2Fnature22797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival</span></div><div class="casAuthors">Wang, Haizhen; Nicolay, Brandon N.; Chick, Joel M.; Gao, Xueliang; Geng, Yan; Ren, Hong; Gao, Hui; Yang, Guizhi; Williams, Juliet A.; Suski, Jan M.; Keibler, Mark A.; Sicinska, Ewa; Gerdemann, Ulrike; Haining, W. Nicholas; Roberts, Thomas M.; Polyak, Kornelia; Gygi, Steven P.; Dyson, Nicholas J.; Sicinski, Piotr</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7658</span>),
    <span class="NLM_cas:pages">426-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">D-type cyclins (D1, D2 and D3) and their assocd. cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation.  Inhibitors of CDK4 and CDK6 are currently being tested in clin. trials for patients with several cancer types, with promising results.  Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2.  This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways.  Inhibition of cyclin D3-CDK6 in tumor cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione.  This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumor cells.  The pro-survival function of cyclin D-assocd. kinase operates in tumors expressing high levels of cyclin D3-CDK6 complexes.  We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumor subsets that undergo cell death and tumor regression upon inhibition of CDK4 and CDK6.  Cyclin D3-CDK6, through its ability to link cell cycle and cell metab., represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD4-8f9Q8KErVg90H21EOLACvtfcHk0lgH2gy7KUcVYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Oqtb0%253D&md5=f2539399d1c4fb2163fb245d25c07843</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnature22797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22797%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNicolay%26aufirst%3DB.%2BN.%26aulast%3DChick%26aufirst%3DJ.%2BM.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26aulast%3DSuski%26aufirst%3DJ.%2BM.%26aulast%3DKeibler%26aufirst%3DM.%2BA.%26aulast%3DSicinska%26aufirst%3DE.%26aulast%3DGerdemann%26aufirst%3DU.%26aulast%3DHaining%26aufirst%3DW.%2BN.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DPolyak%26aufirst%3DK.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DDyson%26aufirst%3DN.%2BJ.%26aulast%3DSicinski%26aufirst%3DP.%26atitle%3DThe%2520metabolic%2520function%2520of%2520cyclin%2520d3-cdk6%2520kinase%2520in%2520cancer%2520cell%2520survival%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D426%26epage%3D430%26doi%3D10.1038%2Fnature22797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pabla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buege, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprowl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilyeva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janke, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlatter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarimboli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparreboom, A.</span></span> <span> </span><span class="NLM_article-title">Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both cdk4/6 and oct2 functions</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">5231</span>– <span class="NLM_lpage">5236</span>, <span class="refDoi"> DOI: 10.1073/pnas.1424313112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1073%2Fpnas.1424313112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=5231-5236&author=N.+Pablaauthor=A.+A.+Gibsonauthor=M.+Buegeauthor=S.+S.+Ongauthor=L.+Liauthor=S.+Huauthor=G.+Duauthor=J.+A.+Sprowlauthor=A.+Vasilyevaauthor=L.+J.+Jankeauthor=E.+Schlatterauthor=T.+Chenauthor=G.+Ciarimboliauthor=A.+Sparreboom&title=Mitigation+of+acute+kidney+injury+by+cell-cycle+inhibitors+that+suppress+both+cdk4%2F6+and+oct2+functions&doi=10.1073%2Fpnas.1424313112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1424313112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1424313112%26sid%3Dliteratum%253Aachs%26aulast%3DPabla%26aufirst%3DN.%26aulast%3DGibson%26aufirst%3DA.%2BA.%26aulast%3DBuege%26aufirst%3DM.%26aulast%3DOng%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DSprowl%26aufirst%3DJ.%2BA.%26aulast%3DVasilyeva%26aufirst%3DA.%26aulast%3DJanke%26aufirst%3DL.%2BJ.%26aulast%3DSchlatter%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DCiarimboli%26aufirst%3DG.%26aulast%3DSparreboom%26aufirst%3DA.%26atitle%3DMitigation%2520of%2520acute%2520kidney%2520injury%2520by%2520cell-cycle%2520inhibitors%2520that%2520suppress%2520both%2520cdk4%252F6%2520and%2520oct2%2520functions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D5231%26epage%3D5236%26doi%3D10.1073%2Fpnas.1424313112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eschbach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmierczak, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimer, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirner-Eppeneder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keinrath, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solyanik, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartenstein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyran, C. C.</span></span> <span> </span><span class="NLM_article-title">(18)f-fdg-pet/ct and diffusion-weighted mri for monitoring a braf and cdk 4/6 inhibitor combination therapy in a murine model of human melanoma</span>. <i>Cancer imaging: the official publication of the International Cancer Imaging Society</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2</span>, <span class="refDoi"> DOI: 10.1186/s40644-018-0135-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.1186%2Fs40644-018-0135-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=29347968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=1%3ACAS%3A280%3ADC%252BC1MvitFajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=2&author=R.+S.+Eschbachauthor=P.+M.+Kazmierczakauthor=M.+M.+Heimerauthor=A.+Todicaauthor=H.+Hirner-Eppenederauthor=M.+J.+Schneiderauthor=G.+Keinrathauthor=O.+Solyanikauthor=J.+Olivierauthor=W.+G.+Kunzauthor=M.+F.+Reiserauthor=P.+Bartensteinauthor=J.+Rickeauthor=C.+C.+Cyran&title=%2818%29f-fdg-pet%2Fct+and+diffusion-weighted+mri+for+monitoring+a+braf+and+cdk+4%2F6+inhibitor+combination+therapy+in+a+murine+model+of+human+melanoma&doi=10.1186%2Fs40644-018-0135-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">(18)F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma</span></div><div class="casAuthors">Eschbach Ralf S; Kazmierczak Philipp M; Heimer Maurice M; Hirner-Eppeneder Heidrun; Schneider Moritz J; Keinrath Georg; Solyanik Olga; Kunz Wolfgang G; Reiser Maximilian F; Ricke Jens; Cyran Clemens C; Todica Andrei; Olivier Jessica; Bartenstein Peter; Schneider Moritz J</div><div class="citationInfo"><span class="NLM_cas:title">Cancer imaging : the official publication of the International Cancer Imaging Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of BRAF-V600-mutant human melanoma monitored by (18)F-FDG-PET/CT and diffusion-weighted MRI (DW-MRI).  METHODS:  Human BRAF-V600-mutant melanoma (A375) xenograft-bearing balb/c nude mice (n = 21) were imaged by (18)F-FDG-PET/CT and DW-MRI before (day 0) and after (day 7) a 1-week BRAF and CDK 4/6 inhibitor combination therapy (n = 12; dabrafenib, 20 mg/kg/d; ribociclib, 100 mg/kg/d) or placebo (n = 9).  Animals were scanned on a small animal PET after intravenous administration of 20 MBq (18)F-FDG.  Tumor glucose uptake was calculated as the tumor-to-liver-ratio (TTL).  Unenhanced CT data sets were subsequently acquired for anatomic coregistration.  Tumor diffusivity was assessed by DW-MRI using the apparent diffusion coefficient (ADC).  Anti-tumor therapy effects were assessed by ex vivo immunohistochemistry for validation purposes (microvascular density - CD31; tumor cell proliferation - Ki-67).  RESULTS:  Tumor glucose uptake was significantly suppressed under therapy (αTTLTherapy - 1.00 ± 0.53 vs. αTTLControl 0.85 ± 1.21; p < 0.001).  In addition, tumor diffusivity was significantly elevated following the BRAF and CDK 4/6 inhibitor combination therapy (αADCTherapy 0.12 ± 0.14 × 10(-3) mm(2)/s; αADCControl - 0.12 ± 0.06 × 10(-3) mm(2)/s; p < 0.001).  Immunohistochemistry revealed a significant suppression of microvascular density (CD31, 147 ± 48 vs. 287 ± 92; p = 0.001) and proliferation (Ki-67, 3718 ± 998 vs. 5389 ± 1332; p = 0.007) in the therapy compared to the control group.  CONCLUSION:  A novel BRAF and CDK 4/6 inhibitor combination therapy exhibited significant anti-angiogenic and anti-proliferative effects in experimental human melanomas, monitored by (18)F-FDG-PET/CT and DW-MRI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBjd8AjXu4mJ6KlWarZTAzfW6udTcc2eY6Qe7Zxm1RK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvitFajsw%253D%253D&md5=188448387b42004292c567ce4a2b1065</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1186%2Fs40644-018-0135-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40644-018-0135-y%26sid%3Dliteratum%253Aachs%26aulast%3DEschbach%26aufirst%3DR.%2BS.%26aulast%3DKazmierczak%26aufirst%3DP.%2BM.%26aulast%3DHeimer%26aufirst%3DM.%2BM.%26aulast%3DTodica%26aufirst%3DA.%26aulast%3DHirner-Eppeneder%26aufirst%3DH.%26aulast%3DSchneider%26aufirst%3DM.%2BJ.%26aulast%3DKeinrath%26aufirst%3DG.%26aulast%3DSolyanik%26aufirst%3DO.%26aulast%3DOlivier%26aufirst%3DJ.%26aulast%3DKunz%26aufirst%3DW.%2BG.%26aulast%3DReiser%26aufirst%3DM.%2BF.%26aulast%3DBartenstein%26aufirst%3DP.%26aulast%3DRicke%26aufirst%3DJ.%26aulast%3DCyran%26aufirst%3DC.%2BC.%26atitle%3D%252818%2529f-fdg-pet%252Fct%2520and%2520diffusion-weighted%2520mri%2520for%2520monitoring%2520a%2520braf%2520and%2520cdk%25204%252F6%2520inhibitor%2520combination%2520therapy%2520in%2520a%2520murine%2520model%2520of%2520human%2520melanoma%26jtitle%3DCancer%2520imaging%253A%2520the%2520official%2520publication%2520of%2520the%2520International%2520Cancer%2520Imaging%2520Society%26date%3D2018%26volume%3D18%26spage%3D2%26doi%3D10.1186%2Fs40644-018-0135-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chartier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najmanovich, R.</span></span> <span> </span><span class="NLM_article-title">Kinome render: A stand-alone and web-accessible tool to annotate the human protein kinome tree</span>. <i>PeerJ</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e126</span>, <span class="refDoi"> DOI: 10.7717/peerj.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=10.7717%2Fpeerj.126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;key=23940838" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=e126&author=M.+Chartierauthor=T.+Chenardauthor=J.+Barkerauthor=R.+Najmanovich&title=Kinome+render%3A+A+stand-alone+and+web-accessible+tool+to+annotate+the+human+protein+kinome+tree&doi=10.7717%2Fpeerj.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.126%26sid%3Dliteratum%253Aachs%26aulast%3DChartier%26aufirst%3DM.%26aulast%3DChenard%26aufirst%3DT.%26aulast%3DBarker%26aufirst%3DJ.%26aulast%3DNajmanovich%26aufirst%3DR.%26atitle%3DKinome%2520render%253A%2520A%2520stand-alone%2520and%2520web-accessible%2520tool%2520to%2520annotate%2520the%2520human%2520protein%2520kinome%2520tree%26jtitle%3DPeerJ%26date%3D2013%26volume%3D1%26spage%3De126%26doi%3D10.7717%2Fpeerj.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EZ5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EZ5','PDB','4EZ5'); return false;">PDB: 4EZ5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BCF','PDB','4BCF'); return false;">PDB: 4BCF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX','PDB','4BKX'); return false;">PDB: 4BKX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i118"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00209">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23120"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00209">10.1021/acs.jmedchem.8b00209</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Pharmacophore features we defined based on the complex structure between CDK4 and HDAC1 with their ligands; preliminary screen of dual-action compounds; in vitro growth inhibitory activities of dual-action compounds; GI<sub>50</sub> value of compound <b>6e</b>; kinase profiling results of compound <b>6e</b>; molecular docking of the best candidate for enzyme inhibition; <sup>1</sup>H and <sup>13</sup>C spectra of compounds; ESI-HRMS spectra and HPLC purity analysis for compound <b>6e</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_001.pdf">jm8b00209_si_001.pdf (7.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00209/suppl_file/jm8b00209_si_002.csv">jm8b00209_si_002.csv (3.76 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00209&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00209%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00209" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679976678cf23d88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
